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Summary 
Death Receptor 3 (DR3) is a death domain (DD) containing member of the Tumour 
Necrosis Factor Receptor Superfamily (TNFRSF) and has a single acknowledged 
TNFSF ligand called TNF-like protein 1A (TL1A). Previous research has implicated 
roles for DR3 in host immune defence and in various inflammatory diseases such as 
rheumatoid arthritis, inflammatory bowel disease (IBD), atherosclerosis and allergic 
lung inflammation. This thesis investigated a potential role for DR3 in co-ordinating 
the innate immune response, using an in vivo Staphylococcus epidermidis 
supernatant (SES) model of acute peritoneal inflammation. A further point of 
investigation looked at the effect of the absence of DR3 on thickening of the 
peritoneal membrane induced by repeated SES inflammation.  
My results showed that the DR3/TL1A pathway is not essential in maintaining the 
number of peritoneal or blood leukocytes during naive conditions. Stromal DR3 was 
found to be important in co-ordinating the innate immune response after the 
induction of acute SES induced inflammation, with significantly lower numbers of 
specific myeloid and lymphoid cell subsets accumulating in the peritoneal cavity of 
DR3 knockout (DR3-/-) mice. Despite this reduction in selected leukocyte numbers, 
the proportion of infiltrating cells exhibiting proliferation and cell death was 
unaffected by the absence of DR3. However reduced leukocyte numbers were 
associated with a significant reduction in the concentration of multiple 
chemoattractants in DR3-/- peritoneal supernatants compared to those from DR3+/+ 
mice. Quantitative RT-PCR data (qPCR) were consistent with the peritoneal 
membrane being a source of many of these chemoattractants. 
vi 
 
Results presented here identify for the first time a pro-inflammatory role for stromal 
DR3 in the innate immune response. However after repeatedly inducing 
inflammatory conditions DR3 promoted thickening of the peritoneal membrane, 
while an absence of DR3 prevented aberrant inflammation-induced tissue fibrosis. 
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1.1 The Tumour Necrosis Factor Superfamily  
1.1.1 History 
Observations based on the effects of the Tumour Necrosis Factor Superfamily 
(TNFSF) date back to the mid-19th century, when tumours from cancer patients were 
shown to regress after acute bacterial infection (Brunes et al. 1868). The name 
Tumour Necrosis Factor (TNF) was not used until 1975 with reference to these 
observations (Carswell, Old et al. 1975). By 1985 another cytotoxic protein had been 
discovered, known as Lymphotoxin (LT). Comparison of LT and TNF found 30 % 
amino acid sequence homology between them and common cell surface receptors 
(Aggarwal 2003), suggesting the presence of a larger gene superfamily. This was 
confirmed with the discovery of 2 Tumour Necrosis Factor Receptor Superfamily 
(TNFRSF) members in 1989, CD40 (Stamenkovic, Clark et al. 1989) and 4-1BB 
(Weissman 1989), and many more in subsequent years through sequencing using 
expressed sequence tags (ESTs).  
 
The late 1990s saw a final surge in TNFRSF discovery initiated by the human 
genome project, which identified more remote relatives such as TWEAKR (Wiley, 
Cassiano et al. 2001) and BAFFR (Thompson, Bixler et al. 2001). Currently the 
TNFSF comprises 19 members which link to 29 TNFRSF members (Aggarwal 
2003) forming more than 40 distinct TNFSF-TNFRSF interactions (Figure 1.1) 
(Idriss and Naismith 2000; Ashkenazi 2002; Ware 2008). 
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1.1.2 Structure and binding of TNFSF members and their receptors 
The 19 TNFSF members are type 2 homotrimeric transmembrane proteins that can 
be embedded within the cell surface (pro form, cell to cell interaction) or cleaved 
from the membrane (mature form, soluble molecule) (Idriss and Naismith 2000). 
Within the extracellular region, the TNFSF include a homologous section of around 
150 amino acids, known as the TNF homology domain (THD), however 15-35 % of 
the THD of each member is divergent, allowing specific binding to members of the 
TNFRSF (Orlinick and Chao 1998; Bodmer, Schneider et al. 2002).   
The 29 TNFRSF members are mostly type 1 transmembrane proteins (with the 
exception of the soluble DcR3 and OPG), which are made up of 3 receptor 
monomers that are defined by their number (between 1 and 4) of extracellular 
cysteine-rich domains (MacEwan 2002; Bossen, Ingold et al. 2006). TNFRs with 
multiple cysteine-rich domains (between 2 and 4) have an extended configuration 
that combines with TNFSF members by using all 3 receptor monomers, which bind 
crevasses between pairs of TNFSF member monomers (Banner, Darcy et al. 1993; 
Hymowitz, Christinger et al. 1999; Hymowitz, Patel et al. 2005). However TNFRs 
with 1 cysteine-rich domain have a more condensed formation that only attaches to 1 
TNFSF member monomer (Hymowitz, Patel et al. 2005).  
Within the 29 members that make up the TNFRSF is a subpopulation of 8 receptors 
which share a homologous death domain (DD) region in the cytoplasmic tail, so 
called as this region recruits adaptor proteins that activate executioner caspases 
which can promote apoptosis (Ashkenazi 2002). These death receptors are believed 
to share a single common ancestor that incorporated a cytoplasmic DD, rather than 
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DDs evolving individually in separate evolutionary events for each receptor 
(Locksley, Killeen et al. 2001). 
 
1.1.3 Intracellular receptor signalling by TNFSF members 
Once a TNFSF member is bound to its TNFRSF ligand one of two intracellular 
signalling cascades can be initiated (Locksley, Killeen et al. 2001); which signalling 
pathway employed is dependent on the cytoplasmic adaptor proteins the TNFRSF 
member recruits (Ashkenazi and Dixit 1998). TNFRSF members associated with a 
DD can engage the cell’s apoptotic mechanism by assembling an intracellular death 
inducing signalling complex (DISC) (Shen and Pervaiz 2006). The DISC can 
include the adaptor proteins Fas-associated death domain protein (FADD),       
TNFR-associated death domain protein (TRADD) (Locksley, Killeen et al. 2001) 
and Receptor interacting protein (RIP) (Shen and Pervaiz 2006) and the cysteine 
proteases Caspase 8 and 10 (Bodmer, Holler et al. 2000; Wang, Chun et al. 2001).  
These initiator caspases may then activate pro forms of executioner caspases 
(Caspase 3, 6 and 7) that are responsible for initiating apoptosis (Figure 1.2) 
(Ashkenazi and Dixit 1998).    
The other signalling cascade is available to all TNFRSF members linked to an 
intracellular TNF receptor-associated factor (TRAF) binding motif (Ashkenazi and 
Dixit 1998). Following TNFSF/TNFRSF binding recruited TRAFs, along with 
cellular-Inhibitor of apoptosis 2 (cIAP2) form a complex which can initiate the 
canonical Nuclear factor kappa B (NFκB) pathway via ubiquitination of molecules 
in the signal complex, most notably RIP1 (Skaug, Jiang et al. 2009; Dynek, 
Goncharov et al. 2010; Verhelst, Carpentier et al. 2011). Ubiquitination is a 3 
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enzyme post transcriptional process by which ubiquitin (a 76 amino acid 
polypeptide) is joined to a target protein; 1) an ATP dependent thiolester bond is 
formed between the C-terminal of ubiquitin and the active site of the ubiquitin 
activating enzyme (E1), 2) ubiquitin is then transported to the ubiquitin conjugating 
enzyme (E2) before, 3) being attached via its C-terminal by an isopeptide bond to 
the epsilon amino group of a lysine residue (an essential amino acid) on the target 
protein (in this case RIP1) by a ubiquitin protein ligase (E3 e.g TRAF2, cIAP2) 
(Skaug, Jiang et al. 2009; Verhelst, Carpentier et al. 2011). RIP1 is then 
polyubiquitinated with lysine (K) ubiquitin chains, as lysine residues on ubiquitin 
itself allow covalent attachment of other ubiquitins, polyubiquitin chains formed by 
different lysine residues on ubiquitin (e.g K63, K48, K11, linear) can have 
differential structure and downstream effects (Skaug, Jiang et al. 2009; Verhelst, 
Carpentier et al. 2011).  
Polyubiquitination of RIP1 then leads to the recruitment of TAK1 (a mitogen-
activated 3 kinase (MAP3K) molecule) and the IκB kinase complex (IKK) via 
binding of TAB2 (an adaptor protein of TAK1) and IKKγ (otherwise known as 
NEMO, the modulator subunit of IKK that activates the p50/RelA dimer, NFκB 
family members) to ubiquitin chains via specialised ubiquitin binding domains 
(UBAN) (Haas, Emmerich et al. 2009; Rahighi, Ikeda et al. 2009; Skaug, Jiang et al. 
2009; Tokunaga, Sakata et al. 2009; Gerlach, Cordier et al. 2011). This binding to 
polyubiquitin chains stabilises the signalling complex and either promotes IKKγ 
activation by direct transformation of IKKγ, TAK1 phosphorylation of IKK or close 
proximity of IKKγ subsections due to ubiquitination promoting trans-
autophosphorylation (Skaug, Jiang et al. 2009; Ikeda, Crosetto et al. 2010; Walczak, 
Iwai et al. 2012). IKK can then phosphorylate Inhibitor of kappa B (IκB) leading to 
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its polyubiquitination (on lysine 21 and 22) triggering its degradation by the 
proteasome, permitting p50/RelA influence in the nucleus and triggering gene 
transcription (Shen and Pervaiz 2006; Verhelst, Carpentier et al. 2011) (Figure 1.2). 
In addition to canonical NFκB signalling a subset of TNFRSF members including; 
BAFFR (Claudio, Brown et al. 2002; Kayagaki, Yan et al. 2002), LTβR (Dejardin, 
Droin et al. 2002; Norris and Ware 2007), CD40 (Bishop, Moore et al. 2007), 
TWEAKR (Brown, Richards et al. 2003; Saitoh, Nakayama et al. 2003), RANK 
(Novack, Yin et al. 2003; Vaira, Johnson et al. 2008), CD30 (Nishikori, Ohno et al. 
2005; Nonaka, Horie et al. 2005), CD27 (Ramakrishnan, Wang et al. 2004) and 
TNFR2 (Munroe and Bishop 2004; Rauert, Wicovsky et al. 2010) can signal using a 
non-canonical NFκB pathway (Xiao, Harhaj et al. 2001).  
Rather than the canonical pathway (which relies on degradation of the inhibitor 
IκB), non-canonical signalling depends on an inducible processing mechanism that 
is dependent on NFκB inducing kinase (NIK), a MAP3K molecule which is essential 
in processing p100 (Xiao, Harhaj et al. 2001; Claudio, Brown et al. 2002; Coope, 
Atkinson et al. 2002; Dejardin, Droin et al. 2002; Kayagaki, Yan et al. 2002; 
Novack, Yin et al. 2003; Sun 2011). p100 is the precursor of p52, which is one of 
the NFκB family members (along with RelB) that promotes gene transcription in this 
signalling pathway, but p100 also acts as an IκB-like protein preventing the 
translocation of RelB to the nucleus (Coope, Atkinson et al. 2002; Solan, Miyoshi et 
al. 2002; Derudder, Dejardin et al. 2003). Following TNFSF-TNFRSF binding 
TRAFs (predominantly TRAF2 and TRAF3) are recruited into the TRAF binding 
motif and their degradation promotes NIK activation (Sun 2010). NIK via the kinase 
IKKα (but not IKKβ or IKKγ) (Senftleben, Cao et al. 2001) then phosphorylates  
p100 at the NIK responsive domain (found at the C-terminal, near the inhibitory 
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ankyrin repeat domain and processing inhibitory domain regions) leading to its 
polyubiquitination and processing by the proteasome (Heusch, Lin et al. 1999; Xiao, 
Harhaj et al. 2001; Liang, Zhang et al. 2006) activating the p52/RelB, that can effect 
target genes (Figure 1.2).  
Through these mechanisms of signalling, the TNFRSF can have dramatic effects on 
the cell, from typical cytokine responses, proliferation and differentiation to cell 
death (apoptosis).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 - Intracellular signalling by TNFRSF members. Signalling is dependent 
on adaptor proteins recruited to the intracellular portion of the TNFRSF and their 
differential association with downstream signalling cascades, that can exert different 
outcomes for the cell. TNFRSF members containing a death domain can signal for 
apoptosis via a DISC, which consists of adaptor proteins FADD, TRADD and RIP 
and initiator caspases, which activate executioner caspases that are responsible for 
initiating apoptosis. The canonical NFκB pathway is accessible to TNFRSF members 
associated with a TRAF binding motif. TRAFs along with cIAP2 initiate NFκB 
signalling via RIP1 and TAK1 which recruit and activate IKK, IKK then triggers 
degradation of IκB allowing p50/RelA access to the nucleus. In addition to canonical 
signalling a subset of the TNFRSF can signal via a non-canonical NFκB pathway, 
which depends on inducible processing of p100 by NIK. p100 is the precursor of p52, 
but also acts as an IκB-like protein stopping translocation of RelB to the nucleus. 
After activation TRAFs activate NIK that via IKKα phosphorylates p100 activating 
p52/RelB, which can affect gene transcription in the nucleus. Figure adapted from 
Baud and Karin 2001; Yeh 2002 and Sun 2011. 
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1.2 Death Receptor 3  
TNFR1 was the first identified member of the TNFRSF and Death Receptor 3 (DR3) 
is its closest known relative. It was discovered due to its homology with TNFR1 and 
has been implicated in causing a variety of cellular responses from proliferation to 
initiation of apoptotic pathways. 
 
1.2.1 Human DR3 
The human DR3 (hDR3) gene was simultaneously discovered by a number of 
different laboratories, the majority of whom screened complementary DNA (cDNA) 
libraries with ESTs for sequence homology with TNFR1 and Fas; one group used a 
functional binding assay, namely a yeast 2-hybrid system incorporating the TNFR1 
DD as a target (Kitson, Raven et al. 1996). Thus the DR3 gene (Chinnaiyan, 
Orourke et al. 1996) has been cited under an array of different names; these are 
TRAMP (Bodmer, Burns et al. 1997), LARD (Screaton, Xu et al. 1997), TR3 (Tan, 
Harrop et al. 1997), Wsl-1 (Kitson, Raven et al. 1996) and Apo3 (Marsters, Sheridan 
et al. 1996), though it is officially recorded in the National Center for Biotechnology 
Information (NCBI) database under TNFRSF25. The location of DR3 in the human 
genome was pinpointed using fluorescence in situ hybridisation (FISH) to the short 
arm of chromosome 1 between regions p36.2 (Bodmer, Burns et al. 1997) and p36.3 
(Marsters, Sheridan et al. 1996),  near several other TNFSF and TNFRSF members 
(including; TNFR2, 4-1BB, CD30, OX40) suggesting clustering in the genome 
(Bodmer, Burns et al. 1997).  
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The DR3 gene consists of 1665 base pairs in 10 exons, which encode a type 1 
transmembrane protein of around 417 amino acids with 4 cysteine-rich repeats and a 
DD (Kitson, Raven et al. 1996; Screaton, Xu et al. 1997). DR3 and TNFR1 share     
29 % of their overall cDNA sequence with 28 % homology in the extracellular 
domain (ECD) and 32 % in the intracellular domain (ICD), though this increases to 
48 % in the DD (Marsters, Sheridan et al. 1996). After TNFR1, DR3 shares most 
resemblance to Fas, with which it shares 23 % of its overall sequence (Bodmer, 
Burns et al. 1997).  At least 13 splice variants of hDR3 have been identified, 9 of 
which lack a transmembrane domain suggesting the presence of soluble forms that 
will be discussed in more detail in Section 1.2.3.1 (Screaton, Xu et al. 1997).  
 
1.2.2 Mouse DR3  
The mouse homologue of the hDR3 gene was isolated in 2001, by screening a 129Sv 
mouse genomic library with a full-length hDR3 cDNA. Screening identified a single 
cDNA clone and reverse transcription polymerase chain reaction (RT-PCR) and 
sequencing was used to characterise exon-intron boundaries, as reduced homology at 
the 5’ end of the gene limited the signal from hDR3 probes in this region. The 
genomic location of the mouse homologue was pinpointed using FISH to 
chromosome 4 region E1, which is syntenic with the location of the hDR3 gene 
(Wang, Kitson et al. 2001).  
 
Analysis of mouse DR3 (mDR3) cDNA indicates the coding portion of the gene 
spans 5kb and, similar to hDR3, contains 10 exons. The mDR3 gene shares 
significant similarities to its human counterpart, with a 55 % identical base pair 
sequence; homology rises even further at the protein level to 63 % across the whole 
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protein, including a highly conserved DD exhibiting 94 % homology. The ECDs of 
hDR3 and mDR3 share 52 % amino acid homology; both have 2 N-linked 
glycosylation sites and 25 of the 28 cysteine residues are conserved, though mDR3 
has a 2 amino acid substitution and a 9 amino acid deletion in the second half of the 
3rd cysteine-rich repeat leading to the absence of 2 cysteine residues and a switch 
between cysteine and phenylalanine (in humans) with threonine and cysteine (in 
mice). However these alterations are not predicted to affect interactions with the 
ligand, as the first section of the 3rd cysteine-rich repeat maintains a fundamentally 
similar structure and it is this region along with the 2nd cysteine-rich repeat, which is 
believed to bind its ligand TL1A (Section 1.2.5) (Wang, Kitson et al. 2001).  
 
1.2.3 Expression of DR3 
1.2.3.1 Human DR3 expression and Decoy receptor 3 (DcR3) 
Unlike TNFR1, which is ubiquitously expressed in all tissues, DR3 is more 
selective. Northern blot analysis initially identified 3.4-4kb hDR3 RNA transcripts 
in the thymus, spleen, colon, small intestine, brain, foetal lung, prostate and 
peripheral blood T cells (Chinnaiyan, Orourke et al. 1996; Kitson, Raven et al. 1996; 
Marsters, Sheridan et al. 1996; Bodmer, Burns et al. 1997; Screaton, Xu et al. 1997). 
However later studies have also detected DR3 expression in the epidermis and 
dermis of skin (Bamias, Evangelou et al. 2011), vascular endothelial cells (VECs) 
and tubular epithelial cells (TECs) of rejecting or injured renal allografts (Al-Lamki, 
Wang et al. 2008), foam cells in atherosclerotic plaques from carotid 
endoarterectomy tissue (Kang, Kim et al. 2005) and on activated B cells (Cavallini, 
Lovato et al. 2013), monocytes (Kang, Kim et al. 2005), NK cells (Papadakis, Prehn 
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et al. 2004) and bone marrow differentiated osteoblasts (Borysenko, Garcia-Palacios 
et al. 2006). 
The hDR3 gene was initially reported to produce 12 splice variants, the majority of 
which are truncated forms of the full-length DR3 transcript and produced by splicing 
out one or more exons resulting in stop codons (Screaton, Xu et al. 1997). Of these 
12 splice variants 9 lack a transmembrane domain suggesting they are secreted in a 
soluble form (Screaton, Xu et al. 1997). However a 13th longer variant was later 
classified (initially named DR3β) that contained 2 insertions producing a sequence 
of 28 amino acids longer than the 417 amino acids reported for the original DR3 
protein. Expression of this variant appears to be more restricted with its presence 
only on lymphoid T cell and immature B cell lines (Warzocha, Ribeiro et al. 1998). 
In addition to soluble hDR3 splice variants, a soluble decoy receptor is also found in 
humans, known as Decoy receptor 3 (DcR3, also known as TR6 and M68). DcR3 
expression has been found in several tissues, including; the spleen, stomach, colon, 
lung, spinal cord, lymph node and weakly in the thymus, but is overexpressed in 
cancerous tumours and during inflammatory diseases (Pitti, Marsters et al. 1998; Yu, 
Kwon et al. 1999; Bai, Connolly et al. 2000; Connolly, Cho et al. 2001; Zhang, 
Salcedo et al. 2001; Yang, Wang et al. 2004; Han and Wu 2009). Indeed increased 
DcR3 has been linked with more severe tumour and inflammatory disease 
progression (Roth, Isenmann et al. 2001; Chen, Yang et al. 2009), including 
peritonitis (Chang, Lin et al. 2012).  
Structurally DcR3 contains a repeat of the TNFRSF’s extracellular region but has no 
transmembrane region, thus it forms a soluble protein that can competitively bind 
DR3’s ligand TL1A (Section 1.2.5) (Migone, Zhang et al. 2002). In addition to 
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disrupting DR3/TL1A interactions, DcR3 can also bind Fas ligand and LIGHT and 
so can also encroach on their signalling pathways (Pitti, Marsters et al. 1998; Yu, 
Kwon et al. 1999). Initially DcR3 was viewed as an anti-inflammatory molecule, 
which competes with DR3, Fas and HVEM to bind their respective ligands, 
therefore DcR3 can act to neutralise their effects and dampen down the 
inflammatory response (Zhang, Salcedo et al. 2001). However more recent studies in 
Crohn’s disease have suggested DcR3 could also promote inflammation by blocking 
apoptosis (Macher-Goeppinger, Aulmann et al. 2008).  
 
1.2.3.2 Mouse DR3 expression 
Mouse DR3 expression was initially analysed by Northern blot and transcripts were 
identified in the brain, spleen, thymus, skin, heart, kidney, liver and on activated T 
cells (Wang, Kitson et al. 2001) (Figure 1.3). Later studies also confirmed DR3 
expression in the synovial membrane and fat pad of the inflamed knee joint (Wang, 
Newton et al. appendix) and on differentiated CD4+ T cell subsets; including T 
helper 17 (Th17) (Pappu, Borodovsky et al. 2008; Jones, Stumhofer et al. 2011) and 
regulatory T (Treg) cells (Fang, Adkins et al. 2008; Pappu, Borodovsky et al. 2008) 
as well as CD8+ T cells (Fang, Adkins et al. 2008; Twohig, Marsden et al. 2012) and 
NKT cells (Fang, Adkins et al. 2008; Twohig, Marsden et al. 2012).  
Significant differences were found in the number, length and expression pattern of 
mouse transcripts compared to hDR3, with 3 found between 1.8-7kb compared to 4 
in hDR3. Further all of these 4 main hDR3 transcripts were seen in the human spleen 
and brain whilst only the larger 7kb transcript was found in the mouse brain, heart 
and kidney, with only the 2 smaller mDR3 transcripts of 1.8kb and 2.8kb observed 
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in the mouse spleen and thymus suggesting the function of DR3 may vary between 
species (Figure 1.3) (Wang, Kitson et al. 2001). 
Variants of mDR3 are also produced by alternative splicing of one or more exons, 
but fewer are found in the mouse with 3 isoforms identified (variant 1- full-length 
membrane-bound, variant 2- soluble form and variant 3- truncated membrane-
bound) (Wang, Kitson et al. 2001). Current investigations using DR3 mRNA suggest 
these mouse isoforms may be differentially regulated and may perform different 
immunological functions (Bamias, Mishina et al. 2006; Pappu, Borodovsky et al. 
2008; Twohig, Marsden et al. 2012), which could explain some of the differing 
functions ascribed to DR3. However, exactly how different DR3 variants are 
regulated on the surface and how this relates to function is not yet known. 
Nor has any mouse homologue of DcR3 been identified in the mouse, though it has 
been theorised that soluble DR3 (sDR3) in mice may perform a comparable role to 
DcR3 (Bamias, Mishina et al. 2006; Pappu, Borodovsky et al. 2008). However the 
function of sDR3 is yet to be determined and does not clarify the sustained existence 
of sDR3 isoforms, as well as DcR3 in humans (Screaton, Xu et al. 1997). 
 
 
 
 
 
 
Figure 1.3 - DR3 expression in the mouse. Mouse DR3 (mDR3) was 
originally shown by Northern blot to be expressed in the brain, spleen, 
thymus, skin, heart, kidney, liver and on activated T cells. However later 
studies also found mDR3 on the synovial membrane and fat pad of the 
inflamed knee joint, differentiated CD4+ T cell subsets, CD8+ T cells and 
NKT cells. Figure taken from Wang et al. 2001. 
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1.2.4 Signalling through DR3 
DR3 signalling occurs via a similar mechanism to other DD containing TNFRSF 
members (Section 1.1.3) (Figure 1.4). After TL1A binding DR3 signals for 
proliferation through canonical NFκB activation (Kitson, Raven et al. 1996; 
Bodmer, Burns et al. 1997), which was confirmed using a luciferase reporter gene 
that was amplified in a dose-dependent manner in the presence of DR3 (Bodmer, 
Burns et al. 1997). Whilst DR3 signalling can support cell survival (Chinnaiyan, 
Orourke et al. 1996; Kitson, Raven et al. 1996; Bodmer, Burns et al. 1997), 
overexpression on 293 T cells resulted in an 18 % increase in cell death (Screaton, 
Xu et al. 1997) (Kitson, Raven et al. 1996).  
Thus to further understand the two contrasting pathways initiated by DR3, TF-1 
cells (a DR3 expressing human erythroleukemic cell line) were used to investigate 
the formation of signalling complexes. The DISC was found to contain adaptor 
proteins which favour survival pathways (Wen, Zhuang et al. 2003), whilst limited 
apoptotic molecules were found in the signalling complex. Apoptosis was only 
initiated after blockade of NFκB, preventing the production of the c-IAP2 (Wen, 
Zhuang et al. 2003). Thus initial signalling molecules recruited after TNFSF-
TNFRSF binding favour cell survival. However survival signals may be overridden 
if protein synthesis and proliferation signals are inhibited within the cell (Migone, 
Zhang et al. 2002).  
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Figure 1.4 - DR3 and its intracellular signalling cascades. After TL1A 
binds DR3, adaptor proteins bind to the intracellular portion of DR3 forming 
a death inducing signalling complex (DISC). It is these effector molecules 
within the DISC that link DR3 into downstream signalling pathways such as 
the NFκB pathway, via RIP and TRAF2 and the caspase pathway by TRADD 
and FADD . Figure adapted from Ashkenazi 2002. 
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1.2.5 TNF-like protein 1A (TL1A) 
Early investigations identified TWEAK (also known as Apo3L and TNFSF12) as 
the TNFSF member which bound DR3 (Marsters, Sheridan et al. 1998). However 
further research suggested this was not the case (Lynch, Wang et al. 1999) and 
TWEAK signalling was detected in DR3 knockout (DR3-/-) cells (Kaptein, Jansen et 
al. 2000). TWEAK has since been shown to bind the TNFRSF member TWEAKR 
(also known as Fn14) (Wiley, Cassiano et al. 2001) and DR3 was found to bind the 
TNFSF member TL1A (also known as TNFSF15), which was discovered using 
ESTs (Migone, Zhang et al. 2002) and its specificity confirmed using DR3-/- mice 
(Bull, Williams et al. 2008; Meylan, Davidson et al. 2008; Twohig, Marsden et al. 
2012).  
In addition to DR3, TL1A can also be bound by DcR3 in humans (Migone, Zhang et 
al. 2002), though currently TL1A is the only identified TNFSF member that binds 
DR3 (and vice versa in mouse) (Migone, Zhang et al. 2002). It has also been 
suggested that DR3 on colon carcinoma cells can bind the adhesion molecule           
E-selectin, promoting tumour adhesion to endothelial cells and migratory and 
survival pathways in the tumour (Gout, Morin et al. 2006; Porquet, Poirier et al. 
2011).  
TL1A is a homotrimeric type 2 protein of 252 amino acids and a longer variant of 
vascular endothelial growth inhibitor (VEGI, also known as TL1) (Migone, Zhang et 
al. 2002) that has formerly been shown to be produced by the endothelium and 
prevent tumour development and endothelial expansion (Tan, Harrop et al. 1997; 
Yue, Ni et al. 1999; Zhai, Ni et al. 1999; Zhai, Yu et al. 1999). Both TL1A and 
VEGI were mapped to the TNFSF15 gene on the long arm of chromosome 9 in the 
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region q32 (Zhang, Wang et al. 2009). Compared to VEGI, TL1A was found to be 
the predominant full-length translation product of the TNFSF15 gene able to 
generate the transmembrane domain (allowing both membrane-bound and soluble 
TL1A) and the initial conserved β strand found in other TNFSF members. TL1A 
was also produced in significantly greater quantities (15 times higher) than VEGI 
(Migone, Zhang et al. 2002). Within the TNFSF, TL1A is most closely related to 
TNFR1’s ligand TNFα to which it shares 24.6 % homology followed by FasL      
(22.9 %) (Migone, Zhang et al. 2002). Human and mouse TL1A are very similar 
showing 63.7 % cDNA sequence identity (Migone, Zhang et al. 2002).  
Following the induction of inflammation, upregulation of TL1A expression has been 
detected on multiple tissues including the kidney, prostate, placenta, stomach, 
intestine, lung, spleen, thymus, skin, brain, renal allografts and atheromatous arteries 
(Migone, Zhang et al. 2002; Al-Lamki, Wang et al. 2008; Twohig, Roberts et al. 
2010; Bamias, Evangelou et al. 2011; Bamias, Stamatelopoulos et al. 2013) and 
TL1A production has been noted by multiple cell types including endothelial cells 
(Migone, Zhang et al. 2002; Al-Lamki, Wang et al. 2008), chondrocytes, fibroblasts 
(Zhang, Wang et al. 2009), monocytes (Bamias, Martin et al. 2003; Bamias, Mishina 
et al. 2006; Cassatella, da Silva et al. 2007; Prehn, Thomas et al. 2007; Meylan, 
Davidson et al. 2008) and T cells (Bamias, Martin et al. 2003; Meylan, Davidson et 
al. 2008). However how TL1A is induced varies between different tissues and cell 
subsets.  
TL1A expression (either membrane-bound or soluble form) on chondrocytes, 
fibroblasts and endothelial cells is upregulated after stimulation with other            
pro-inflammatory cytokines (TNFα and Interleukin 1β (IL1β)) (Migone, Zhang et al. 
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2002; Zhang, Wang et al. 2009), whereas release of TL1A (soluble form) from 
monocytes (including macrophages and dendritic cells) occurs after stimulation with 
LPS or immune complexes (IC) via Toll Like Receptors (TLRs) and Fragment 
crystallisable gamma receptors (FCγRs), respectively (Cassatella, da Silva et al. 
2007; Prehn, Thomas et al. 2007; Meylan, Davidson et al. 2008). Upregulation of 
soluble TL1A production by T cells was seen after activation with anti-CD3 and/or 
anti-CD28, though this was dependent on DR3 expression, suggesting T cell TL1A 
secretion acts later than other sources of TL1A to sustain its own DR3 expression in 
an autocrine manner (Meylan, Davidson et al. 2008).  
Different sources of TL1A and mechanisms of release suggest TL1A may fulfil 
several different functions. Initially TL1A was shown to act as a CD4+ T cell          
co-stimulator promoting IL2-dependent proliferation and the release of                 
pro-inflammatory cytokines (Interferon γ (IFNγ) and Granulocyte-macrophage 
colony-stimulating factor (GM-CSF)) that activate cell defences by recruiting 
peripheral blood leukocytes to the site of infection (Migone, Zhang et al. 2002). 
However, since this finding, TL1A has been found to promote other CD4+ T cell 
responses such as, Th1 differentiation, via TL1A acting in synergy with IL12 and 
IL18, which promotes the release of IFNγ (Bamias, Martin et al. 2003; Bamias, 
Mishina et al. 2006). TL1A co-stimulation with IL12 may also enhance IFNγ release 
from NK cells (Papadakis, Prehn et al. 2004) and TL1A was seen to increase 
cytotoxity of IL12/IL18 activated NK cells (Heidemann, Chavez et al. 2010). In 
addition to its role in Th1 responses, TL1A was found to promote the accumulation 
of effector Th2 cells that provoke the release of IL13 by NKT cells (Fang, Adkins et 
al. 2008; Meylan, Davidson et al. 2008). 
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TL1A can maintain already differentiated Th17 cells but inhibit Th17 differentiation 
from naive T cells (Jones, Stumhofer et al. 2011) and was also shown to co-stimulate 
IL2-dependent Treg expansion (Schreiber, Wolf et al. 2010; Taraban, Slebioda et al. 
2011). However the functional result of this may depend on the context of 
inflammation, as while TL1A-dependent Treg proliferation conveyed resistance in 
allergic lung inflammation (Schreiber, Wolf et al. 2010) their suppressive effects 
were overcome by TL1A-dependent Th17 effects in the ileum of TL1A-transgenic 
mice, causing goblet cell hyperplasia (Taraban, Slebioda et al. 2011). TL1A 
regulation of IL2-independent CD8+ T cell expansion has been found in viral host 
defence (Twohig, Marsden et al. 2012) and TL1A’s control of IL2-dependent CD4+ 
T cell expansion has also been confirmed in both bacterial and viral challenge 
studies (Buchan, Taraban et al. 2012; Twohig, Marsden et al. 2012).  
 
1.2.6 DR3 and health 
Thus far only cellular interactions and pathways initiated by DR3 have been 
described, but what is known about the results of these interactions in terms of 
health and disease models? 
 
1.2.6.1 Inflammatory bowel disease (IBD) 
Both TL1A (on macrophages, CD4+ and CD8+ T cells and plasma cells) and DR3 
(expressed on CD4+ and CD8+ T cells) are upregulated in the intestinal lamina 
propria of patients suffering from Crohn’s disease and ulcerative colitis, while 
increased TL1A levels also correlated with disease severity (Bamias, Martin et al. 
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2003). TL1A and DR3 were also elevated in 2 mouse strains (TNFΔARE mice; which 
are deficient in TNF adenosine-uracil (AU) rich elements (ARE), that are important 
in destabilisation and repression of TNF mRNA translation, resulting in higher and 
more sustained production of TNF and SAMP1/YitFc mice; that are a sub-strain of 
SAMP1/Yit mice, which were in turn developed from a sub-strain of AKR/J mice 
that unexpectedly acquired a senescence accelerated phenotype (including terminal 
ileitis), likely due to breeding with another unknown strain and were further 
selectively inbred) which spontaneously develop mouse ileitis, the mouse equivalent 
of IBD (Bamias, Mishina et al. 2006). In these experimental mouse disease models, 
increased TL1A expression on monocytes and CD11c+ APC (dendritic cells) (Prehn, 
Thomas et al. 2007) bound upregulated full-length DR3, that was preferentially 
expressed on activated CD4+ CCR9+ memory T cells (Bamias, Mishina et al. 2006), 
which have been implicated as a causative cell in this disease (Papadakis, Zhu et al. 
2005). TL1A interaction with mDR3 on these cells can then act in synergy with 
IL12 and IL18 (released from NK cells, cytotoxic and memory T cells) to co-
stimulate IFNγ production (Bamias, Mishina et al. 2006), which was found to be 
upregulated in IBD patients promoting chronic inflammation of the intestinal 
mucosa (Bamias, Martin et al. 2003; Papadakis, Zhu et al. 2005). These findings 
suggest TL1A is important during the effector phase in Th1 inflammatory disease 
(Papadakis, Zhu et al. 2005).   
In addition to Th1 effects, Th17 responses have also been associated with Crohn’s 
disease progression (Fuss, Neurath et al. 1996; Matsuoka, Inoue et al. 2004). Lamina 
propria macrophages from Crohn’s disease patients were found to produce IL23, 
which can act in synergy with TL1A (also released by the lamina propria) to produce 
IL17 as well as IFNγ (Kamada, Hisamatsu et al. 2010). TL1A released by lamina 
24 
 
propria macrophages have also been suggested to promote Th17 differentiation from 
naive T cells (Kamada, Hisamatsu et al. 2010), though this has been disputed in 
other studies (Jones, Stumhofer et al. 2011). Dual TL1A-dependent Th1 and Th17 
responses were also noted in the mouse Dextran sodium sulphate (DSS) induced 
chronic colitis model and Gαi2-/- mice (that lack the alphai2 subunit from G proteins, 
which are a family of GTP binding proteins important in signal transduction), which 
develop spontaneous colitis. In these mouse models TL1A promoted the release of 
both IFNγ in synergy with IL12 (also noted by Bamias et al.) and IL17 in synergy 
with IL23. Furthermore, addition of an anti-TL1A neutralising antibody lowered 
Th1 and Th17 response and reduced markers of chronic colitis (Takedatsu, 
Michelsen et al. 2008).  
Phenotyping of TL1A-transgenic mice (which constitutively produce DR3’s only 
identified ligand TL1A on DCs) initially appeared normal during early development 
(first 2 months), with standard fertility and measurements of the colon, small 
intestine and spleen observed in transgenic mice. However after 6 (Taraban, 
Slebioda et al. 2011) and 10 months (Shih, Barrett et al. 2011), inflammation was 
identified in the small intestine (goblet cell hyperplasia) and greater fibrosis was 
seen in the intestine and colon compared to wildtype mice. Increased activation of 
leukocytes present in these mice also produced increased levels of IFNγ, IL13 and 
IL17 and an increase in gut homing chemokine receptors (CCR9 and CCR10) on T 
cells. Tregs also increased in these mice though pro-inflammatory signals were 
reported to overcome their suppressive effects (Shih, Barrett et al. 2011; Taraban, 
Slebioda et al. 2011).  
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Genetically, TNFSF15 polymorphisms have also been shown to correlate with the 
development of Crohn’s disease in Japanese and European patients (Yamazaki, 
McGovern et al. 2005; Tremelling, Massey et al. 2008). This was confirmed in 
Swedish and American groups, which also identified the allele rs4263839 in 
TNFSF15 as a potential risk allele in Crohn’s disease (Zucchelli, Camilleri et al. 
2011). To date TNFSF15 is the only gene which has been linked to both European 
and Asian IBD (Shih, Kwan et al. 2009). 
 
1.2.6.2 Atherosclerosis  
TL1A is highly expressed in the foam cell region of carotid atherosclerotic plaques 
in humans (Kang, Kim et al. 2005; Kim, Kang et al. 2008). Foam cells are 
differentiated from macrophages, thus previous studies have used THP1 cells (a 
human peripheral blood monocyte cell line) to investigate DR3 activation (Kim, Lee 
et al. 2001; Kang, Kim et al. 2005; Kim, Kang et al. 2008). Addition of an anti-DR3 
antibody to THP1 cells induced the matrix metalloproteinases MMP1, MMP9 and 
MMP13 (Kim, Lee et al. 2001), which have been reported to destabilise the 
atherosclerotic plaque (Kim, Lee et al. 2001). Following the addition of IFNγ with 
the anti-DR3 antibody, IL8, CCL2 and TNFα was also detected (Kang, Kim et al. 
2005). However addition of TL1A rather than the anti-DR3 antibody only induced 
MMP9 and IL8 in a dose-dependent fashion (Kang, Kim et al. 2005). 
It has also been suggested that TL1A binding of DR3 may drive differentiation of 
macrophages in this region into foam cells as seen with other TNFSF members, such 
as TNFα (Rus, Niculescu et al. 1991; Mei, Chen et al. 2007; Persson, Nilsson et al. 
2008), by promoting cholesterol (low density lipoprotein) uptake and reducing 
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cholesterol efflux from the cell. DR3/TL1A interaction achieves this by (i) 
promoting scavenger receptors and proteins important in incorporating low density 
lipoprotein (LDL) into the cell, such as; SR-A, CD36, LPL and SR-PSOX and (ii) 
decreasing ATP-binding cassette (ABC) transporter members and proteins, such as; 
ABCA1, ABCG1 and apoE which are important in cholesterol transport from the 
cell (McLaren, Calder et al. 2010).  
These findings suggest DR3/TL1A may play a complex role in the carotid 
atherosclerotic plaque.  
 
1.2.6.3 Arthritis  
TL1A was found to be elevated in serum of patients suffering from rheumatoid 
arthritis (Bamias, Siakavellas et al. 2008) and has been associated with increased 
bone and cartilage destruction (Cassatella, da Silva et al. 2007; Bamias, Siakavellas 
et al. 2008; Zhang, Wang et al. 2009). Arthritis is mediated by a Th1 immune 
response that includes the release of the inflammatory cytokines TNFα and IL1β, 
which were found to induce TL1A from fibroblast-like synoviocytes and 
mononuclear phagocytes (Cassatella, da Silva et al. 2007; Zhang, Wang et al. 2009).  
Further investigation using 2 mouse models of arthritis (Antigen induced arthritis 
(AIA) and Collagen induced arthritis (CIA)) found increased TL1A and DR3 
expression in wildtype (DR3+/+) mice, but reduced neutrophil recruitment, MMP9 
levels (Wang, Newton et al. appendix) and osteoclastogenesis (bone 
destruction/reabsorbtion) (Bull, Williams et al. 2008) in DR3-/- mice, which resulted 
in reduced cartilage damage (Wang, Newton et al. appendix; Bull, Williams et al. 
2008) and bone pathology (Bull, Williams et al. 2008; Zhang, Wang et al. 2009). 
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Manipulation of the DR3/TL1A interaction also altered bone pathology, which was 
more severe in AIA following TL1A injections, but ameliorated by a neutralising 
anti-TL1A antibody in both AIA and CIA (Bull, Williams et al. 2008).   
Additionally a DR3 gene duplication was identified in humans by FISH and 
sequencing and this duplication was shown to be more prominent in rheumatoid 
arthritis patients (Osawa, Takami et al. 2004). 
Thus TL1A has been implicated as a pro-inflammatory cytokine in rheumatoid 
arthritis patients.  
 
1.2.6.4 Allergic lung inflammation  
Allergic lung inflammation is a defining characteristic of asthma and was provoked 
in mice by a local injection of ovalbumin (Ova) following systemic priming with 
Ova and aluminium hydroxide (Alum) (Gavett, Chen et al. 1994). TL1A interaction 
with DR3 was found to promote allergic lung inflammation by CD4+ T cell 
differentiation into Th2 cells, caused by release of IL13 by NKT cells and increased 
eosinophil and mucus accumulation (Fang, Adkins et al. 2008; Meylan, Davidson et 
al. 2008). DR3/TL1A effects in allergic lung inflammation have been confirmed 
using (i) an antagonistic anti-TL1A antibody (Fang, Adkins et al. 2008) and (ii) 
DR3-/- mice (Meylan, Davidson et al. 2008). Both of these disruptions of the 
DR3/TL1A interaction resulted in amelioration of lung inflammation including, 
lower levels of IL13 and other Th2 cytokines (IL4 and IL5), fewer T cells, NK cells 
and eosinophils in the bronchoalveolar lavage (BAL) and reduced mucus volume. 
28 
 
These findings suggest DR3/TL1A enhances allergic lung inflammation by 
developing a Th2 autoimmune response.  
 
1.2.6.5 Experimental autoimmune encephalitis (EAE) 
Increased DR3 expression was found on Th17 cells during EAE, an autoimmune 
disease model driven by Th17 and Th1 subsets. Further study using TL1A-/- and 
particularly DR3-/- mice noted significantly reduced paralysis compared to TL1A+/+ 
and DR3+/+ mice. Additionally, adoptive transfer of TL1A-/- and DR3-/- T cells into 
TL1A+/+ and DR3+/+ mice respectively was also shown to attenuate paralysis 
(Meylan, Davidson et al. 2008; Pappu, Borodovsky et al. 2008).  
The mechanism by which DR3/TL1A enhances EAE is not yet fully understood, 
however it appears from studies in DR3-/- mice that DR3 promotes increased T cell 
numbers in the spinal cord (Meylan, Davidson et al. 2008). DR3/TL1A may then act 
differentially on CD4+ T cells based on activation status, maintaining the effector 
phenotype of prior differentiated Th17 cells, while not supporting Th17 
development (differentiation or proliferation) from naive T cells (Pappu, 
Borodovsky et al. 2008; Jones, Stumhofer et al. 2011).  
Thus TL1A interaction with DR3 on activated T cells is necessary for autoimmune 
damage in EAE. 
 
1.2.6.6 Antimicrobial immunity 
DR3/TL1A interaction has been associated with promoting host defence in both 
bacterial (Buchan, Taraban et al. 2012) and viral infections (Twohig, Marsden et al. 
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2012). Following Salmonella enterica infection the bacteria replicates in the spleen, 
where TL1A was found to be upregulated in macrophages (after 4 hours). A second 
peak of TL1A (day 14) also overlapped with CD4+ T cell proliferation in the spleen 
and study of DR3-/- mice found reduced numbers and percentage proliferation of 
CD4+ T cells (on day 14) compared to DR3+/+ mice. DR3-/- CD4+ T cells also 
displayed a more immature phenotype, with lower numbers of IFNγ+ and primed T 
cells compared to those found in DR3+/+ mice.  
The Th1 response is central in clearing S. enterica infection and, unsurprisingly, 
elimination of this bacteria from the spleen in DR3-/- mice (and in follow up studies 
in the liver) was compromised compared to their DR3+/+ counterparts. Further, 
injection of S. enterica into RAG-/- mice (that do not contain mature T and B 
lymphocytes, as absence of recombination activation genes prevents rearrangement 
of immunoglobulin and T cell receptor genes) which had received DR3-/- T cells 
displayed increased bacterial load and delayed kinetics compared to RAG-/- mice 
with DR3+/+ T cells, confirming bacterial removal to be both DR3 and T cell 
dependent (Buchan, Taraban et al. 2012). 
DR3-/- mice have also been associated with increased viral loads following mouse 
cytomegalovirus (MCMV) and Vaccinia infection. Similarly to S. enterica infection, 
DR3-/- CD4+ T cells were present at lower numbers and displayed reduced 
proliferation, activation and IFNγ production after viral infection. However unlike    
S. enterica infection DR3 also mediated CD8+ T cell immunity, in which similar 
defects to CD4+ T cells were observed (Twohig, Marsden et al. 2012). These viral 
infection studies also noted differential regulation of DR3 splice variants, with 
upregulation of the full-length variant 1 (also noted by Bamias et al 2006 in mouse 
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models of IBD) and the soluble variant 2 following infection (Twohig, Marsden et 
al. 2012).   
These studies indicate DR3 may play an important role in mediating host defence to 
pathogens by affecting the Th1 response and its action may be associated with 
careful regulation of splice variants. 
 
1.2.7 Mouse DR3 knockout model  
The DR3-/- mouse was made to investigate any non-redundant DR3 function in vivo. 
DR3-/- mice were generated by disrupting exon 1 and substituting all coding exons of 
the DR3 gene, eliminating the possibility of the expression of full-length DR3 or any 
of its splice variants. The DR3 gene was replaced with a β galactosidase (lacZ) gene, 
an internal ribosome entry site (IRES) and a neomycin resistance gene, which were 
bordered by loxP regions (Wang, Thern et al. 2001) (Figure 1.5).  
 
DR3-/- mice had significantly enlarged thymuses compared to DR3+/+ and 
heterozygous (DR3+/-) mice with an increase in size of around 10 % at 2-5 weeks 
rising to 30 % by 29-32 weeks of age, yet this was not due to increased thymocyte 
proliferation and/or turnover. DR3-/- mice showed impaired negative selection in the 
thymus, though they were not found to suffer from any autoimmune diseases. Other 
than these observations, normal development akin to DR3+/+ and DR3+/- littermates 
was seen in the DR3-/- spleen, brain heart, kidney, thymus lymph node and Peyer’s 
patches. 
 
 
Figure removed by author for copyright 
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1.3 The Peritoneum  
1.3.1 Anatomy  
The peritoneum is made up of an uninterrupted serous membrane that assembles into 
a closed sack covering the abdominal wall, internal viscera and base of the 
diaphragm. The membrane can be split into 3 separate sections: (i) the partial 
peritoneum, which covers the anterior, lateral and posterior abdominal walls, the 
bottom of the diaphragm and the pelvis; (ii) The visceral peritoneum that encloses 
the intra-peritoneal organs and the abdominal viscera, containing a hanging fold 
called the mesentery; (iii) The omentum fold of the peritoneum which is suspended 
from the greater curvature of the stomach and originates from the dorsal mesentery 
(Figure 1.6) (Hjelle, Millerhjelle et al. 1995; Nagy and Jackman 1998).  
 
 
 
 
 
 
 
 
 
 
Figure 1.6 - The peritoneum. The peritoneal membrane forms a closed sack 
which can be divided into 3 different areas; (i) the partial peritoneum, that 
envelops the anterior, lateral and posterior abdominal walls, the bottom of the 
diaphragm and the pelvis, (ii) the visceral peritoneum, which contains the 
mesentery and surrounds the intra-peritoneal organs and the abdominal 
viscera and (iii) the omentum fold that hangs from the greater curvature of the 
stomach and originates from the dorsal mesentery. Figure adapted from 
Bowen 2006 and Agur, Drake 2004. 
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1.3.2 The peritoneal membrane  
The peritoneal membrane is composed of 2 cell layers: (i) the mesothelium, that is 
an epithelial-like monolayer which is split by a discontinuous cell layer from; (ii) the 
interstitium (or compact zone), that forms a basal layer of connective tissue that 
supports the mesothelium (Digenis 1984; Krediet, Lindholm et al. 2000). Blood 
vessels are also present in the peritoneum and alongside the lymphatic system, can 
play an important role in movement of peripheral blood leukocytes into and out of 
the peritoneal cavity during an inflammatory response (Figure 1.7) (Nagy and 
Jackman 1998; Williams, Craig et al. 2002). 
 
1.3.2.1 Mesothelial layer 
The mesothelium is responsible for preserving homeostasis in the peritoneal cavity 
by coordinating the movement of leukocytes and solutes into the cavity (Mutsaers 
2004; Yung and Chan 2009) and plays an essential role in organising the initial 
immune response after peritoneal infection (i.e. chemokine release) (Lanfrancone, 
Boraschi et al. 1992; Topley, Brown et al. 1993; Hurst, Wilkinson et al. 2001; 
McLoughlin, Witowski et al. 2003; McLoughlin, Hurst et al. 2004; Jones 2005).  
The mesothelial monolayer is entirely made up of mesothelial cells that group 
collectively to form a continuous layer of compressed cells. These mesothelial cells 
are the most numerous cells found within the peritoneal cavity and contain 
projecting nuclei, rough endoplasmic reticulum, microvilli and pinocytic vesicles 
(Digenis 1984; Dipaolo, Sacchi et al. 1986; Rubin, Clawson et al. 1988; Dobbie and 
Anderson 1996). Mesothelial cells join together and to the interstitium by anchoring 
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junctions (made up of desmosomes and adherence junctions), whereas gap junctions 
in the membrane manage messages sent by cells in this layer (Simionescu and 
Simionescu 1977).  
The mesothelium is held in place by a base layer found underneath the mesothelial 
monolayer made of glycoproteins, proteoglycans and type collagen 4 and may be 
maintained by the mesothelial layer itself (Rennard, Jaurand et al. 1984; Nagy and 
Jackman 1998). 
 
1.3.2.2 Interstitium 
The interstitium layer contains slack connective tissue formed by extracellular 
matrix (ECM) which includes elastin, fibronectin, type collagen 1 and type collagen 
3, that together produce a structured formation that gives flexibility and strength 
(Flessner 1997; Witz, Montoya-Rodriguez et al. 2001). The interstitium can be 
important in regulating the passage of macromolecules and cells through the 
peritoneal membrane via glycosaminoglycans, which can produce a gel-like 
structure of differing aperture dimensions and charge density (Flessner 1997). The 
movement of nutrients, electrolytes, hormones, water molecules and gases from 
capillaries to resident cells in the cavity is governed by the aqueous environment 
within the interstitium (Nagy and Jackman 1998).  
 
 
 
Figure 1.7 - Peritoneal membrane structure. Section of the peritoneal 
membrane showing the mesothelial layer and interstitium, which are 
separated by a discontinuous base layer. Figure also displays cells and 
proteins found in these layers.  
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1.4 The peritoneal inflammatory response  
1.4.1 Immune cells present in the peritoneal cavity and their response to a 
bacterial infection 
Different cell subsets present in the peritoneal cavity can act to produce an 
immunological response due to injury or infection. The main cell types present in a 
naive mouse cavity are mesothelial cells, resident macrophages and resident B1 
cells. Other cell subsets such as NK cells, NKT cells, T cells, eosinophils and mast 
cells are also present but at lower numbers in the cavity (Turchyn, Baginski et al. 
2007; Kolaczkowska 2010; Kolaczkowska, Koziol et al. 2010). 
During a bacterial challenge acute peritoneal inflammation is provoked when foreign 
material is detected by TLRs which promotes the release of pro-inflammatory 
cytokines (i.e. TNFα and IL1) by resident leukocytes such as resident macrophages 
(Turchyn, Baginski et al. 2007). These pro-inflammatory cytokines can act to release 
inflammatory mediators including neutrophil chemoattractants, which have a          
N-terminal tripeptide sequence of glutamic acid, leucine and arginine (ELR+ motif) 
(Hartmann, Tschettier et al. 1997; Zabel, Zuniga et al. 2006). ELR+ chemoattractants 
lead to an initial influx of neutrophils from the peripheral blood into the cavity 
(Figure 1.8) (Hurst, Wilkinson et al. 2001; McLoughlin, Witowski et al. 2003; 
McLoughlin, Hurst et al. 2004; Jones 2005). Other inflammatory mediators may also 
help direct the immune response such as adhesion molecules, which allow strong 
association between leukocytes in the blood and mesothelial cells encouraging 
migration into the cavity (Figure 1.9) (Springer 1990; Jonjic, Peri et al. 1992; 
Suassuna, Dasneves et al. 1994; Liberek, Topley et al. 1996; Hams, Colmont et al. 
2008).  
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Later in the inflammatory response, neutrophils upregulate apoptotic markers on 
their cell surface allowing phagocytosis by resident macrophages and clearance from 
the cavity (Sanui, Yoshida et al. 1982; Savill, Wyllie et al. 1989; Akgul, Moulding et 
al. 2001). Other chemoattractants then cause a shift in the leukocyte subsets 
recruited into the cavity; promoting the influx of monocytes from the peripheral 
blood and a later accumulation of lymphocytes (Figure 1.8) (Topley, Liberek et al. 
1996; Jones 2005). Acute inflammation is then resolved by apoptosis or drainage of 
monocytes into the lymphatic system and the removal of lymphocytes, though the 
mechanism by which they are removed is yet to be established (Bellingan, Caldwell 
et al. 1996; Messmer and Pfeilschifter 2000). 
 
 
 
 
 
 
 
 
 
 
 
Le
uk
oc
yt
e 
In
flu
x 
EARLY PHASE LATE PHASE 
Figure 1.8 - Staphylococcus epidermidis supernatant (SES) induced acute 
inflammation cellular recruitment profile. Induction of acute SES 
inflammation promotes an early phase of inflammation, that is primarily 
made up of an initial influx of neutrophils. This is followed by a later more 
sustained phase of other myeloid and lymphoid cell subset accumulation into 
the cavity. Figure adapted from Jones 2005. 
 
39 
Figure 1.9 - Leukocyte recruitment from the peripheral blood and into the 
peritoneal cavity during inflammation. Following detection of a foreign 
stimulus constitutive expression of adhesion molecules is enhanced on the 
activated endothelium and inducible chemoattractants are released from the 
cavity. These molecules then promote leukocytes to move across the 
endothelium and out of the blood stream by 1) margination, 2) capture, 3) 
rolling, 4) adhesion and 5) transmigration. Leukocytes then pass though the 
interstitium towards the cavity via glycosaminoglycans and the chemotactic 
gradient. Leukocytes then cross the mesothelial layer and enter the cavity by a 
similar mechanism used to leave the blood stream.  
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Repeated episodes of peritoneal inflammation can result in a recurrent inflammatory 
state where activated T cells are maintained in the cavity (Fielding et al. appendix). 
Pro-inflammatory cytokines may act on these T cells encouraging the release of 
IFNγ (Buchan, Taraban et al. 2012; Fielding et al. appendix). This IFNγ can promote 
Signal Transducer and Activator of Transcription 1 (STAT1) signalling by the 
peritoneal membrane increasing chemoattractant production and so stronger 
accumulation of leukocytes (Boehm, Klamp et al. 1997; Gabay 2006; Fielding et al. 
appendix) (Figure 1.10).  
Recruited leukocytes can maintain the inflammatory phenotype by producing more 
pro-inflammatory cytokines, chemokines and degrading factors (Fielding et al. 
appendix). These degrading factors such as MMPs and reactive oxygen species 
(Nitric oxide (NO), Hydrogen peroxide (H2O2)) can lead to tissue damage (Duffield, 
Erwig et al. 2000; Duffield, Ware et al. 2001; Kipari and Hughes 2002; Serbina, 
Salazar-Mather et al. 2003; Gueders, Foidart et al. 2006; Stary, Bangert et al. 2007) 
and Transforming growth factor beta (TGFβ) release to repair the tissue. However 
TGFβ may disrupt the homeostatic turnover of the extracellular matrix promoting 
epithelial to mesenchymal transition (EMT) of mesothelial cells, resulting in 
changes to the structure (fibrosis) of the peritoneal membrane (Bissell, Wang et al. 
1995; Williams, Craig et al. 2002; Selgas, Bajo et al. 2006; Wynn 2007) (Figure 
1.11). 
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Figure 1.11 -  Deterioration of the peritoneal membrane after repeated 
episodes of peritoneal inflammation. The left panel depicts a healthy mouse 
peritoneal membrane prior to any peritoneal inflammation. Whereas the right 
panel demonstrates the transformation of the membrane after multiple 
inflammatory events, characterised by a marked increase in fibrosis 
(thickening) of the mesothelial cell layer. Membrane stained using 
haematoxylin and eosin, bar corresponds to 25μm (MC- mesothelial cell 
layer, SMC- sub mesothelial compact zone). 
 
43 
44 
 
1.4.2 Resident macrophages  
Resident peritoneal macrophages originate in the bone marrow as CD34+ myeloid 
progenitor cells and differentiate into monocytes expressing a CX3CR1Lo CCR2+ 
GR1+ phenotype before being released into the blood stream (Geissmann, Jung et al. 
2003; Gordon and Taylor 2005). Under unchallenged conditions, monocytes can 
switch their phenotypic and functional properties (via an intermediate cellular 
subset) and express a CX3CR1Hi CCR2- GR1- resident phenotype (Sunderkotter, 
Nikolic et al. 2004). These resident monocytes are then recruited into the peritoneal 
cavity by CX3CL1, where they differentiate into resident macrophages restocking 
the residential population (Sunderkotter, Nikolic et al. 2004; Gordon and Taylor 
2005). Maintenance of this local population can also occur by local proliferation of 
these cells in the cavity (Gordon and Taylor 2005; Davies, Rosas et al. 2011). 
Resident macrophages are important in maintaining homeostasis within the cavity by 
removing senescent cells and controlling the process of tissue repair and 
modification (Taylor, Martinez-Pomares et al. 2005).  
When a foreign substance is detected in the cavity, resident macrophages are the first 
cell type to respond and play a key role in directing the innate immune response, 
through the release of pro-inflammatory cytokines (such as TNFα and IL1β) which 
can promote the upregulation of inflammatory mediators including adhesion 
molecules and chemoattractant release by other cell types (Desouza and Ferreira 
1985; Dunn, Barke et al. 1985; Fieren 1996). Peritoneal macrophages are also able 
to directly remove invading organisms from the cavity by phagocytosis. Using 
pattern recognition receptors (PRRs) on their surface e.g. mannose receptors, 
peritoneal macrophages detect conserved molecular patterns known as pathogen 
associated molecular patterns (PAMPs) (Taylor, Martinez-Pomares et al. 2005). 
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Depending on the microorganism peritoneal macrophages are not able to take up 
invading organisms immediately, as some pathogens must first be opsonised 
(enhances binding) by immunoglobulin, C3b and fibronectin. Once this process has 
been completed phagocytosis of the pathogen can occur (Griffin 1981; Holmes 
1994). The exceptions to this rule are the Gram negative bacterium Escherichia coli 
and the Gram positive Staphylococcus aureus as peritoneal macrophages have the 
ability to bind (via immunoglobulin to cell wall protein A of these bacterium) and 
phagocytose these cells directly (Holmes 1994).  
After uptake into the peritoneal macrophage the pathogen is surrounded by a 
vacuole, which is bound by lysosomes in the cytoplasm of the cell. These lysosomes 
contain digestive enzymes that synthesise reactive oxygen (H2O2) and reactive 
nitrogen (NO) species killing the pathogen. Peritoneal macrophages are also able to 
release these proteolytic products into the cavity to increase the removal rate of 
infection or process the products of the now destroyed pathogen to its surface and 
act as an APC. These processed products along with Major histocompatiability 
complex (MHC) class II can then promote the adaptive immune response by 
interacting with T cells inducing their activation, differentiation and proliferation 
(Nathan and Root 1977; Nathan, Silverstein et al. 1979; Sasada and Johnston 1980; 
Nathan and Hibbs 1991; Holmes 1994).  
Peritoneal macrophages are also important in the clearance of recruited leukocytes, 
such as neutrophils once the pathogen has been removed, preventing exacerbated 
inflammation and promoting a return to homeostatic conditions in the cavity (Fadok, 
McDonald et al. 1998). This dampening of inflammatory capabilities is also 
important in reducing the likelihood of an autoimmune response (Pickering, Botto et 
al. 2000). 
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1.4.3 Mesothelial cells 
Mesothelial cells are central to regulating the peritoneal environment and are 
essential in engaging and directing the inflammatory response (Topley, Petersen et 
al. 1994). Following the release of pro-inflammatory cytokines by resident 
peritoneal leukocytes mesothelial cells can release chemokines (such as KC, CCL2 
and CCL5) which produce a gradient promoting the recruitment of leukocytes from 
the circulation into the cavity (Betjes, Tuk et al. 1993; Kinnaert, DeWilde et al. 
1996; Liberek, Topley et al. 1996; Li, Davenport et al. 1998; Visser, Tekstra et al. 
1998; Robson, McLoughlin et al. 2001).  
Pro-inflammatory cytokines also upregulate the expression of InterCellular 
Adhesion Molecule-1 (ICAM-1) (which binds CD11a or CD11b found on all 
leukocytes) and VasCular Adhesion Molecule-1 (VCAM-1) (which binds 
CD49d/CD29 usually found on monocytes) on mesothelial cells, which enhance 
binding of leukocytes to the peritoneal membrane (Jonjic, Peri et al. 1992; Cannistra, 
Ottensmeier et al. 1994; Suassuna, Dasneves et al. 1994; Liberek, Topley et al. 
1996). Variation of these adhesion molecules may also allow mesothelial cells to 
selectively regulate the type of cells recruited into the cavity, e.g. decreasing 
neutrophil attachment and increasing monocyte/macrophage binding, through 
increasing the proportion of VCAM-1 receptors compared to ICAM-1 receptors 
present on the peritoneal membrane cell surface (Springer 1990; Liberek, Topley et 
al. 1996).  
Cell migration across the peritoneal membrane is further increased by prostaglandins 
(PGI2 and PGE2), which mesothelial cells enhance by amplifying the levels of 
transcription and translation of Cyclooxygenase-2 (Cox-2) mRNA. These 
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prostaglandins augment the permeability of the peritoneal membrane itself allowing 
easier passage of leukocytes into the cavity (Coene, Vanhove et al. 1982; Steinhauer 
and Schollmeyer 1986; Topley, Petersen et al. 1994).  
Mesothelial cells also assist the acquired immune response by the presentation of 
foreign antigens on their surface and activating leukocytes in the cavity. When a 
pathogen invades the peritoneal cavity, IFNγ release acts on mesothelial cells to 
upregulate the number of MHC class II molecules and human lymphocyte       
antigen-DR (HLA-DR) on their cell surface and in conjunction with IL15 
encourages the activation and proliferation of B, T and NK cells (Valle, 
Deglinnocenti et al. 1995; Gjersten, Saeterdal et al. 1996; Hausmann, Rogachev et 
al. 2000).  
 
1.4.4 Neutrophils  
Neutrophils develop from myeloid progenitors in the bone marrow and move into 
the circulatory system, where they are present at high concentrations. Neutrophils 
are incapable of proliferating, have a limited life span (~3 days) and are programmed 
to apoptose when recruited into tissues (Akgul, Moulding et al. 2001). Whilst 
neutrophils are not found in the naive cavity, they are the first cell subset to be 
recruited into the cavity from the peripheral blood during the innate immune 
response after the invasion of a pathogen (Hurst, Wilkinson et al. 2001; 
McLoughlin, Witowski et al. 2003; McLoughlin, Hurst et al. 2004; Jones 2005). 
Neutrophils accumulate due to the rapid release of the chemoattractant CXCL8 by 
mesothelial cells and the upregulation of adhesion molecules on the mesothelial cell 
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surface, which promote margination and transmigration into the cavity (Borregaard 
and Cowland 1997). 
Once in the cavity neutrophils remove invading organisms by phagocytosis and 
destroy them intracellularly using digestive enzymes. Additionally granules 
(containing more antimicrobial proteins e.g. β defensins) present within the 
neutrophil release their contents into the cavity, killing more of the pathogen 
(Borregaard and Cowland 1997; Faurschou and Borregaard 2003; Dale, Boxer et al. 
2008). TLR4 activated platelets can also promote the release of neutrophil 
extracellular traps (NETs) from neutrophils into the cavity. NETs are made of 
chromatin and serine protease, which produce a dense region of antimicrobial 
products that can attach to and destroy pathogens and possibly provide a physical 
barrier reducing the dissemination of microbes (Brinkmann, Reichard et al. 2004; 
Clark, Ma et al. 2007).  
Aside from pathogen removal, neutrophils can also promote the accumulation of 
myeloid and lymphocytic leukocytes involved in the inflammatory response by 
secreting cytokines (such as TNFα, IL1β) and chemoattractants (such as CCL3, 
CCL4 and CXCL10) whilst in the cavity (Kasama, Strieter et al. 1993; Kasama, 
Strieter et al. 1994; Cassatella, Gasperini et al. 1997; Cassatella, Gasperini et al. 
1997; Scapini, Lapinet-Vera et al. 2000; Molesworth-Kenyon, Popham et al. 2012).  
 
1.4.5 Inflammatory macrophages  
Inflammatory macrophages are produced in the bone marrow from the same CD34+ 
myeloid progenitor cells as resident macrophages (Geissmann, Jung et al. 2003). 
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However when these cells are released into the circulation they maintain their 
inflammatory CX3CR1Lo CCR2+ GR1+ phenotype, so are not chemotactically 
recruited into the peritoneal cavity during naive conditions (Geissmann, Jung et al. 
2003; Gordon and Taylor 2005).  
During inflammatory conditions these monocytes are recruited via the release of 
chemoattractants by mesothelial cells and other leukocytes in the cavity, such as 
neutrophils and extravasation is promoted by the upregulation of adhesion molecules 
(Springer 1990; Geissmann, Jung et al. 2003; Jones 2005; Auffray, Fogg et al. 
2007). Once in the cavity inflammatory monocytes undergo maturation into 
inflammatory macrophages and eliminate the pathogen by equivalent processes to 
resident macrophages (Section 1.4.2) (Gordon and Taylor 2005; Gordon 2007). 
However inflammatory macrophages have a much greater destructive action than 
their resident counterparts (Taylor and Gordon 2003; Gordon and Taylor 2005). 
Once the infection is cleared, inflammatory macrophages are believed to be removed 
from the cavity by either apoptosis or drainage into the lymphatic system (Bellingan, 
Caldwell et al. 1996; Messmer and Pfeilschifter 2000). 
 
1.4.6 Peritoneal lymphocytes  
B cells are the most common lymphocytic cells found in the naive cavity and these 
can be further split into the abundant resident B1 cells and more scarce infiltrating 
B2 cells. In addition to B cells a small population of other resident lymphocytes are 
also found in the naive cavity; including CD4+ T, CD8+ T, γδ T, NK and NKT cell 
subsets (Hastings, Tumang et al. 2006; Turchyn, Baginski et al. 2007; 
Kolaczkowska, Koziol et al. 2009).  
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It has been suggested that some of these resident lymphocytes may be produced 
independently of the thymus in lymphoid structures known as milky spots, present in 
the omentum of the peritoneal membrane (Borisov 1964). These cells may also 
undergo differentiation within the peritoneal cavity i.e. producing T cells which 
present the homodimer surface marker CD8α+β- (Hartmann, Maassen et al. 1995). 
However the bulk of resident lymphocytes present within the cavity undergo 
development in the bone marrow and thymus. Recruitment into the cavity then 
occurs by the release of chemokines, and migration aided by adhesion molecules 
(ICAM-1 and VCAM-1) on mesothelial cells (Springer 1990; Cannistra, 
Ottensmeier et al. 1994; Visser, Tekstra et al. 1998; McLoughlin, Jenkins et al. 
2005). Further accumulation of these lymphocytes can occur during an inflammatory 
response, which if maintained can result in the development of a recurrent 
inflammatory state that may promote T cell differentiation into mature Th1 cells and 
IFNγ release (Jones 2005; Fielding et al. appendix). 
 
1.5 Chemokines  
Chemokines are a specific group of related cytokines which vary from 8-14 kDa in 
size and are responsible for regulating inflammatory leukocyte subset activation and 
migration (Strieter, Standiford et al. 1996; Baggiolini and Loetscher 2000), by 
interacting with 7 transmembrane G protein coupled receptors and are vital for host 
defence (Wu, Larosa et al. 1993; Kuang, Wu et al. 1996). Chemokines also fulfil an 
important function in maintenance of a steady state environment, expansion and 
cancer metastasis (Baggiolini and Loetscher 2000; Zlotnik and Yoshie 2000).  
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Chemokines can be separated into 4 subsets, based on the location of their               
N-terminal cysteines, which are highly conserved and important in tertiary structure 
formation. Cysteines are either found next to each other (CC chemokines), separated 
by a single amino acid (CXC chemokines), 3 amino acids (CX3C chemokine), or 
have only one N-terminal cysteine (XC chemokines) (Houck and Chang 1977; 
Adams and Lloyd 1997; Baggiolini, Dewald et al. 1997; Bazan, Bacon et al. 1997; 
Baggiolini 1998; Segerer, Nelson et al. 2000; Zlotnik and Yoshie 2000) (Figure 
1.12). 
All chemokines can be viewed as either constitutive or inducible, though there is 
crossover in function of most. Constitutive chemokines (CCL12, CCL17, CCL25 
and CXCL12) are important in maintaining homeostasis by controlling leukocyte 
movement into secondary tissues. Inducible chemokines, however, are secreted in 
reaction to an infectious or immune response and are charged with regulating 
leukocyte chemotaxis to the site of inflammation.  
 
 
 
 
 
 
 
 
N
eu
tr
op
hi
l  
B 
ce
ll 
Im
m
at
ur
e 
D
Cs
 
M
at
ur
e 
D
Cs
 
M
on
oc
yt
es
 
Eo
si
no
ph
ils
 
Ba
so
ph
ils
 
N
ai
ve
 T
 c
el
ls
 
M
em
or
y 
T 
ce
lls
 
Th
1 
T 
ce
lls
 
Th
2 
T 
ce
lls
 
Tr
eg
 T
 c
el
ls
 
N
K 
ce
lls
 
M
as
t c
el
ls
 
Family 
CXC 
CC 
XC 
CX3C 
IL8 
GCP2 
NAP2 
ENA78 
GROα 
GROβ 
GROγ 
PF4 
IP10 
Mig 
ITAC 
SDF1α/β 
BCA1 
 
BRAK 
MCP1 
MCP4 
MCP3 
MCP2 
MIP1β 
MIP1αS 
MIP1αP 
RANTES 
MIPIF1 
HCC1 
HCC2 
HCC4 
Eotaxin 
Eotaxin2 
Eotaxin3 
TARC 
MDC 
MIP3α 
ELC 
SLC 
I309 
TECK 
MEC 
PARC 
Lymphotactin 
SCM1β 
Fractalkine 
CXCL8 
CXCL6 
CXCL7  
CXCL5 
CXCL1 
CXCL2 
CXCL3 
CXCL4 
CXCL10 
CXCL9 
CXCL11 
CXCL12 
CXCL13 
CXCL16 
CXCL14 
CCL2 
CCL13 
CCL7 
CCL8 
CCL4 
CCL3 
CCL3LI 
CCL5 
CCL23 
CCL14 
CCL15 
CCL16 
CCL11 
CCL24 
CCL26 
CCL17 
CCL22 
CCL20 
CCL19 
CCL21 
CCL1 
CCL25 
CCL27 
CCL18 
XCL1 
XCL2 
CX3CL1 
CXCR1 
CXCR2 
CXCR3 
CXCR4 
CXCR5 
CXCR6 
Unknown 
CCR2 
CCR5 
CCR1 
CCR3 
CCR4 
CCR6 
CCR7 
CCR8 
CCR9 
CCR10 
Unknown 
XCR1 
CX3CR1 
Receptor Chemokine 
Old name New name 
Main leukocyte target 
Figure 1.12 - Chemokines and the chemokine receptors which they bind. 
Chemokines  (new classification- light blue text, old classification- dark blue 
text) and their receptors (red text) can be subdivided into 3 separate families  
CXC, CC, XC and CX3C (green text). Many of these chemokines, especially 
in the CC family are able to bind many different chemokine receptors 
allowing them to recruit different leukocyte subsets depending on the context 
of inflammation. Figure adapted from Viola & Luster 2007. 
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1.5.1 CXC chemokines  
The CXC chemokine subset can be further subdivided into 2 groups by the presence 
(or lack) of an ELR motif located at the N terminus prior to the first cysteine. CXC 
chemokines that are ELR+ (CXCL1-8) are important very early during an 
inflammatory event and bind the chemokine receptors CXCR1 and CXCR2, that are 
found on neutrophils promoting their movement into the tissue (Strieter, Burdick et 
al. 2005). Once neutrophils reach the site of inflammation, ELR+ CXC chemokines 
can further aid the immune response by encouraging neutrophil degranulation, the 
release of proteolytic enzymes and activation of the respiratory burst through 
NADPH oxidase (Jones, Wolf et al. 1996; Jones, Dewald et al. 1997).  
ELR- CXC chemoattractants are predominantly inducible chemokines important in 
recruiting lymphocyte subsets during an inflammatory event, by binding the 
chemokine receptors CXCR3 (bound by CXCL9-11) and CXCR5 (bound by 
CXCL13). However the ELR- CXC chemokine CXCL12 differs from other ELR- 
CXC chemokines in that it is constitutive. CXCL12 binds CXCR4, which is found 
on a variety of cell types and concerns itself with homeostatic control such as 
lymphocyte maturation and directly progenitor cells into the correct areas of the 
bone marrow (Baggiolini 1998; Lapidot, Dar et al. 2005).  
 
1.5.2 CC chemokines 
CC chemokines are the largest subset of chemokines and even more promiscuous 
than any of the other chemokine families. This allows them to act on a greater 
variety of cell types including monocytes, basophils, eosinophils, T cells, NK and 
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NKT cells. Release of inducible CC chemokines (CCL2, CCL8, CCL11 and CCL5) 
after an inflammatory stimulus promotes the movement of these cell subsets to the 
site of infection. Constitutive CC chemokines (CCL12, CCL17 and CCL25) are 
released in the lymph node, thymus and other lymphoid tissues and are required to 
direct T cell movement to secondary lymph nodes (Baggiolini 1998; Kim, Pelus et 
al. 1998). 
 
1.5.3 CX3C and XC chemokines 
Both of these 2 subsets of chemokines only have one member. CX3CL1 is the 
member of the CX3C subset and in addition to having 3 amino acids separating its 2 
N-terminal cysteines, it is also the only identified membrane-bound chemokine 
(attached by a mucin stalk) and functions as both a chemokine and an adhesion 
molecule.  
XCL1 is in turn the only member of the XC chemokine subset (though it does share 
homology with the CC subset of chemokines) and has lost 2 of the 4 cysteines 
present in all other chemokines, 1 of which is one of the 2 N-terminal cysteines 
which are used to characterise chemokine subsets.  
 
1.5.4 Chemokine receptor/ligand interaction and subsequent downstream 
signalling  
There are 7 transmembrane domain G protein coupled receptors that bind all known 
chemokines (Wu, Larosa et al. 1993; Kuang, Wu et al. 1996; Murdoch and Finn 
2000). Many receptors can bind multiple chemokines, thus individual chemokines 
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are capable of the recruitment of more than one cell subset so regulation of receptor 
expression on cells is vital to ensure specificity of chemokine action (Kuang, Wu et 
al. 1996; Segerer, Nelson et al. 2000; Moser, Wolf et al. 2004). In addition to these 
classical receptors there are a small number of atypical chemokine receptors (such as 
Duffy antigen receptor for chemokines (DARC), D6, CXCR7 and CCXCKR) which 
are defined by an apparent absence in signalling after chemokine binding. This lack 
of signalling in atypical chemokine receptors is predominantly due to a missing or 
modified DRYLAIV motif (located in the second intracellular loop of the receptor) 
which is important in connecting the receptor to the G protein. However these 
atypical chemokine receptors can impact chemokine/receptor interactions by acting 
as internalising receptors that either; 1) take up and degrade chemokines (such as 
D6) or 2) transfer internalised chemoattractants through biological barriers (DARC) 
(Mantovani, Locati et al. 2001; Graham 2009; Ulvmar, Hub et al. 2011).  
When a chemokine binds its ligand the extracellular section of the receptor changes 
shape, permitting the intracellular section to stimulate the G protein. The G protein 
is made up of 3 subunits (α,β and γ) and after chemokine binding the exchange of 
GDP for GTP leads to the separation of the α subunit from the βγ complex. This split 
can activate other intracellular pathways including increased intracellular calcium, 
activation of the MAP3K pathway, Phosphatidylinositol 3-kinase (PI3K) and NFκβ 
pathway (Murdoch and Finn 2000; Rossi and Zlotnik 2000). 
 
1.6  Aims 
There were 3 primary aims of this thesis that can be summarised as follows: 
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• Examine TL1A and DR3 expression patterns in the peritoneal cavity. The 
expression profile of DR3 was determined on leukocytes and on the stroma in 
the naive cavity and whether this expression changed after the induction of an 
acute Staphylococcus epidermidis supernatant (SES) induced inflammatory 
event was investigated. The peritoneal membrane and resident macrophages 
were also investigated as potential sources of TL1A following the induction of 
acute inflammation.   
 
• Investigate the role of DR3 in the peritoneal cavity during; (i) homeostasis, 
(ii) innate inflammation and (iii) repeated inflammation using an in vivo 
experimental mouse model of SES induced inflammation. Resident 
peritoneal and peripheral blood leukocytes were characterised in DR3-/- mice 
and compared to DR3+/+ mice, to determine if DR3 played a role in maintaining 
homeostasis. The potential role of DR3 in the accumulation of leukocytes during 
the early and late phase of innate inflammation were then examined by 
challenging with SES. Any DR3-dependent affects on fibrosis of the mesothelial 
layer were then studied following repeated induction of inflammation.  
 
 
• Establish the mechanism DR3 may utilise to affect the numbers of specific 
leukocyte subsets during acute inflammation. Cell subset proliferation and 
chemokine levels from supernatants were determined in DR3-/- mice and 
compared to DR3+/+ mice following SES challenge. The peritoneal membrane 
was also investigated as a potential source of chemoattractants in DR3+/+ mice 
and how this may vary in DR3-/- mice during acute inflammation.   
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Chapter 2 - Materials and Methods 
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2.1 Reagents  
2.1.1 Chemicals  
All chemicals were purchased from Sigma-Aldrich Co. Ltd (Poole, Dorset) unless 
otherwise stated 
 
2.1.2 Solutions  
Orange G (DNA loading buffer)  
2.5 mg/ml Orange G loading dye in 2x Tris/Borate/EDTA (TBE) containing 30 % 
(w/v) glycerol 
 
Eosin solution  
10 mg/ml Eosin dissolved in distilled H2O  
 
FACS buffer  
PBS containing 1 % (v/v) Foetal calf serum (FCS) and 2 mM EDTA  
 
Freezing Medium  
90 % (v/v) FCS and 10 % (v/v) Dimethyl sulfoxide (DMSO) 
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Lysis buffer  
0.5 ml 50 mM TRIS-HCl (pH 8), 1ml 10 % (w/v) SDS, 2 ml 0.5M EDTA, 1 ml 1 M 
NaCl, 100 μl 10mg/ml proteinase K (Roche), 5 ml distilled H2O  
 
10 % Neutral Buffered Formal Saline (NBFS) 
3.7 % (w/v) Formaldehyde, 46 mM Sodium phosphate dibasic (Na2HPO4) 
 
Phosphate Buffered Saline (PBS) 
0.8 % (w/v) sodium chloride, 0.2 % (w/v) potassium chloride, 0.12 % (v/v) 
anhydrous sodium hydrogen phosphate at pH 7.4  
 
Wash Buffer (PBS-Tween20) 
PBS containing 0.05 % (v/v) Tween20  
 
RAW 264 Culture medium  
Dulbecco’s Modified Eagle’s Medium-10 (DMEM-10) (Invitrogen Ltd, Paisley, 
UK) with 10 % (v/v) FCS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 U/ml 
Streptomycin, 5 mg/ml Insulin/Transferrin and 0.4 mg/ml Hydrocotisone. 
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TBE (10X) 
54 g TRIS, 27.5 Boric acid dissolved in distilled H2O to final volume of 990 ml and 
10 ml 1M EDTA pH 8 added.  
 
TBE agarose gel 
1x TBE containing 1.6 % (w/v) agarose  
 
Tris Buffered Saline (TBS)  
0.05 M Tris, 0.15 M NaCl pH 7.6 
 
2.2 Animals and in vivo experiments  
2.2.1 Housing conditions and Home Office approval  
All animals were housed in the Joint Biological Services Unit (at Heath Park, Cardiff 
University) at a room temperature range of 18-23 ˚C and a relative humidity of 55 ± 
10 % on a 12 hour light/dark cycle. Animals were kept in filter top containers until 
they were transferred to conventional housing for intra-peritoneal (i.p.) 
administration of SES. Food and water was available to the animal’s ad libitum, as 
well as environmental enrichment in the form of cardboard tubes. DR3+/+ and DR3-/- 
animals were bred in house on a C57/BLK6J background. All experimental 
procedures complied with the Home Office approved licence 30/2401.  
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2.2.2 Genotyping  
2.2.2.1 DNA extraction 
Ear punches were lysed at 56 ˚C overnight in lysis buffer, DNA was extracted by the 
addition of 310 μl 5M sodium chloride (NaCl), which was vortexed and left at room 
temperature for 1 hour. This was centrifuged at 13000 rpm for 25 minutes, and       
800 μl of the aqueous phase was removed and added to 500 μl of chilled (-20 ˚C) 
isopropanol. This was vortexed and centrifuged at 13000 rpm for 10 minutes. The 
supernatant was removed and the pellet resuspended in 500 μl of 70 % ethanol for     
30 minutes at room temperature. This was centrifuged at 13000 rpm for 10 minutes 
and supernatant removed. Any remaining ethanol was removed by air-drying for       
1 hour at 37 ˚C. The remaining pellet was resuspended in 50 μl distilled H2O (for 
longer storage resuspended in 10 mM Tris) and incubated at 37 ˚C for 3 hours.  
 
2.2.2.2 Genotyping PCR 
Using thin walled PCR tubes, 8 µl of the DNA extracted (Section 2.2.2.1) was added 
to 20 µl of distilled H2O. A master mix was made up consisting of 5 µl 
Deoxynucleotide triphosphates (dNTPs), 4 µl 10x PCR buffer, 1.2 µl of Magnesium 
chloride (MgCl2) , 0.2 µl 100 μM Av1 primer, 0.4 µl 100 μM 4F primer, 0.8 µl      
100 μM 2R primer and 0.5 µl Taq DNA polymerase per sample. This master mix 
(12.1 µl) was aliquoted into the PCR tubes and the samples were run on a 
thermocycler (Hangzhou Long Gene Scientific Instruments Co, Zhejiang, China) 
using the following program.  
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Primers: 
Av1- 5’ CAT CGC CTT CTA TCG CCT TC 3’ 
2R- 5’ GAA AGG ATG AAA CTT GCC TGT TGG 3’  
4F- 5’ AGA AGG AGA AAG TCA GTA GGA CCG 3’ 
 
Thermocycling program:  
Denaturation:  94 ˚C for 5 minutes                      
Annealing:  62.5 ˚C for 30 seconds    1 cycle  
Extension:  72 ˚C for 40 seconds 
 
Denaturation:  94 ˚C for 30 seconds                      
Annealing:  62.5 ˚C for 30 seconds    33 cycle  
Extension:  72 ˚C for 40 seconds 
 
Denaturation:  95 ˚C for 30 seconds                      
Annealing:  62.5 ˚C for 30 seconds    1 cycle  
Extension:  72 ˚C for 5 minutes 
 
63 
 
After completion of the PCR protocol, DNA from the samples was separated by size 
using gel electrophoresis. Samples were mixed with 4 µl of Orange G loading buffer 
and 20 µl of each sample was loaded onto a 1.6 % gel (v/v), which included 7.5 µl of 
ethidium bromide, this gel was submerged under 1x TBE buffer in a gel tank. The 
samples (including a positive and negative control) along with a 100 base pair (bp) 
DNA ladder were run for 90 minutes at 100 volts and visualised under UV light 
(Ultra-Violet Products Ltd, Trinity Hall Farm Estate, Cambridge, UK) (Figure 2.1).    
 
2.2.3 Harvesting of peripheral blood and intra-peritoneal cell populations  
2.2.3.1 Intra-peritoneal lavage 
Mice were sacrificed using a rising concentration of carbon dioxide (CO2), followed 
by cervical dislocation (schedule 1). The peritoneal membrane was exposed by 
removing the skin over the abdomen. A ventflon 2 intra-venous cannula (18 gauge 
(G), 45 mm) (Becton Dickinson Ltd, Cowley, Oxford, UK) was inserted through the 
abdominal wall and into the cavity, the intra-venous cannula was removed leaving 
the ventflon in the cavity. The peritoneal cavity was lavaged using a 2.5 ml syringe 
(Becton Dickinson Ltd, Cowley, Oxford, UK) containing 2 ml of PBS, which was 
attached to the plastic injection port of the ventflon and plunger depressed. Fluid was 
allowed to reside in the cavity for 30-60 seconds and then as much as possible       
(1.7 ml-2.0 ml) was recovered into the 2.5 ml syringe via the ventflon and stored on 
ice in a 2 ml eppendorf tube (Greiner Bio One Ltd, Stonehouse, UK).   
 
 
1Kb Ladder Samples 
400bp 
300bp 
DR3-/- DR3+/- DR3+/+ 
Figure 2.1 – DR3 genotyping PCR gel. Sample DNA was separated by size 
using gel electrophoresis (1.6% TBE agarose gel (v/v) and 7.5μl of ethidium 
bromide, submerged in 1x TBE buffer) and visualised under UV light. DR3+/+ 
mice were identified by one band at a molecular weight of 280bp, which equates 
to the DR3 gene coding region. DR3-/- mice were identified by one band at a 
larger molecular weight of 320bp, that equates to the inserted construct which 
replaced the DR3 gene. DR3+/- mice were identified by two bands, which are 
made up of both the DR3+/+ band (280bp) and DR3-/- band (320bp) as DR3+/- mice 
contain both DR3+/+ and DR3-/- alleles.  
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2.2.3.2 Cardiac puncture 
Mice were sacrificed using a rising concentration of CO2 followed by cervical 
dislocation (schedule 1). The heart was exposed by pinning back the rib cage and a 
25 G, 16 mm needle (Becton Dickinson Ltd, Cowley, Oxford, UK) containing 1 μl 
of heparin, attached to a 2.5 ml syringe (Becton Dickinson Ltd, Cowley, Oxford, 
UK) was inserted into the heart ventricle. Blood was collected in the syringe by 
maintaining a constant pressure by slowly pulling back the syringe plunger, to avoid 
collapsing the heart. As much blood as possible was extracted into the syringe and 
stored on ice in a 2 ml eppendorf tube.   
 
2.2.4 Determination of peritoneal leukocyte numbers 
Total number of peritoneal leukocytes present in each peritoneal lavage sample was 
counted using a Coulter counter Z2 (Beckman Coulter UK Ltd., Oakley Court, High 
Wycombe, UK). Well-mixed lavage (20 µl) was diluted in 20 ml of isoton 2 
balanced electrolyte solution (Beckman Coulter UK Ltd., Oakley Court, High 
Wycombe, UK) in a Coulter vial and inserted into the machine. From this, 2 counts 
were taken and averaged to give the number of cells per ml.   
 
2.2.5 S. epidermidis supernatant (SES) 
2.2.5.1 Preparation of S. epidermidis supernatant 
A stored S. epidermidis stock (from the peritoneal effluent of a peritonitis patient), 
on Dorset egg medium slopes (Oxoid, Basingstoke, UK) was used to inoculate a 
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Diagnostic Sensitivity testing (DST) agar plate (Oxoid, Basingstoke, UK) and 
incubated at 37 ˚C (Heraeus Instruments, Buckinghamshire, UK) for 48 hours. A 
single colony of S. epidermidis (white circular colony) was inoculated into 500 ml of 
Nutrient broth 2 (Oxoid, Basingstoke, UK) and incubated overnight at 37 ˚C with 
shaking (170 rpm). The bacterial culture was centrifuged at 4000 g for 20 minutes at 
20 ˚C (Sorvall Laboratory Centrifuges, Buckinghamshire, UK). The supernatant was 
removed and bacteria (pellet) resuspended in Tyrodes salt solution (Sigma-Aldrich 
Co. Ltd, Poole, Dorset, UK) until an optical density (using a Beckman DU-64 
spectrophotometer, Beckman Coulter UK Ltd., Oakley Court, High Wycombe, UK) 
of 0.5 at 560 nm was achieved (which is equivalent 5x108 colony forming units/     
per ml) and incubated for 24 hours at 37 ˚C.  
The bacterial culture was centrifuged at 4000 g for 30 minutes at 20 ˚C and the 
supernatant removed and filter sterilised (0.22 μl Stericup filter bottle, Millipore, 
Livingston, UK) to eliminate any remaining live bacteria. Once filtered, excess salts 
in the solution were removed by transferring 60 ml aliquots of the solution into 
dialysis membrane tubing (Medicell International Ltd, London, UK), which was 
fastened at either end and placed in water (at a ratio of 2 tubes/5 litres). The water 
was changed 4 times every 12 hours, to maintain the osmotic gradient. This final 
solution was pooled and dispensed into 10 ml aliquots which were freeze dried and 
kept at -70 ˚C until use.   
 
2.2.5.2 S. epidermidis supernatant activity bioassay  
To replicate levels of SES activity between in vivo experiments SES activity was 
standardised. To assess this, SES induced IL6 release from the mouse macrophage 
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cell line RAW 264 (European Collection of Cell Cultures, Sailsbury, Wiltshire) was 
measured using a commercially available ELISA (Figure 2.2).  
 
2.2.5.3 RAW 264 mouse macrophage culture 
RAW 264 cells were cultured in 75 cm2 cell culture flasks (Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) containing supplemented DMEM-10 
(Invitrogen Ltd, Paisley, UK). These cells were kept in a humidified incubator in an 
atmosphere of 5 % CO2. Cells were passaged every 3-4 days, using 5 ml 0.05 % 
Trypsin-EDTA (Invitrogen Ltd, Paisley, UK) to detach cells from the surface of the 
flask. Once detached the Trypsin-EDTA was inactivated by the addition of 10 ml of 
fresh supplemented DMEM-10.  
Once a density of 7.5x104 cells/ml was reached, RAW 264 cells were seeded into    
24 well plates in 1 ml volumes of DMEM-10 and were allowed to adhere for 3 
hours. A freeze dried aliquot of SES was reconstituted with DMEM-10 and serial 
dilutions prepared (Dilutions- Neat, 1/2, 1/10, 1/50, 1/100). These SES dilutions 
were added to the RAW 264 cells and along with an unstimulated negative control 
incubated for 24 hours. Supernatants were then collected in eppendorfs and stored at 
-70 ˚C until quantitation for IL6 by ELISA (Figure 2.2).  
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Figure 2.2 – In vitro bioactivity assay of S. epidermidis supernatant (SES) 
on RAW 264 cells. A) RAW 264 cells (a mouse leukaemic monocyte-
macrophage cell line) were used to test each batch of SES before its use in 
vivo, this was accomplished by stimulating RAW 264 cells at a density of 
7.5x104 cells/ml with several dilutions of SES (Neat, 1/2, 1/10, 1/50, 1/100 
and a negative DMEM control). After a 24 hour incubation, supernatants were 
removed and SES quantified by measuring IL6 levels by ELISA (each symbol 
represents IL6 production per 7.5x104 RAW 264 cells/ml). B) Optical density 
(OD) was measured at 450 nm using a FLUOstar microplate reader (Omega 
BMG Labtech), IL6 levels were then calculated from the OD using IL6 
standards to plot a standard curve, producing a linear equation                                                
(Y= 294.23 x -10.43, R2 = 0.9957). This equation was used to calculate IL6 
concentration from the optical density.  
Optical Density (450nm) 
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2.2.5.4 Cryopreservation of cells  
Cells were put into suspension using Trypsin-EDTA and centrifuged at 400 g for      
4 minutes. The supernatant was poured away and cells resuspended in freezing 
media and aliquoted into cryovials at 1x106 cells per ml. All cryovials were placed in 
a Nalgene 5100 Cryo 1 ˚C freezing container containing isopropanol at room 
temperature and left in a -70˚C freezer overnight. Cryovials were then moved into 
liquid nitrogen storage. 
 
2.2.6 Intra-peritoneal administration of S. epidermidis supernatant 
Before all injections, all animals were gently scruffed to expose the abdominal area. 
SES (500 μl) (which was prepared under sterile conditions in a MicroFlow 
Biological class 2 safety cabinet) was injected i.p. using a 1 ml syringe (Becton 
Dickinson Ltd, Cowley, Oxford, UK) attached to a 25 G, 16 mm needle (Becton 
Dickinson Ltd, Cowley, Oxford, UK). I.p. injections were made into the lower 
abdomen, (avoiding the bladder) using the line of the hip as a guide to run parallel 
with the abdominal skin surface. Post injection, animals were placed in a separate 
cage where their recovery was observed.   
 
2.2.6.1 Acute model of SES induced peritoneal inflammation  
Each mouse received a single i.p. injection of 500 μl of SES as outlined above. Mice 
were sacrificed by schedule 1 at 8 defined time points over a 96 hour time course and 
the contents of the peritoneal cavity collected by peritoneal lavage (Section 2.2.3.1) 
and membrane collected by snap freezing in liquid nitrogen.  
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2.2.6.2 Recurrent model of SES induced peritoneal inflammation  
Repeated inflammation was induced in mice by 4x 500 μl i.p. injections of SES 
(administered as outlined in Section 2.2.6) over the time course. Each mouse 
received one i.p. injection per week for 4 weeks (injections administered on day 0, 7, 
14 and 21) and aged to the endpoint (day 49) of the time course. Mice were 
sacrificed by schedule 1 and the contents of the peritoneal cavity collected by lavage 
(Section 2.2.3.1) and membrane collected and fixed using 10 % neutral buffered 
formal saline (NBFS) (Section 2.6.1).  
 
2.3 Phenotypic analysis of peritoneal leukocytes using flow cytometry  
2.3.1 Preparation of peritoneal leukocytes for flow cytometry 
Peritoneal leukocytes were harvested from the cavity of mice as previously described 
in Section 2.2.3.1. These leukocytes were isolated by centrifugation at 1600 g for      
2 minutes in 15 ml centrifuge tubes (Corning B.V. Life Sciences, Amsterdam, 
Netherlands). The supernatant was removed without disturbing the cell pellet and 
frozen down at -70 ˚C for chemokine testing. The cell pellet was resuspended in 1 ml 
of FACS buffer and 200 μl of cells were added to the assigned well of a U bottomed 
96 well plate (NUNC A/S Roskilde, Denmark).  
 
2.3.2 Staining of peritoneal leukocytes with fluorochrome conjugated antibodies 
Once peritoneal leukocytes had been transferred to the U bottomed 96 well plate 
they were centrifuged at 1600 g for 2 minutes and supernatant removed without 
disturbing the pellet. Cells were reuspended by gently tapping the plate, followed by 
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the addition of 50 μl of Fc Block (CD16/CD32) diluted (1/200) in FACS buffer to all 
wells and incubated at 4 ˚C for 30 minutes. Cells on the plate were centrifuged at 
1600 g for 2 minutes and supernatant discarded. All primary conjugated antibody 
cocktails were diluted to their optimum concentration (verified by titration) in FACS 
buffer (Table 2.1) and 50 μl was added to the appropriate wells and incubated at 4 ˚C 
for 30 minutes. Identical antibody preparation of isotype control and single colour 
controls were carried out, and only FACS buffer was added to 1 well of cells to 
provide an unstained control sample. The best antibody dilutions were determined by 
antibody dose response titration measurements. After incubation, cells were 
centrifuged at 1600 g for 2 minutes and supernatant removed. Cells were washed       
3 times with 200 μl of FACS buffer and centrifuged at 1600 g for 2 minutes between 
each wash. Where required (DR3 staining) cells were incubated at 4 ˚C for               
30 minutes with a suitable fluorochrome conjugated streptavidin secondary to bind a 
biotinylated primary antibody. Cells were washed 3 times with 200 μl of FACS 
buffer and centrifuged at 1600 g for 2 minutes between each wash. The contents of 
each well were resuspended in 200 μl of FACS buffer and transferred into 
microtubes for analysis via flow cytometry.  
 
2.3.3 Preparation of peripheral blood leukocytes for flow cytometry  
Prior to staining peripheral blood leukocytes, as outlined above in Section 2.3.1 
contaminating red blood cells (RBC) were lysed from the sample. Cells were 
pelleted by centrifuging at 1600 g for 2 minutes, the supernatant was removed and 
cells resuspended in 5 ml of 1x RBC lysis buffer (Biolegend) (diluted 1/10 from a 
10x concentrated stock using deionised water) for 5 minutes on ice. The reaction was 
stopped by adding 20 ml of PBS to the sample; cells were centrifuged at 1600 g for    
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2 minutes and supernatant removed. Peripheral blood leukocytes were resuspended 
in FACS buffer and counted as outlined in Section 2.2.4, 200 μl of cells were added 
to the assigned well of a U bottomed 96 well plate and antibody staining carried out 
as show in Section 2.3.1. 
 
2.3.4 Intracellular staining of peritoneal leukocytes 
Peritoneal leukocytes were fixed in 4 % paraformaldehyde and spun at 1600 g for     
2 minutes, the supernatant was removed and cells permeabilised using 100 μl of 
saponin buffer (500 ml 1x PBS, 2.5 ml 10 % sodium azide, 2.5 g saponin) for          
20 minutes at 4 ˚C. Following permeabilisation cells were centrifuged at 1600 g for        
2 minutes and supernatant removed, cells were reuspended by gently tapping the 
plate. The intracellular antibody was diluted to its optimum concentration (Table 2.1) 
in saponin buffer and 50 μl was added per well and incubated at 4 ˚C for 30 minutes. 
Cells were washed twice with saponin buffer and centrifuged at 1600 g for 2 minutes 
between each wash, a final wash with FACS buffer and spin at 1600 g for 2 minutes 
was carried out and cells resuspended in 200 μl of FACS buffer and transferred into 
microtubes for analysis via flow cytometry. 
 
2.3.5 DR3 staining for analysis of peritoneal leukocytes by flow cytometry  
DR3 staining was achieved following the steps outlined in Section 2.3.1, up to the 
addition of 50 μl of Fc Block (CD16/CD32) in diluted FACS buffer. Following this 
step, cells were resuspended in 200 μl FACS buffer containing 1 % (v/v) normal 
goat serum and incubated for 30 minutes at 4 ˚C. Cells were centrifuged at 1600 g 
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for 2 minutes and supernatant discarded. The biotinylated DR3 antibody (or 
biotinylated Goat IgG isotype control) along with any other primary antibodies were 
added at their optimum concentration (Table 2.1) in FACS buffer containing 0.5 % 
normal goat serum and incubated for 30 minutes at 4 ˚C. The remainder of the steps 
described in Section 2.3.1, including the addition of fluorochrome conjugated 
secondary reagents, were then followed. 
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Table 2.1 - Mouse antibodies used for flow cytometry 
 Antibody Fluorochrome Supplier Clone Catalogue 
Number 
Dilution Isotype 
Target 
Antibody CD19 FITC 
BD 
Pharmingen ID3 557398 1/200 Rat IgG2a 
 MHC 2 (I-A/I-E) 
 FITC 
BD 
Pharmingen 2G9 553623 1/200 Rat IgG2a 
 CD8a 
 FITC 
BD 
Pharmingen 53-6.7 553030 1/100 Rat IgG2a 
 KI67 FITC BD Pharmingen 
MOPC-
21 556026 1/5 
Mouse 
IgG1 
 NK1.1 PE BD Pharmingen PK136 553165 
1/200 
 
Mouse 
IgG2a 
 
B220 (CD45R) PE Invitrogen RA3-6B2 RM2604 
1/200 
 Rat IgG2a 
 Ly-6B.2 PE AbD Serotec 7/4 MCA771PE 1/200  Rat IgG2a 
 Gr-1 PerCP-cy5.5 BD Pharmingen 
RB6-
8C5 552093 
1/500 
 Rat IgG2b 
 
CD4 PerCP-cy5.5 BD Pharmingen RM 4-5 550954 
1/200 
 Rat IgG2a 
 CD11c PE-Cy7 BD Pharmingen CX1 558078 
1/100 
 Rat IgG2b 
 Ly-6G 
 V450 BD Horizon 1A8 560603 1/200 Rat IgG2a 
 CD44 V450 BD Horizon IM7 560452 1/200 Rat IgG2b 
 F4/80 
 APC Invitrogen BM8 MF48005 1/400 Rat IgG2a 
 TCR αβ 
 APC 
Caltag 
Laboratories H57-597 HM3605 1/100 
Hamster 
IgG 
 CD11b 
 APC-Cy7 
BD 
Pharmingen M1/70 557657 1/500 Rat IgG2b 
 CD3 
 APC-Cy7 
BD 
Pharmingen 17A2 560590 1/400 Rat IgG2b 
 DR3 Biotin RnD Systems * BAF2437 1/100 Goat IgG  
Isotype 
Controls 
Rat IgG2a 
 FITC 
BD 
Pharmingen R35-95 554688 
1/100 
 - 
Rat IgG2b 
 PE 
BD 
Pharmingen A95-1 553989 
1/100 
 - 
 Mouse IgG2a 
 APC RnD Systems 20102 IC003A 
1/200 
 - 
 Hamster IgG 
 APC-Cy7 BioLegend HTK888 400927 1/100 - 
 Goat IgG 
 Biotin RnD Systems * BAF108 1/100 - 
Other 
 
CD16/CD32 (Fc 
Block) Purified 
BD 
Pharmingen 2.4G2 553142 
1/200 
 Rat IgG2b 
Streptavidin APC Invitrogen - S-32362 1/500 - 
7AAD - BD Pharmingen     
 
*Polyclonal antibody 
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2.3.6 Flow cytometry acquisition  
Data on peritoneal leukocytes stained with fluorochrome conjugated antibodies were 
collected by running cells (including the unstained, isotype and single colour 
controls) through a Beckman Coulter CyAn™ ADP Analyzer Flow Cytometer 
(Beckman Coulter Ltd, High Wycombe, UK). All analysis and compensation was 
carried out offline in Summit software v4.2 (Beckman Coulter Ltd, High Wycombe, 
UK). 
 
2.3.7 Beckman Coulter CyAn™ ADP Analyzer Flow Cytometer operation 
procedure and cell acquisition  
Operation of the Beckman Coulter CyAn was achieved using the Summit computer 
program. Following the manufacturer’s guidelines a protocol was designed, 
including either histograms or dot plots of the required parameters. Data were 
acquired by placing the sample tube on the probe. Events were collected 
automatically, following an initial boost at the start of acquisition. Once sufficient 
events were acquired, the F2 and F3 keys stopped and saved the sample data 
collected, this was repeated for all samples (all compensation was carried out offline 
and will be addressed later). Once all sample data were collected the flow cytometer 
was shut down. 
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2.3.8 Multi-parameter flow cytometry compensation  
The Beckman Coulter CyAn™ ADP Analyzer Flow Cytometer allows 9 cellular 
markers to be analysed at once providing the emission peaks of different 
fluorochromes are sufficiently separated to be detected by different detectors (Table 
2.2), though the emission tails of neighbouring channels fluorochromes overlap 
(spectral overlap). This was overcome by using the compensation function in the 
Summit software, as outlined by the manufacturer’s instructions. 
 
Table 2.2 - Flow cytometry fluorochromes and related detectors  
 
 
 
 
 
 
Detector  Fluorochrome 
 
 
Abbreviation  Emission peak  
 
Laser Voltage 
FL1 Fluorescein isothiocyanate FITC 
 
521 nm Argon 488 550 
FL2 Phycoerythrin PE 
 
578 nm Argon 488 650 
FL3 Phycoerythrin Texas Red PE Texas Red 
 
615 nm Argon 488 700 
FL4 Peridinin-chlorophyll protein- 
cyanine5.5 
PerCP-cy5.5 695 nm Argon 488 750 
FL5 Phycoerythrin   Cyanine 7 PE cy7 
 
767 nm Argon 488 752 
FL6 Violet 450 V450 
 
448 nm He-Ne 633 600 
FL8 Allophycocyanin  APC 
 
660 nm Violet 405 850 
FL9 Allophycocyanin   Cyanine 7 APC cy7 
 
767 nm Violet 405 900 
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2.3.9 Calculation of peritoneal leukocyte populations  
The previously designed protocol (Section 2.3.7) contained dot plots which divided 
the total leukocyte population into various subsets (Figure 2.3-2.5) using previous 
defined cellular phenotypic markers (Table 2.3), (which are linked to an appropriate 
fluorochrome) on the XY axis. Gates were drawn around the identified 
subpopulation providing the percentage of that subpopulation in the sample. This 
percentage was used to find the total number of that subpopulation in the sample by 
multiplying the subpopulation percentage against the total leukocyte cell count 
(determined in Section 2.2.4).   
 
2.3.10 Cell sorting of resident macrophages 
Cells were harvested from the cavity as described in Section 2.2.3.1 and stained with 
the fluorochrome conjugated antibodies CD11b and F4/80 outlined in Section 2.3.2. 
Leukocytes were then outsourced to Central Biotechnology Services (CBS) for cell 
sorting; this involved passing all leukocytes though a BD Aria flow cytometer which 
separated resident macrophages (CD11b+, F4/80+) from other cell subsets, producing 
a pure population.  
 
 
 
 
 
78 
79 
80 
81 
 
Table 2.3 - Cell markers used to identify phenotype of different cell lineages and 
subsets  
Leukocyte subpopulation Cell markers to split cell subpopulations 
by flow cytometry 
 
T cells 
 
CD3+ / TCR+ 
T helper cells 
 
CD4+ / CD3+ / TCR+ 
T cytotoxic cells 
 
CD8+ / CD3+ / TCR+ 
NK cells 
 
NK1.1+ / TCR- 
NKT cells 
 
NK1.1+ / TCR+ 
B cells 
 
CD19+ / B220+ 
Resident B1 cells 
 
CD19+ / B220int / CD11Bint 
Infiltrating B2 cells 
 
CD19+ / B220+ / CD11B- 
Resident macrophages 
 
F4/80+ / CD11b+ 
 
Inflammatory macrophages 
 
F4/80int / CD11bint 
 
Dendritic cells 
 
F4/80int / CD11b+ / CD11c+ 
Neutrophils 
 
7/4+ / LY6-G+ 
Eosinophils F4/80int / CD11bint/FSC-A + SSC-A 
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2.4 Enzyme linked immunosorbent assay (ELISA) 
All ELISA’s were purchased from R&D systems unless otherwise stated and were 
carried out in accordance with manufacturer’s instructions (see Table 2.4 for 
individual ELISA information). 
 
Table 2.4 - Mouse ELISA assays used 
 
 
 
 
 
Target 1o capture 
antibody conc.  
2o detection 
antibody conc. 
Top 
standard  
Supplier  Product 
Code 
IL-6 
 
1 in 250 1 in 250 1000 pg/mL BD OptEIA 555240 
KC 
 
2.0 µg/mL 200 ng/mL 1000 pg/mL RnD Systems DY453 
MIP-2 
 
2.0 µg/mL 75 ng/mL 1000 pg/mL RnD Systems DY452 
CXCL5 (LIX) 
 
2.0 µg/mL 400 ng/mL 2000 pg/mL RnD Systems DY443 
CXCL10 (IP-10) 
 
2.0 µg/mL 600 ng/mL 4000 pg/mL RnD Systems DY446 
CXCL13 (BCA-1) 1.0 µg/mL 200 ng/mL 
 
1000 pg/mL RnD Systems DY470 
CCL2 (MCP-1) 
 
0.2  µg/mL 50 ng/mL 250 pg/mL RnD Systems DY479 
CCL3 (MIP-1α) 
 
0.4 µg/mL 100 ng/mL 500 pg/mL RnD Systems DY450 
CCL4 (MIP-1β) 
 
4.0 µg/mL 800 ng/mL 1000 pg/mL RnD Systems DY451 
CCL5 (RANTES) 
 
2.0 µg/mL 400 ng/mL 2000 pg/mL RnD Systems DY478 
CCL7 (MCP-3) 
 
1.0 µg/mL 250 ng/mL 1000 pg/mL Antigenix 
America  
RMF328ckc 
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2.4.1 ELISA protocol 
Briefly, flat bottomed 96 well plates were coated with 100 µl of the appropriately 
diluted monoclonal capture antibody in PBS and incubated overnight at 4 ˚C. The 
plate was washed 5 times with wash buffer and knocked on blue roll to remove any 
remaining buffer from the wells. Plates were blocked using 200 µl of 1 % Bovine 
serum albumin (BSA) in PBS for 1 hour at room temperature. Plates were then 
washed 5 times with wash buffer.  
Samples and standards were diluted in 1 % bovine serum albumin (BSA) in PBS and 
100 µl was added to the appropriate wells and incubated at room temperature for       
2 hours. Plates were washed 5 times with 200 µl of wash buffer before adding 100 µl 
of the biotinylated detection antibody diluted in 1 % BSA in PBS for 2 hours at room 
temperature. Wells were washed a further 5 times with wash buffer and 100 µl of 
streptavidin-horse radish peroxidise (HRP) diluted 1/200 in 1 % BSA in PBS was 
added for 20 minutes at room temperature. Plates were washed a final 5 times with 
wash buffer before the addition of 100 µl of 3, 3’, 5, 5’-Tetramethylbenzidine 
(TMB) substrate solution. Plates were incubated in the dark, after sufficient blue 
colour development (around 10 minutes) all reactions were stopped by adding 50 µl 
of 2 M sulphuric acid.  
The optical density was measured at 450 nm using a FLUOstar microplate reader 
(Omega BMG Labtech). To calculate chemokine levels from the optical density, 
standards were used to plot a standard curve, which was used to produce a linear 
equation. This equation was used to calculate the concentration of the chemokine in 
each sample from its optical density.  
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2.5 Quantitative polymerase chain reaction (qPCR)  
2.5.1 SES stimulation of resident macrophages 
A pure population of resident macrophages (Section 2.3.10) were seeded into a        
48 well plate in 500 μl of 1640 Media developed at the Roswell Park Memorial 
Institute (RPMI-1640) at a density of 1x106 cells/ml and allowed to adhere for           
3 hours. A freeze dried aliquot of SES was reconstituted with RPMI-1640 and a 1/2 
dilution was added to the macrophages and along with an unstimulated negative 
control incubated for 1 hour, RNA from resident macrophages was then extracted. 
 
2.5.2 RNA extraction   
Total RNA was extracted using a RNAeasy mini kit (Qiagen, Crawley, West Sussex, 
UK). Firstly, either (i) a resident macrophage monolayer (Section 2.5.1) was lysed 
using RLT buffer and homogenised by passing though a QiaShredder, or (ii) a piece 
of liquid nitrogen snap frozen peritoneal membrane (Section 2.2.6.1) was broken 
down into a fine powder using a homogeniser (Omni International, Georgia, USA). 
This powder was resuspended in 1 ml of Trizol solution for 5 minutes on ice. To this 
200 µl of chloroform was added per sample and mixed vigorously for 15 seconds 
and left at room temperature for 3 minutes. After this period the solution was spun at 
12000 g for 15 minutes at 4 ˚C and supernatant transferred into a fresh eppendorf.  
An equal volume of 70 % ethanol was added to the supernatant and gently mixed. 
This solution was transferred to an RNAeasy spin column within a 2 ml collection 
tube and spun for 15 seconds at 8000 g and flow through in the collection tube 
discarded. RW1 buffer (700 μl) was added to the same RNAeasy spin column within 
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a 2 ml collection tube and spun for 15 seconds at 8000 g and flow through discarded. 
RPE buffer (500 µl) was added to the same RNAeasy spin column and spun as above 
discarding the flow through and repeated. The RNAeasy spin column was moved 
into a fresh 2 ml collection tube and spun as above for 1 minute. The RNAeasy spin 
column was moved into an eppendorf and 50 µl of RNAse free water added onto the 
membrane within the spin column and spun for 1 minute at 8000 g. The flow 
through was re-pipetted onto the membrane and the spin repeated. The eluted RNA 
in solution was stored at -80 ˚C until required and volume of RNA extracted 
measured using a nanodrop spectrometer. 
 
2.5.3 Reverse transcription 
RNA was diluted to 100 ng/ml and added to a 0.2 ml PCR tube along with 0.5 µl of 
Oligo-dT and 0.5 µl of Random hexamer primers and made up to a final volume of 
10 µl with RNAse free water (Primer Design, Mill Yard, Southampton, UK). The 
primers were annealed to the RNA by heating the PCR tubes on a heat block to        
65 ˚C for 5 minutes and immediately moved onto ice; 10 μl of the extension mix      
(2 μl of nanoscript 10X buffer, 1 μl of 10 mM dNTPs, 2 μl of Dithiothreitol (DTT),    
4 μl RNAse free water and 1 μl nanoscript enzyme) (Primer Design, Mill Yard, 
Southampton, UK) was added to the samples on ice and mixed. These samples were 
left at room temperature for 5 minutes, heated to 55 ˚C for 20 minutes and reaction 
stopped by increasing the temperature to 75 ˚C for 15 minutes. Finally the cDNA 
generated was diluted to a working concentration by adding 180 µl of RNAse free 
water and kept at -20 ˚C until required.  
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2.5.4 Primer design  
The cDNA sequence and the intron-exon boundaries of the test gene were obtained 
from the ensemble website (www.ensemble.org). This cDNA sequence along with a 
sequence of several base pairs from either side of a 3’ intron-exon boundary were 
inputted into the Primer3 program, which generated several possible primers 
producing a product of 80-150 bp. These primers were assessed for their potential to 
form secondary structures (www.sigmagenosys.com/calc/DNACalc.asp) and bind 
other similar sequences from other gene transcripts 
(www.ncbi.nlm.nih.gov/tools/primer-blast). Those least likely to form secondary 
structures or bind to other transcripts were selected to identify the relative quantity of 
test gene mRNA levels in the peritoneal membrane using qPCR.  
 
2.5.5 qPCR   
The cDNA generated in Section 2.5.2 was diluted to 25 ng/ml and 5 μl added per 
reaction along with a mastermix (containing 10 μl 2X qPCR mastermix with SYBR 
green included, 1 μl primer and 4 μl RNAse free water, per reaction) (Primer Design, 
Mill Yard, Southampton, UK) to the test wells of a qPCR plate. The qPCR plate 
wells containing the test primer and mastermix were run alongside a housekeeping 
control gene (β actin) and mastermix as well as –RNA and –RT wells in a Biorad 
iCycler qPCR machine (Biorad, Hemel Hempstead, Hertfordshire, UK) according to 
the following protocol: 
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 Step Time Temperature 
 Enzyme activation 10 minutes 95 ˚C 
Cycling x50 De-naturation 15 seconds 95 ˚C 
 Data collection 60 seconds 60 ˚C 
 Melt curve - - 
  
SYBR green in the 2X qPCR mastermix is a non-specific DNA dye which was used 
to detect the amplification of the desired cDNA product, by measuring the increase 
in fluorescence as SYBR green binds amplifying DNA. However SYBR green has 
the ability to bind any double stranded DNA, such as contaminating DNA and self 
complementary primers, not only the desired cDNA product. Thus to ensure only the 
single desired product was amplified the melt curve of each reaction was scrutinized 
(Figure 2.6).  
To calculate the relative quantity (RQ) of mRNA of the gene of interest from the 
qPCR readout, the amplification data of the gene of interest (known as the Ct value) 
were normalised by subtracting the amplification data from the housekeeping gene, 
(known as dCt) and subtracting the amplification data from the negative control 
(known as the ddCt). These normalised mRNA data were transformed (2^) to give 
relative quantity from which statistics were used to investigate how this gene 
transcription may have changed between experimental groups. 
 
 
 
 
Figure 2.6 – Representative derivative melt curve following qPCR. SYBR 
green is a non-specific DNA dye which can bind any double stranded DNA 
(i.e. contaminating DNA and self complementary primers), therefore it is 
necessary to inspect the melt curve to confirm only the single desired product 
is amplified. This figure shows a representative plot of negative fluorescence 
vs temperature, the single peak at an inflection point of 85 ̊C (melting 
temperature of the desired product) is typical of the amplification of a single 
product. Self complementary primers or contaminating DNA would appear as 
separate peaks on the plot in addition to the desired product.  
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2.6 Histology  
2.6.1 Peritoneal membrane harvest  
A ~1.5 cm by ~1.5 cm square of mouse peritoneal membrane was harvested and 
pinned (without stretching) into a gel based Petri dish containing PBS. The PBS was 
removed and the membrane was fixed in 10 % NBFS for 15 minutes. Peritoneal 
membranes were unpinned and transferred into labelled tissue biopsy cassettes. 
These cassettes were stored in NBFS for 48 hours at 4 ˚C to ensure fixation. 
 
2.6.2 Tissue preparation 
After fixation, membranes were outsourced to CBS for preparation prior to staining. 
This entailed permeating the membrane with paraffin wax in a tissue processor (see 
Table 2.5).  Membranes were then sliced in half and embedded vertically in wax 
blocks. Sections (5 µm) were cut using a microtome, which were then transferred 
onto a waterbath filled with distilled H2O heated to 50 ˚C. Each section was placed 
onto an adhesive microscope slide and incubated overnight at 60 ˚C. These 
peritoneal membrane section slides were then stored at room temperature.  
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Table 2.5 - Peritoneal membrane processing programme  
 
 
 
 
 
 
 
Stage Time Temperature 
70 % Alcohol empty tank 
 
30 minutes Room temperature 
90 % Alcohol empty tank 
 
60 minutes Room temperature 
100 % Alcohol empty tank 
 
60 minutes Room temperature 
100 % Alcohol empty tank 
 
60 minutes Room temperature 
100 % Alcohol empty tank 
 
60 minutes Room temperature 
100 % Alcohol empty tank 
 
60 minutes Room temperature 
100 % Alcohol empty tank 
 
60 minutes Room temperature 
Xylene empty tank 
 
60 minutes 37 ˚C 
Xylene empty tank 
 
60 minutes 37 ˚C 
Xylene empty tank 
 
60 minutes 45 ˚C 
Wax empty tank 
 
120 minutes 60 ˚C 
Wax empty tank 
 
90 minutes 60 ˚C 
Wax empty tank 
 
90 minutes 60 ˚C 
Wax empty tank 
 
90 minutes 60 ˚C 
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2.6.3 Haematoxylin and eosin staining  
Peritoneal membrane sections on slides were deparaffinised with 3 x 5 minutes 
changes of xylene and rehydrated for 3 minutes in each of 4 descending 
concentrations of ethanol (100 %, 100 %, 90 %, and 70 %). Slides were placed into 
running tap water for 5 minutes and dipped in distilled H2O. Slides were submerged 
in Harris’s haematoxylin solution for 90 seconds and running tap water for                
5 minutes. Slides were moved into Scott’s tap water for 30 seconds and running tap 
water again for 5 minutes. Slides were placed in eosin solution for 60 seconds and 
running tap water to prevent over staining of the membranes. Finally sections were 
dehydrated for 3 minutes in 3 ascending concentrations of ethanol (90 %, 100 %, and 
100 %) and submerged in 3 x 5 minutes changes of xylene. A cover slip with Depax 
mounting media was added onto the slide and incubated at 65 ˚C overnight to fix.  
 
2.6.4 Mesothelial layer thickness analysis 
After haematoxylin and eosin staining, the peritoneal membrane sections were 
blinded and pictures were taken at x20 magnification using a Leica DFC490 camera 
attached to a Leica microscope. These pictures were measured using Leica QwinV3 
software. The mesothelial layer of each peritoneal membrane section was measured 
at 6 different points of the membrane in 6 different fields of view; these were 
averaged to give a mean thickness (µm) for that sample. All other samples from all 
time points were measured the same way, ensuring similar sections of the membrane 
were measured to ensure consistent results.    
 
92 
 
2.6.5 DR3 immunohistochemistry (IHC) 
Sections were deparaffinised and rehydrated as shown in Section 2.6.3 and washed 
in running tap water for 5 minutes. Excess water was removed from the slides and 
the peritoneal membrane sections were enclosed in a hydrophobic barrier using a pap 
pen. Each section was covered with peroxidase blocking reagent (from an R&D      
anti-goat HRP-DAB cell and tissue staining kit) for 5 minutes in an incubation 
chamber. Sections were rinsed in TBS buffer and washed in 2 changes of TBS buffer 
for 5 minutes each. Serum blocking reagent D (from the above R&D kit) was added 
for 15 minutes in an incubation chamber, excess serum block was blotted off and 
sections were incubated for a further 15 minutes with avidin blocking reagent (from 
the above R&D kit). Slides were rinsed in TBS buffer and excess buffer blotted off.  
Sections were incubated with the biotinylated polyclonal mDR3 antibody (RnD 
systems) and an identical section incubated with the biotinylated goat IgG isotype 
control at 20 µg/ml for 2 hours in an incubation chamber. Sections were rinsed in 
TBS buffer and washed in 3 changes of TBS buffer for 15 minutes each. Excess 
buffer was removed from the slides and sections incubated with High sensitivity 
streptavidin (HSS)-HRP (from the above R&D kit) for 30 minutes. Sections were 
rinsed in TBS buffer and washed in 3 changes of TBS buffer for 2 minutes each. 
Excess buffer was removed and sections incubated with a mixture of                      
3,3-Diaminobenzidine (DAB) chromogen and DAB buffer (from the above R&D kit, 
1 drop concentrated DAB chromogen in 1 ml DAB buffer) for 3 minutes, slides were 
rinsed in distilled H2O and washed in fresh distilled H2O for 2 minutes.  
Sections were counterstained with Harris’s haematoxylin, dipped in Scott’s tap 
water, dehydrated in 3 ascending concentrations of ethanol, submerged in 3 changes 
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of xylene and mounted with Depax mounting media as shown in Section 2.6.3. 
Pictures of sections were taken under x20 magnification using an Olympus N457 
camera and loaded onto Adobe Photoshop CS4. In Adobe Photoshop CS4 the picture 
was pixelated and brown pixels calculated as a percentage of total pixels.  
 
2.7 Statistical analysis   
All results were expressed as the mean ± standard error of the mean (SEM) and 
analysed using Graphpad prism 5, p values below 0.05 were considered significant. 
The statistical tests used in this study were the parametric, unpaired 2 tailed t-test 
(when comparing the means of 2 groups) and 2 way Analysis of variance (ANOVA) 
(when comparing more than 2 variables) where data were normally distributed and 
the non-parametric, Mann-Whitney test where data were not normally distributed 
(i.e. percentages).  
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Chapter 3 - Phenotypic characterisation of 
the peritoneal cavity and peripheral blood  
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3.1 Introduction 
Previous work in inflammatory and infection models has shown that DR3 regulates 
effector T cell expansion at sites of pathology (Migone, Zhang et al. 2002; Meylan, 
Davidson et al. 2008; Pappu, Borodovsky et al. 2008; Buchan, Taraban et al. 2012; 
Twohig, Marsden et al. 2012), but to date, no studies have investigated the influence 
of DR3 expression on leukocyte populations within the peritoneal cavity. The naive 
mouse peritoneal cavity is predominantly composed of resident macrophages and B1 
cells though other cellular subsets are found in lower numbers (e.g. T cells, 
Dendritic cells, Eosinophils and NK cells) (Turchyn, Baginski et al. 2007; 
Kolaczkowska, Koziol et al. 2009). The aim of this chapter was to determine the 
composition and number of peritoneal leukocytes in the naive cavity of DR3-/- mice 
and compare them to their DR3+/+ counterparts to investigate if DR3 significantly 
influenced leukocyte homeostasis prior to the induction of inflammation. As 
leukocytes are recruited into the cavity from the peripheral blood following an 
inflammatory stimulus, detailed baseline measurements of leukocyte subsets in the 
peripheral blood of DR3-/- mice were also undertaken. DR3 expression patterns on 
these leukocyte subsets and within the peritoneal membrane were also examined to 
identify cell types that were potentially responsive to TL1A. 
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3.2 Results 
3.2.1.1 Total mouse leukocyte numbers in unchallenged DR3+/+ and DR3-/- 
peritoneal cavities  
To examine if DR3 affected the number of resident peritoneal leukocytes in the 
naive cavity, cells were isolated by lavage (Section 2.2.3.1) and cells numbers 
determined using a Coulter counter (Section 2.2.4). DR3-/- mice (2.9 ± 0.2 x106 total 
cells) showed no significant difference in the total number of leukocytes present in 
the naive cavity compared to DR3+/+ mice (2.8 ± 0.2 x106 total cells) (Figure 3.1) 
(Table 3.1).  
 
3.2.1.2 Myeloid cell subset numbers in unchallenged DR3+/+ and DR3-/- 
peritoneal cavities 
Though a deficiency in DR3 did not affect the total number of cells residing in the 
naive cavity, numbers of different leukocyte subsets were calculated to determine if 
loss of DR3 altered the composition of these resident cells. Myeloid cell subsets 
were identified from the lavage by flow cytometry (Section 2.3.2), through use of 
well-characterised extracellular markers (F4/80, CD11b and CD11c) (Table 2.3) and 
variations in their forward and side scatter (FSC/SSC) properties (Figure 2.3). DR3-/- 
and DR3+/+ mice were found to have comparable numbers of resident macrophages 
(DR3+/+ mice 7.2 ± 1.8 x105, DR3-/- mice 6.4 ± 1.6 x105 total resident macrophages) 
(Figure 3.2A), dendritic cells (DR3+/+ mice 5.1 ± 1.6 x103, DR3-/- mice 3.3 ± 0.3 
x103 total dendritic cells) (Figure 3.2B) and eosinophils (DR3+/+ mice 1.9 ± 0.7 x105, 
DR3-/- mice 7.6 ± 0.6 x104 total eosinophils) (Figure 3.2C) in the naive cavity. 
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Figure 3.1 - No significant differences were seen in total peritoneal 
leukocyte numbers in the naive cavity of DR3+/+ and DR3-/- mice. 
Peritoneal leukocytes were isolated from the cavities of mice by peritoneal 
lavage, total cell number was calculated using a Beckman Coulter counter 
Z2 (each symbol represents a single mouse, bar corresponds to mean from 
n=7 or 8, N.S.D by t-test). 
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Figure 3.2 - No significant differences were seen in numbers of resident 
myeloid cell subsets in the unchallenged peritoneal cavity of DR3+/+ and 
DR3-/- mice. Peritoneal leukocytes were isolated by lavage and A) Resident 
Macrophages were identified by a CD11b+ F4/80+ phenotype, B) Dendritic 
cells were identified by a F4/80int CD11bint CD11c+ phenotype and C) 
Eosinophils, identified by a F4/80int CD11bint phenotype and their forward 
and side scatter properties. Subset numbers calculated by percentage 
proportion of total leukocytes, determined using a Beckman Coulter counter 
Z2 (each symbol represents a single mouse, bar corresponds to mean from 
n=5, N.S.D by t-test). 
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3.2.1.3 Lymphocyte cell subset numbers in unchallenged DR3+/+ and DR3-/- 
peritoneal cavities 
Lymphocyte cell subsets in the naive cavity of DR3-/- mice were examined by flow 
cytometry. Antibodies targeted against markers found on the surface of these cells 
(Table 2.3) identified specific lymphocytic cell subsets from the heterogeneous 
leukocyte population (Figure 2.4-2.5). DR3-/- mice (4.6 ± 1.1 x105 total T cells) 
showed no significant difference in the total number of peritoneal T cells in the 
naive cavity compared to DR3+/+ mice (4.5 ± 0.5 x105 total T cells) (Figure 3.3A) 
and both DR3-/- and DR3+/+ shared equivalent numbers of both CD4+ (DR3+/+ mice 
2.9 ± 0.7 x105, DR3-/- mice 3.0 ± 0.4 x105 total CD4+ T cells) (Figure 3.3B) and 
CD8+ (DR3+/+ mice 6.1 ± 1.4 x104, DR3-/- mice 6.9 ± 0.6 x104 total CD8+ T cells) 
(Figure 3.3C) T cell subsets. The number of B cells in the naive cavity of DR3-/- 
mice (9.3 ± 2.9 x105 total B cells) was also not significantly different compared to 
DR3+/+ mice (8.6 ± 1.0 x105 total B cells) (Figure 3.4A) with both genotypes sharing 
similar numbers of B1 (DR3+/+ mice 6.6 ± 1.8 x105, DR3-/- mice 5.4 ± 0.7 x105 total 
B1 cells) (Figure 3.4B) and B2 (DR3+/+ mice 1.5 ± 0.5 x105, DR3-/- mice 1.8 ±       
0.3 x105 total B2 cells) (Figure 3.4C) B cell subsets. The naive peritoneal cavities of 
DR3-/- and DR3+/+ mice also shared comparable numbers of NK (DR3+/+ mice 6.8 ± 
1.7 x104, DR3-/- mice 4.7 ± 0.8 x104 total NK cells) (Figure 3.5A) and NKT cells 
(DR3+/+ mice 7.2 ± 1.8 x104, DR3-/- mice 6.9 ± 0.6 x104 total NKT cells) (Figure 
3.5B).  
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Figure 3.3 - No significant differences were seen in numbers of resident 
T cell subsets in the unchallenged peritoneal cavity of DR3+/+ and DR3-/- 
mice. Peritoneal leukocytes were isolated by lavage and A) T cells were 
identified by a CD3+, TCRαβ+ phenotype, B) T helper cells were identified 
by a CD3+ CD4+, TCRαβ+ phenotype and C) T cytotoxic cells identified by a 
CD3+ CD8+, TCRαβ+ phenotype. Subset numbers calculated by percentage 
proportion of total leukocytes, determined using a Beckman Coulter counter 
Z2 (each symbol represents a single mouse, bar corresponds to mean from 
n=5, N.S.D by t-test).  
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Figure 3.4 - No significant differences were seen in numbers of resident 
B cell subsets in the unchallenged peritoneal cavity of DR3+/+ and DR3-/- 
mice. Peritoneal leukocytes were isolated by lavage and A) B cells were 
identified by a CD19+, B220+ phenotype, B) B1 cells were identified by a 
CD19+ B220int, CD11bint phenotype and C) B2 cells identified by a CD19+ 
B220+, CD11b- phenotype. Subset numbers calculated by percentage 
proportion of total leukocytes, determined using a Beckman Coulter counter 
Z2 (each symbol represents a single mouse, bar corresponds to mean from 
n=4 or 5, N.S.D by t-test).  
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Figure 3.5 - No significant differences were seen in numbers of resident 
NK or NKT cell subsets in the unchallenged peritoneal cavity of DR3+/+ 
and DR3-/- mice. Peritoneal leukocytes were isolated by lavage and A) NK 
cells were identified by a NK1.1+, TCRαβ- phenotype and B) NKT cells 
were identified by a NK1.1+, TCRαβ+ phenotype. Subset numbers calculated 
by percentage proportion of total leukocytes, determined using a Beckman 
Coulter counter Z2 (each symbol represents a single mouse, bar corresponds 
to mean from n=5, N.S.D by t-test). 
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3.2.2.1 Leukocyte proliferation in unchallenged DR3+/+ and DR3-/- peritoneal 
cavities  
Earlier work has implicated DR3 in playing a role in both cell expansion (Taraban, 
Slebioda et al. 2011; Twohig, Marsden et al. 2012) and apoptosis in vivo (Wang, 
Kitson et al. 2001). Alterations in baseline proliferation and apoptosis in the absence 
of DR3 could still explain the similar cell numbers observed in the naive cavity of 
DR3-/- and DR3+/+ mice. Percentages of proliferating resident cells in the naive 
cavity was therefore studied using intracellular staining for Ki67 (Figure 3.6, Gate 
R85), a nuclear protein widely associated with proliferating but not resting cells (G0 
phase). Ki67 is first detected early during the G1 phase of proliferation and 
continuously expressed during the S phase and most of G2/M phase of proliferation, 
but was not found in binucleate cells (Duchrow, Gerdes et al. 1994). Comparable 
levels of Ki67+ cells (Gate R85) were observed in resident myeloid and lymphocyte 
cell subsets in DR3+/+ mice (resident macrophages 10.7 ± 2.0 %, T cells 37.7 ±       
5.5 %, B cells 13.0 ± 0.5 %, NK cells 21.6 ± 2.6 %, NKT cells 21.7 ± 2.6 %) and 
DR3-/- (resident macrophages 7.1 ± 1.1 %, T cells 35.1 ± 3.2 %, B cells 12.2 ±        
1.1 %, NK cells 20.9 ± 2.1 %, NKT cells 20.9 ± 2.1 %) mice in the peritoneal cavity 
(Figure 3.7-3.10) (Table 3.2).  
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Figure 3.6 - Flow cytometry plots representing proliferation in the 
unchallenged peritoneal cavity. Peritoneal leukocytes were isolated from the 
cavity by lavage, permeabilised and proliferation measured using the 
intracellular marker Ki67 (Gate R85). A) isotype control, B) DR3+/+ and           
C) DR3-/-mice. Separation of mitotic phases can be achieved with the DNA 
marker DAPI in conjunction with Ki67. Early proliferative (G1) cells express 
Ki67 but are yet to replicate DNA (Ki67+ DAPIlo). DNA replication does occur 
during S and G2M phase of proliferation (Ki67+ DAPIint/hi). Binucleate cells are 
non-proliferating but are yet to divide into two cells (Ki67- DAPIhi). Once 
divided, cells enter resting (G0) phase (Ki67- DAPIlo). Ki67++ represent cells 
whose nuclear envelope has broken down during mitosis promoting more 
efficient antibody staining.  
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Figure 3.7 - No significant differences were seen in the percentages of 
proliferating resident macrophages in the unchallenged peritoneal 
cavity of DR3+/+ and DR3-/- mice. Peritoneal leukocytes were isolated from 
the cavity by lavage and Resident Macrophages identified by a CD11b+ 
F4/80+ phenotype. Percentages of proliferating resident macrophages were 
calculated by the percentage of the subset positive for the marker Ki67 (each 
symbol represents a single mouse, bar corresponds to mean from n=6, N.S.D 
by Mann-Whitney test). 
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Figure 3.8 - No significant differences were seen in the percentages of 
proliferating T cell subsets in the unchallenged peritoneal cavity of 
DR3+/+ and DR3-/- mice. Peritoneal leukocytes were isolated from the cavity 
by lavage. A) T cells were identified by a CD3+, TCRαβ+ phenotype B) T 
helper cells were identified by a CD3+ CD4+, TCRαβ+ phenotype and C) T 
cytotoxic cells identified by a CD3+ CD8+, TCRαβ+ phenotype. Percentages 
of proliferating T cell subsets were calculated by the percentage of the 
subset positive for the marker Ki67 (each symbol represents a single mouse, 
bar corresponds to mean from n=6, N.S.D by Mann-Whitney test). 
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Figure 3.9 - No significant differences were seen in the percentages of 
proliferating B cells in the unchallenged peritoneal cavity of DR3+/+ and 
DR3-/- mice. Peritoneal leukocytes were isolated from the cavity by lavage. 
Resident B cells were identified by a CD19+, B220+ phenotype. Percentages 
of proliferating B cells were calculated by the percentage of the subset 
positive for the marker Ki67 (each symbol represents a single mouse, bar 
corresponds to mean from n=6, N.S.D by Mann-Whitney test). 
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Figure 3.10 - No significant differences were seen in the percentages of 
proliferating NK or NKT cells in the unchallenged peritoneal cavity of 
DR3+/+ and DR3-/- mice. Peritoneal leukocytes were isolated from the cavity 
by lavage. A) NK cells were identified by a NK1.1+, TCRαβ- phenotype and 
B) NKT cells were identified by a NK1.1+, TCRαβ+ phenotype. Percentages 
of proliferating NK cell subsets were calculated by the percentage of the 
subset positive for the marker Ki67 (each symbol represents a single mouse, 
bar corresponds to mean from n=5 or 6, N.S.D by Mann-Whitney test). 
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3.2.2.2 Apoptosis and cell death in unchallenged DR3+/+ and DR3-/- peritoneal 
cavities 
Apoptosis and cell death of separate leukocyte subsets in the cavities of DR3+/+ and 
DR3-/- mice was measured by the percentage of each subset positive for Annexin V 
in combination with the fluorescent DNA binding dye 7-Aminoactinomycin D  
(7AAD) (Figure 3.11, Gate R74 and R75). Annexin V binds phosphatidylserine in a 
calcium-dependent manner. Normally phosphatidylserine is held on the intracellular 
surface of lipid membranes, however during early apoptosis it translocates to the 
extracellular surface of the cell allowing detection by Annexin V in the absence of 
membrane permeabilisation (Vanoers, Reutelingsperger et al. 1994), while 
separation from dead cells can be achieved as live and early apoptotic cells maintain 
cell membrane integrity and exclude 7AAD (Figure 3.11, Gate R74). However after 
cell death (Figure 3.11, Gate R75), cell membrane integrity is lost and 7AAD and 
Annexin V can pass though the membrane, allowing 7AAD to bind guanine and 
cytosine bases within the nucleus (Philpott, Turner et al. 1996). No significant 
difference in Annexin V positive, 7AAD positive or double positive cells, of any 
leukocyte subset in the naive peritoneal cavity was seen between DR3+/+ (Annexin 
V+ and 7AAD+; resident macrophages 40.7 ± 5.6 %, eosinophils 14.7 ± 1.0 %,         
T cells 17.7 ± 0.5 %, B cells 68.3 ± 1.2 %, NK cells 33.7 ± 5.6 %, NKT cells 17.7 ± 
1.8 %) and DR3-/- mice (Annexin V+ and 7AAD+; resident macrophages 42.5 ±       
1.8 %, eosinophils 15.7 ± 1.1 %, T cells 19 ± 0.9 %, B cells 72.2 ± 3.9 %, NK cells 
27.8 ± 3.2 %, NKT cells 20.4 ± 2.0 %) (Figure 3.12-3.15) (Table 3.2).  
 
 
Figure 3.11 - Flow cytometry plots representing the level of apoptosis 
and cell death in the unchallenged peritoneal cavity. Peritoneal 
leukocytes were isolated from the cavity by lavage. Apoptosis (R74) and 
death (R75) was measured using Annexin V (Y Axis) and 7AAD (X Axis) in 
A) DR3+/+ mice and B) DR3-/- mice. 
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Figure 3.12 - No significant differences were seen in percentage Annexin 
V+ myeloid cells in the unchallenged peritoneal cavity of DR3+/+ and 
DR3-/- mice. Peritoneal leukocytes were isolated by lavage and A) Resident 
Macrophages identified by a CD11b+ F4/80+ phenotype and B) Eosinophils, 
identified by a F4/80int CD11bint phenotype and their forward and side 
scatter properties. Percentage apoptotic and dead cells were calculated by 
the percentage of the subset Annexin V+ and 7AAD+ (each bar represents 
mean of n=6 mice, grey fill represents apoptosis and black fill represents cell 
death, error bars correspond to mean ± SEM, N.S.D by Mann-Whitney test). 
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Figure 3.13 - No significant differences were seen in percentage Annexin 
V+ T cells in the unchallenged peritoneal cavity of DR3+/+ and DR3-/- 
mice. Peritoneal leukocytes were isolated by lavage and A) T cells were 
identified by a CD3+, TCRαβ+ phenotype B) T helper cells were identified 
by a CD3+ CD4+, TCRαβ+ phenotype and C) T cytotoxic cells identified by a 
CD3+ CD8+, TCRαβ+ phenotype. Percentage apoptotic and dead cells were 
calculated by the percentage of the subset Annexin V+ and 7AAD+ (each bar 
represents mean of n=6 mice, grey fill represents apoptosis and black fill 
represents cell death, error bars correspond to mean ± SEM, N.S.D by 
Mann-Whitney test). 
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Figure 3.14 - No significant differences were seen in percentage Annexin 
V+ B cells in the unchallenged peritoneal cavity of DR3+/+ and DR3-/- 
mice. Peritoneal leukocytes were isolated by lavage and A) B cells were 
identified by a CD19+, B220+ phenotype B) B1 cells were identified by a 
CD19+ B220int, CD11bint phenotype and C) B2 cells identified by a CD19+ 
B220+, CD11b- phenotype. Percentage apoptotic and dead cells were 
calculated by the percentage of the subset Annexin V+ and 7AAD+ (each bar 
represents mean of n=6 mice, grey fill represents apoptosis and black fill 
represents cell death, error bars correspond to mean ± SEM, N.S.D by 
Mann-Whitney test). 
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Figure 3.15 - No significant differences were seen in percentage Annexin 
V+ NK and NKT cells in the unchallenged peritoneal cavity of DR3+/+ 
and DR3-/- mice. Peritoneal leukocytes were isolated from the cavity by 
lavage. A) NK cells were identified by a  NK1.1+, TCRαβ-  phenotype and 
B) NKT cells, identified by a NK1.1+, TCRαβ+ phenotype. Percentage 
apoptotic and dead cells were calculated by the percentage of the subset 
Annexin V+ and 7AAD+ (each bar represents mean of n=6 mice, grey fill 
represents apoptosis and black fill represents cell death, error bars 
correspond to mean ± SEM, N.S.D by Mann-Whitney test). 
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3.2.3.1 DR3 expression on the mesothelial layer of the unchallenged peritoneal 
membrane of DR3+/+ and DR3-/- mice 
No previous studies have investigated DR3’s expression profile in the peritoneal 
cavity. Stromal DR3 expression was visualised using a polyclonal antibody by 
immunohistochemistry (Section 2.6.5). Multiple pictures were taken along sections 
of the mesothelial layer from DR3+/+ and DR3-/- mice following staining by the 
polyclonal DR3 antibody or an isotype antibody (Figure 3.16A). Percentage positive 
DR3 (brown) pixels within mesothelial layer of the membrane were calculated using 
Adobe Photoshop CS4. A positive signal for DR3 was recorded on the mesothelial 
layer of the unchallenged membrane of DR3+/+ mice (6.5 ± 0.3 %), with low 
background staining on the DR3-/- (0.3 ± 0.1 %) (Figure 3.16B) (p<0.01) (Table 3.3) 
and isotype controls (0.1 ± <0.1 %). 
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Figure 3.16 - Significant levels of DR3 expression were found on the 
mesothelial layer of the unchallenged peritoneal membrane of DR3+/+ 
mice. A) Representative pictures of DR3 staining in the mesothelial layer of 
the peritoneal membrane (Bar corresponds to 25μm.) B) DR3 expression on 
the membrane was analysed by taking multiple pictures along the section and 
measuring the % of positive (brown) pixels within the mesothelial layer of the 
membrane using Adobe Photoshop CS4 (each symbol represents a single 
mouse, bar corresponds to mean from n=5 or 6, ***p<0.01 by Mann-Whitney 
test). 
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3.2.3.2 DR3 expression on resident lymphocyte cell subsets in the unchallenged 
peritoneal cavity of DR3+/+ and DR3-/- mice 
Leukocyte expression of DR3 was visualised by a polyclonal anti-DR3 antibody and 
flow cytometry. Relative levels of DR3 signal on T cells were estimated using 
median fluorescence intensity (MFI) rather than percentages (which are more easily 
distorted by outliers), as total population shifts were observed. A significantly 
greater fluorescence signal shift above the isotype (4.4 ± 0.3 MFI) was observed in 
both DR3+/+ (24.0 ± 0.8 MFI) (p<0.01) and DR3-/- mice (9.1 ± <0.1 MFI) (p<0.01) for 
the T cell population, suggesting detection of some non-DR3 signal by the 
polyclonal DR3 antibody. However, the fluorescence signal shift was greater in 
DR3+/+, compared to DR3-/- mice (Figure 3.17) (p<0.01). To allow a standardised 
comparison between the two genotypes, relative fluorescence (RF) signal increase 
over isotype control was calculated by dividing the test MFI by the MFI from the 
isotype. RF on DR3+/+ naive peritoneal T cells (5.5 ± 0.2 RF) (Figure 3.17 and 
Figure 3.18A) was found to be significantly greater than on DR3-/- peritoneal T cells 
(2.1± <0.1 RF) (p<0.01), including both CD4+ (DR3+/+ mice 5.9 ± 0.2, DR3-/- mice 
2.1± <0.1 RF) (p<0.01) (Figure 3.18B) and CD8+ (DR3+/+ mice 5.2 ± 1.8, DR3-/- mice 
1.2 ± 0.2 RF) (p<0.01) (Figure 3.18C) subsets.  
MFI ratio however was not used to analyse NK and NKT cell subsets due to a 
separate non-DR3 signal positive population found in DR3-/- NKT cells and both the 
DR3-/- and isotype control of NK cells (Figure 3.19). Instead percent positive and 
MFI of the positive population was used to calculate potential DR3 expression. No 
significant differences were seen in the percentage positive population of NK cells in 
DR3+/+ mice (7 ± 1 %) compared to DR3-/- mice (5.5 ± 0.7 %) or isotype control (6 ± 
<0.1 %); equivalent MFI was also found in the positive population between DR3+/+ 
118 
 
(63 ± 13 MFI) and DR3-/- mice (63 ± 3 MFI). The positive signal in NKT cells was 
however significantly higher in both DR3+/+ (69 ± 9 %) and DR3-/- mice (37 ± 4 %) 
compared to the isotype (9 ± 2 %) (p<0.01). The proportion of percentage positive 
NKT cells was significantly higher in DR3+/+ mice compared to DR3-/- mice 
(p<0.05); the MFI in the NKT positive population of DR3+/+ mice (12 ± 6 MFI) was 
not significantly different to those found in DR3-/- mice (31 ± 9 MFI). No significant 
differences in DR3 signals were observed on macrophages or B cells between 
genotypes or in the isotype control (Figure 3.20). Potential reasons for these 
differences in signals for DR3 in different cell subsets will be discussed in detail in 
Chapter 7. 
 
3.2.4.1 Peripheral blood leukocytes in unchallenged DR3+/+ and DR3-/- mice  
Many cell subsets present in the naive peritoneal cavity are recruited into the cavity 
from the peripheral blood (Topley, Liberek et al. 1996; Jones 2005). To examine if 
DR3 had any effect on the number of leukocytes present in the peripheral blood, 
blood was obtained by cardiac puncture (Section 2.2.3.2), red blood cells lysed and 
remaining leukocytes were counted using a haemocytometer. DR3-/- mice (3.3 ±      
0.6 x106 cells/ml) showed no significant difference in the number of peripheral 
blood leukocytes compared to DR3+/+ mice (2.8 ± 0.3 x 106 cells/ml) (Figure 3.21) 
(Table 3.1).  
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Figure 3.17 - Flow cytometry plots representing level of DR3 expression 
on resident T cell subsets in the unchallenged peritoneal cavity of DR3+/+  
mice. Peritoneal leukocytes were isolated from the cavity by lavage. A) T 
cells were identified by a CD3+, TCRαβ+ phenotype B) T helper cells were 
identified by a CD3+ CD4+, TCRαβ+ phenotype and C) T cytotoxic cells 
identified by a CD3+ CD8+, TCRαβ+ phenotype.  
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Figure 3.18 - Significant levels of DR3 expression were found on resident 
T cell subsets in the unchallenged peritoneal cavity of DR3+/+  mice. 
Peritoneal leukocytes were isolated from the cavity by lavage. A) T cells 
were identified by a CD3+, TCRαβ+ phenotype (p<0.01) B) T helper cells 
were identified by a CD3+ CD4+, TCRαβ+ phenotype (p<0.01) C) and T 
cytotoxic cells identified by a CD3+ CD8+, TCRαβ+ phenotype (p<0.01). 
Ratio of DR3 expression on subsets was calculated by the MFI fold increase 
compared to the isotype (each symbol represents a single mouse, bar 
corresponds to mean from n=3, analysed by Mann-Whitney test). 
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Figure 3.19 - Flow cytometry plots representing DR3 staining on 
resident NK and NKT cells in the unchallenged peritoneal cavity of 
DR3+/+  mice. Peritoneal leukocytes were isolated from the cavity by lavage. 
A) NK cells were identified by a NK1.1+, TCRαβ- phenotype and B) NKT 
cells were identified by a NK1.1+, TCRαβ+ phenotype. 
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Figure 3.20 - Flow cytometry plots representing DR3 staining on 
macrophages and B cells in the unchallenged peritoneal cavity. 
Peritoneal leukocytes were isolated from the cavity by lavage. A) Resident 
Macrophages were identified by a CD11b+ F4/80+ phenotype and B) B cells 
were identified by a CD19+, B220+ phenotype. 
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Figure 3.21 - No significant differences were seen in peripheral blood 
leukocyte numbers between unchallenged DR3+/+ and DR3-/- mice. 
Peripheral blood leukocytes were collected by cardiac puncture of the heart. 
Leukocyte numbers were calculated, after red blood cell lysis using a 
haemocytometer (each symbol represents a single mouse, bar corresponds to 
mean from n=7 or 9, N.S.D by t-test). 
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3.2.4.2 Myeloid cell subset numbers in the peripheral blood of unchallenged 
DR3+/+ and DR3-/- mice 
To scrutinise if the absence of DR3 changed the composition of the leukocyte 
subsets in the peripheral blood, myeloid subsets were separated from the total 
leukocyte population. Similar numbers of all peripheral blood myeloid subsets tested 
(Monocytes: DR3+/+ mice 4.2 ± 1.0 x105, DR3-/- mice 4.7 ± 1.6 x105 cells/ml - 
Figure 3.22A, Neutrophils: DR3+/+ mice 2.3 ± 0.6 x105, DR3-/- mice 4.1 ± 2.2 x105 
cells/ml - Figure 3.22B, and Eosinophils: DR3+/+ mice 5.2 ± 1.3 x104, DR3-/- mice 
3.5 ± 0.8 x104 cells/ml - Figure 3.22C) were found in both genotypes. 
 
3.2.4.3 Lymphoid cell subset numbers in the peripheral blood of unchallenged 
DR3+/+ and DR3-/- mice 
The absence of DR3 had no effect on the number of T cells found in the peripheral 
blood (DR3+/+ mice 4.0 ± 0.5 x105, DR3-/- mice 4.5 ± 0.6 x105 cells/ml) (Figure 
3.23A) with no significant difference found in either CD4+ (DR3+/+ mice 2.3 ±       
0.3 x105, DR3-/- mice 2.7 ± 0.4 x105 cells/ml) (Figure 3.23B) or CD8+ (DR3+/+ mice 
1.6 ± 0.2 x105, DR3-/- mice 1.8 ± 0.2 x105 cells/ml) (Figure 3.23C) T cell subsets 
compared to naive DR3+/+ peripheral blood. Other peripheral blood lymphocytes 
investigated such as B cells (DR3+/+ mice 9.6 ± 1.8 x105, DR3-/- mice 1.0 ± 0.2 x106 
cells/ml) (Figure 3.24), NK cells (DR3+/+ mice 8.3 ± 1.4 x104, DR3-/- mice 7.2 ±       
1.0 x104 cells/ml) (Figure 3.25A) and NKT cells (DR3+/+ mice 1.3 ± 0.2 x104, DR3-/- 
mice 1.3 ± 0.2 x104 cells/ml) (Figure 3.25B) had analogous numbers between the 2 
genotypes. 
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Figure 3.22 - No significant differences were seen in the numbers of 
peripheral blood myeloid cell subsets between unchallenged DR3+/+  and 
DR3-/- mice. Peripheral blood leukocytes were collected by cardiac puncture 
of the heart. A) Monocytes were identified by a CD11bint F4/80int phenotype 
B) Neutrophils were identified by a 7/4+ Ly6G+ phenotype and C) 
Eosinophils, identified by a F4/80int CD11bint phenotype and their forward 
and side scatter properties. Subset numbers calculated by percentage 
proportion of total leukocytes/per ml (each symbol represents a single 
mouse, bar corresponds to mean from n=4 or 5, N.S.D by t-test). 
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Figure 3.23 - No significant differences were seen in the numbers of 
peripheral blood T cell subsets between unchallenged DR3+/+  and DR3-/- 
mice. Peripheral blood leukocytes were collected by cardiac puncture of the 
heart. A) T cells were identified by a CD3+, TCRαβ+ phenotype, B) T helper 
cells were identified by a CD3+ CD4+, TCRαβ+ phenotype and C) T 
cytotoxic cells identified by a CD3+ CD8+, TCRαβ+ phenotype. Subset 
numbers calculated by percentage proportion of total leukocytes/per ml 
(each symbol represents a single mouse, bar corresponds to mean from n=4 
or 5, N.S.D by t-test). 
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Figure 3.24 - No significant differences were seen in the numbers of 
peripheral blood B cells between unchallenged DR3+/+  and DR3-/- mice.  
Peripheral blood leukocytes were collected by cardiac puncture of the heart. 
B cells were identified by a CD19+, B220+ phenotype and numbers 
calculated by percentage proportion of total leukocytes/per ml (each symbol 
represents a single mouse, bar corresponds to mean from n=4 or 5, N.S.D by 
t-test). 
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Figure 3.25 - No significant differences were seen in the numbers of 
peripheral blood NK or NKT cell subsets between unchallenged DR3+/+  
and DR3-/- mice. Peripheral blood leukocytes were collected by cardiac 
puncture of the heart. A) NK cells were identified by a NK1.1+, TCRαβ- 
phenotype and B) NKT cells were identified by a NK1.1+, TCRαβ+ 
phenotype. Subset numbers calculated by percentage proportion of total 
leukocytes/per ml (each symbol represents a single mouse, bar corresponds 
to mean from n=4 or 5, N.S.D by t-test). 
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3.3 Summary 
• DR3 was not essential for maintaining the total residential leukocyte number in 
the naive peritoneal cavity.  
• Equivalent numbers of all leukocyte subsets were identified in the naive cavity 
of DR3-/- mice compared to DR3+/+ mice. 
• DR3 had no effect on proliferation or apoptotic mechanisms in the naive cavity.  
• DR3 was expressed on the mesothelial layer of the peritoneal membrane and on 
T cell subsets in the naive cavity. 
• Similar numbers of peripheral blood cell subsets were found in DR3-/- compared 
to DR3+/+ mice. 
• These data imply DR3 is not essential for homeostatic maintenance of leukocyte 
numbers in the peritoneal cavity or peripheral blood.    
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^ % DR3 expression on the mesothelial layer of the peritoneal membrane,  
* Median fluorescence intensity (MFI) ratio calculated by gating on specified subset 
and dividing its median from the DR3 test stain by the median of the isotype ± SEM 
(n = 3),            
† MFI calculated by subtracting median from the DR3 test stain by the median of the 
isotype ± SEM (n = 3),  
# MFI of positive population calculated by subtracting median of positive cells from 
the DR3 test stain in DR3+/+ and DR3-/- mice by the median of the isotype ± SEM      
(n = 3), 
$ Significance between two genotypes using Mann Whitney test, N.S.D = no 
significant difference.  
 
 
 
 
DR3 Expression 
Cell subset DR3+/+ DR3-/-  Significance$ 
% DR3 on peritoneal membrane^ 6.5 ± 0.3 0.3 ± 0.1 p<0.01 
DR3 MFI ratio* on T Cells 5.5 ± 0.2 2.1± <0.1 p<0.01 
DR3 MFI† on T Cells 19.7 ± 0.3 4.6 ± <0.1 p<0.01 
DR3 MFI ratio* on CD4+ T Cells 5.9 ± 0.2 2.1± <0.1 p<0.01 
DR3 MFI† on CD4+ T Cells 23.1 ± 0.5 5.1 ± <0.1 p<0.01 
DR3 MFI ratio* on CD8+ T Cells 3.4 ± 0.2 1.2 ± 0.2 p<0.01 
DR3 MFI† on CD8+ T Cells 7.8 ± 0.1 0.9 ± 0.9 p<0.01 
%  DR3 positive NK Cells  7 ± 1 5.5 ± 0.7 N.S.D 
DR3 MFI of NK Cell positive population# 63 ± 13 63 ± 3 N.S.D 
%  DR3 positive NKT Cells 69 ± 9 37 ± 4 p<0.05 
DR3 MFI of NKT Cell positive population 12 ± 6 31 ± 9 N.S.D 
Table 3.3 - Summary of DR3 expression 
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Chapter 4 - The role of DR3 in 
accumulation of leukocytes into the 
peritoneal cavity during the early stages of 
an in vivo acute inflammatory event 
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4.1 Introduction 
Other studies have shown that DR3/TL1A interaction can influence effector T cell 
proliferation and cytokine production, identifying it as a potential therapeutic target 
(Bamias, Mishina et al. 2006; Fang, Adkins et al. 2008; Meylan, Davidson et al. 
2008; Buchan, Taraban et al. 2012; Twohig, Marsden et al. 2012). To date, the affect 
of DR3 expression on the innate immune response in the peritoneal cavity has not 
been studied. Prior to the induction of inflammation, the absence of DR3 was found 
to have no significant impact on maintaining the leukocyte profile in the naive cavity 
and peripheral blood (Chapter 3).  
Peritoneal inflammation was induced by an i.p. injection of SES, which promotes a 
biphasic innate immune response (Jones 2005). The early phase (defined in this 
thesis as within the first 24 hours) is composed of an initial leukocyte influx 
predominately of neutrophils (peak 6-12 hours) from the peripheral blood, which are 
then cleared and replaced by other infiltrating cell subsets (Topley, Liberek et al. 
1996; Jones 2005). The late phase (post 24 hours) (Chapter 5) entails a further 
increase in the number of leukocytes present in the peritoneal cavity, with the influx 
of other (particularly lymphocytic) cell subsets before inflammation begins to be 
resolved (Jones 2005; McLoughlin, Jenkins et al. 2005).  
The aim of this chapter was to dissect the impact of the absence of DR3 on this early 
response to a bacterial inflammatory hit, including investigation of cell types that 
were a potential source of TL1A and alterations in DR3 expression following SES 
challenge. 
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4.2 Results  
4.2.1.1 Relative quantity (RQ) of TL1A mRNA in DR3+/+ and DR3-/- peritoneal 
membranes after SES induced inflammation 
Thus far no previous studies have investigated TL1A’s expression profile in the 
peritoneal cavity, though earlier work has shown an increase in TL1A levels after 
induction of inflammation (Bamias, Martin et al. 2003; Meylan, Davidson et al. 
2008; Saruta, Michelsen et al. 2009). The RQ (outlined in Section 2.5) of TL1A 
mRNA in the peritoneal membrane was investigated by qPCR.  TL1A mRNA did 
not increase in the membrane following SES challenge (Figure 4.1) and equivalent 
RQ of TL1A mRNA was found in the membrane of DR3+/+ and DR3-/- mice.  
 
4.2.1.2 RQ of TL1A mRNA in DR3+/+ and DR3-/- resident macrophages after 
SES stimulation 
Elevated RQ of TL1A mRNA in macrophages has previously been shown following 
LPS stimulation (Meylan, Davidson et al. 2008). RQ of TL1A mRNA was 
investigated in cell sorted peritoneal resident macrophages (Section 2.3.10) by qPCR 
(Section 2.5). Increased RQ of TL1A mRNA was found in DR3+/+ (28.4 ± 9 RQ) 
(p=0.03) and DR3-/- (18.2 ± 7 RQ) (p=0.02) resident macrophages 1 hour after         
ex vivo challenge with SES compared to unstimulated resident macrophages (Figure 
4.2). Consequently resident macrophages in the naive cavity and not the peritoneal 
membrane appear to be a source of TL1A after stimulating with SES.  
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Figure 4.1 - No significant differences were seen in the relative quantity 
of TL1A mRNA in the peritoneal membrane of DR3+/+ mice and DR3-/- 
mice after induction of SES inflammation. Inflammation in the cavity was 
induced via an i.p. injection of SES and peritoneal membranes analysed for 
RQ of TL1A mRNA by qPCR (each symbol represents mean of n=5 DR3+/+ 
mice (▲) and DR3-/- mice (▽) per time point, error bars correspond to mean 
± SEM, N.S.D by ANOVA).  
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Figure 4.2 - Increased relative quantity of TL1A mRNA was found in 
DR3+/+ and DR3-/- resident macrophages 1 hour after stimulation using 
SES. Resident macrophages were sorted from other leukocytes found in the 
peritoneal cavity and seeded into a 48 well plate. Macrophages were 
challenged with SES and analysed for RQ of TL1A mRNA by qPCR (each 
bar represents mean of 17 pooled DR3+/+ mice () and DR3-/- mice  (☐) from 
4 replicate experiments, error bars correspond to mean ± SEM).  
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4.2.1.3 DR3 expression on the mesothelial layer of the peritoneal membrane of 
DR3+/+ and DR3-/- mice after SES induced inflammation  
DR3 was detected on the mesothelial layer of the unchallenged peritoneal membrane 
(Section 3.2.3.1) (Figure 3.16), so DR3 expression was followed after the induction 
of inflammation. Multiple pictures were taken along sections of the mesothelial layer 
over an inflammatory time course from DR3+/+ and DR3-/- mice (Figure 4.3). DR3 
expression could no longer be detected 6 hours after SES challenge in DR3+/+ mice 
(0.4 ± 0.4 % positive pixels). However DR3 expression returned 12 hours after 
inflammation was induced (7.6 ± 1.6 %) before disappearing again by 24 hours (0.1 
± 0.1 %) and for the remainder of the time course (Figure 4.4). Low background 
staining was detected on the DR3-/- (0.1 ± <0.1 %) (Figure 4.4) (p<0.01) and isotype 
control (0.1 ± <0.1 %). 
 
 
  
Isotype 
            6hr
  
            
12hr
  
            
24hr
  
DR3-/- DR3+/+ 
Figure 4.3 - Significant levels of DR3 expression were found on the 
mesothelial layer of the peritoneal membrane of DR3+/+ mice after 12 
hours of SES inflammation. Inflammation in the cavity was induced via an 
i.p. injection of SES. Peritoneal membranes were harvested, fixed, sectioned 
and stained for DR3 expression. Representative pictures show no DR3 staining 
in the mesothelial layer of DR3+/+ mice after 6 hours of inflammation, though 
DR3 is present after 12 hours yet this expression is lost again 24 hours after 
SES challenge (Bar corresponds to 25μm.) 
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Figure 4.4 - Significant levels of DR3 expression were found on the 
peritoneal membrane of DR3+/+  mice after 12 hours of SES inflammation. 
Inflammation in the cavity was induced via an i.p. injection of SES. 
Peritoneal membranes were harvested, fixed, sectioned and stained for DR3 
expression. DR3 expression on the membrane was analysed by taking 
multiple pictures along the section and measuring the % of positive (brown) 
pixels within the mesothelial layer of the membrane using Adobe Photoshop 
CS4 (each symbol represents mean of n=3 DR3+/+ mice (▲) and DR3-/- mice  
(▽) per time point, error bars correspond to mean ± SEM, p<0.01 by 
Kruskal-Wallis test, ***p<0.001 by Mann Whitney test).  
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4.2.1.4 DR3 expression on lymphocyte cell subsets in the peritoneal cavity of 
DR3+/+ and DR3-/- mice after SES induced inflammation.  
Alteration in DR3 expression on T and NK lymphocyte subsets after SES challenge 
was determined by a polyclonal DR3 antibody and flow cytometry. For T cells, MFI 
rather than percentages were used to estimate relative level of DR3 signal as 
discussed in Chapter 3. Significantly greater fluorescence signal shift above the 
isotype (7.2 ± 0.5 MFI after 12 hours) was once again observed in both DR3+/+ (22.2 ± 
3.1 MFI after 12 hours) (p<0.01) and DR3-/- mice (9.8 ± 0.2 MFI after 12 hours) 
(p<0.05) in the T cell population, implying recognition of some non-DR3 signal by 
the polyclonal DR3 antibody. However, the fluorescence signal shift was 
consistently greater in DR3+/+, compared to DR3-/- mice (p<0.05 after 12 hours). 
Relative DR3 expression was therefore estimated using a standardised RF signal 
relative to the isotype control and was calculated by dividing the test MFI by the 
MFI from the isotype. Following induction of inflammation RF on DR3+/+ T cells 
(3.0 ± 0.4 RF after 12 hours) was found to be significantly greater than on DR3-/- 
peritoneal T cells (1.5 ± <0.1 RF after 12 hours) (p<0.01), however RF on DR3+/+      
T cells after SES challenge was significantly reduced compared to naive DR3+/+          
T cells (5.5 ± 0.2 RF) (Figure 4.5A). Investigation of T cell subsets showed different 
DR3 RF expression profiles in DR3+/+ mice; CD8+ T cells lost all DR3 expression 
during inflammation (1.0 ± <0.1 RF after 12 hours) (Figure 4.5C) compared to naive 
CD8+ T cells (5.2 ± 1.8 RF), whereas RF on DR3+/+ CD4+ T cells was seen to 
fluctuate over the time course (4.1 ± 0.6 RF after 12 hours) (Figure 4.5B). 
MFI ratio was not used to analyse NK and NKT cell subsets due to a separate      
non-DR3 signal positive population found in DR3-/- NKT cells and both the DR3-/- 
and isotype control of NK cells (Figure 3.19). Instead percent positive and MFI of 
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the positive population was used to calculate potential DR3 expression. No 
significant differences were seen in the percentage positive population of NK cells at 
any point throughout the time course in DR3+/+ mice (3.4 ± 1 % after 12 hours) 
compared to DR3-/- mice (2.4 ± 0.2 % after 12 hours) or isotype control (1.6 ±       
0.2 % after 12 hours) (Figure 4.6A), equivalent MFI was also found in the positive 
population between DR3+/+ (26.7 ± 1.4 MFI after 12 hours) and DR3-/- mice over the 
time course (27 ± 1 MFI after 12 hours). Percent positive NKT cells however was 
significantly higher in naive DR3+/+ mice (69 ± 9 %) compared to DR3-/- mice         
(37 ± 4 %) (p<0.05) and the isotype (9 ± 2 %) (p<0.01), though the percentage 
positive in DR3+/+ mice fell over the time course (53 ± 1.9 % after 24 hours) (Figure 
4.6B); the MFI in the NKT positive population of DR3+/+ mice (27 ± 1 MFI after      
24 hours) was not significantly different to those found in DR3-/- mice (27 ± 1 MFI 
after 24 hours).  
In summary, DR3 expression was found on tissue and multiple cell subsets in the 
peritoneal cavity and fluctuated following SES challenge. On the peritoneal 
membrane, it was initially expressed but showed a biphasic pattern being absent at    
6 and 24 hours. On CD8+ T cells, cell surface DR3 was found initially but lost 
within 6 hours. In contrast, DR3 expression on CD4+ T cells and NKT cells was 
found throughout the first 24 hours after SES challenge. These tissues and cell types 
are potential targets for the action of TL1A. 
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Figure 4.5 - Significant levels of DR3 expression were found on CD4+, but 
not CD8+, T cells in the peritoneal cavity of DR3+/+ mice after induction of 
SES inflammation. Inflammation in the cavity was induced via an i.p. injection 
of SES and leukocytes isolated from the cavity by lavage. A) T cells were 
identified by a CD3+, TCRαβ+ phenotype (p<0.01 by ANOVA, Bonferroni post 
hoc test **p<0.01 after 12h and ***p<0.001 after 0, 6 and 24h) B) T helper cells 
were identified by a CD3+ CD4+, TCRαβ+ phenotype (p<0.01 by ANOVA, 
Bonferroni post hoc test ***p<0.001 after all time points) and C) T cytotoxic 
cells identified by a CD3+ CD8+, TCRαβ+ phenotype (Bonferroni post hoc test 
**p<0.01 after 0h). Ratio of DR3 expression on subsets was calculated by the 
MFI fold increase compared to the isotype (each symbol represents mean of n=3 
DR3+/+ mice (▲) and DR3-/- mice  (▽) per time point, error bars correspond to 
mean ± SEM, analysed by ANOVA and Bonferroni post hoc test). 
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Figure 4.6 - Significant levels of DR3 expression were found on NKT 
cells but not NK cells in the peritoneal cavity of DR3+/+ mice compared 
to DR3-/- mice after induction of SES inflammation. Inflammation in the 
cavity was induced via an i.p. injection of SES. Peritoneal leukocytes were 
isolated from the cavity by lavage. A) NK cells were identified by a NK1.1+, 
TCRαβ- phenotype and B) NKT helper cells were identified by a NK1.1+, 
TCRαβ+ phenotype (p<0.01 by Kruskal-Wallis test, Mann Whitney test 
*p<0.05 after 0 and 6h). Percentage positive population was used to 
calculate potential DR3 expression (each symbol represents mean of n=3 
DR3+/+ mice (▲) and DR3-/- mice  (▽) per time point, error bars correspond 
to mean ± SEM, analysed by Kruskal-Wallis test, and Mann Whitney test) 
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4.2.2.1 Accumulation of mouse leukocytes in the DR3+/+ and DR3-/- peritoneal 
cavity during early stages of SES induced inflammation 
Total leukocytes in the cavity during the early stage of inflammation were isolated 
by lavage at defined time points after SES challenge (Section 2.2.3.1) and counted 
by a Coulter counter (Section 2.2.4). There was a substantial increase in number of 
leukocytes in the cavity of both genotypes 1 hour after SES challenge, and total 
number of leukocytes continued to increase throughout the first 24 hours (Figure 
1.9). DR3-/- mice displayed a similar profile of leukocyte accumulation as DR3+/+ 
mice, though a trend towards lower cell numbers was observed in the DR3-/- cavity 
after both 6 hours (DR3+/+ mice 7.1 ± 1.6 x106, DR3-/- mice 5.6 ± 0.4 x106 total cells) 
(p=0.35) and 24 hours (DR3+/+ mice 8.2 ± 1.4 x106, DR3-/- mice 5.5 ± 1.0 x106 total 
cells) (p=0.19). The latter time point may be considered a transition point between 
early and late stages of acute inflammation in this model (Figure 4.7).  
 
 
 
 
 
 
 
 
 
Figure 4.7 - No significant differences were seen in total peritoneal 
leukocyte numbers in the cavity of DR3+/+ compared to DR3-/- mice 
following SES induced inflammation. Inflammation was induced via an i.p. 
injection of 500μl of SES. Peritoneal leukocytes were isolated from the cavity 
by lavage, total cell number over the time course was calculated using a 
Beckman Coulter counter Z2 (each symbol represents mean of n=6 DR3+/+ 
mice (▲) and DR3-/- mice  (▽) per time point, error bars correspond to mean 
± SEM, N.S.D by ANOVA).  
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4.2.2.2 Neutrophil numbers in DR3+/+ and DR3-/- peritoneal cavities during 
early stages of SES induced inflammation 
Although the numbers of total infiltrating leukocytes were not significantly different 
between DR3+/+ and DR3-/- mice, the trend towards lower numbers in DR3-/- animals 
warranted a closer analysis of individual leukocyte subsets. Neutrophils rapidly 
entered the DR3-/- and DR3+/+ cavity (within 1 hour of inflammation being induced) 
and peaked in the DR3+/+ cavity 6 hours after challenge (Figure 4.8A). DR3-/- mice 
were found to have significantly lower numbers of neutrophils in their peritoneal 
cavity during the early stage of inflammation (p<0.01) (Figure 4.8B). Peak variation 
in neutrophil number between the 2 genotypes was observed 6 hours after the 
induction of SES inflammation (DR3+/+ mice 2.6 ± 0.8 x106, DR3-/- mice 9.0 ±       
2.6 x105 total neutrophils) (p<0.01, Bonferonni’s post hoc test), matching the first 
time point when a trend towards lower total leukocyte numbers in the DR3-/- cavity 
was observed (Figure 4.7).  
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Figure 4.8 - Significantly higher numbers of neutrophils accumulated in 
the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after 
induction of SES inflammation. Inflammation was induced via an i.p. 
injection of SES. Peritoneal leukocytes were isolated from the cavity by 
lavage. A) Neutrophils were identified by a 7/4+ Ly6G+  CD11bint F4/80int  
phenotype. (Gate R26) B) Neutrophil numbers at each time point were 
calculated by percentage proportion of total leukocytes, determined using a 
Beckman Coulter counter Z2 (each symbol represents mean of n=6 DR3+/+ 
mice (▲) and DR3-/- mice  (▽) per time point, error bars correspond to mean 
± SEM, p<0.01 by ANOVA with peak impairment 6hr after inflammation, 
**p<0.01 by Bonferroni post hoc test). 
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4.2.2.3 Accumulation of other myeloid cell subsets in the DR3+/+ and DR3-/- 
peritoneal cavity during early stages of SES induced inflammation 
Other myeloid cell subsets including resident macrophages, inflammatory 
macrophages and eosinophils (Figure 2.3) were also investigated. Resident 
macrophages composed the majority of all myeloid cells in the naive cavity (Figure 
3.2) but after challenging with SES there was a significant increase in the number of 
eosinophils and particularly inflammatory macrophages (Figure 4.9). Over the first 
24 hours, DR3-/- mice (2.8 ± 0.5 x105 total resident macrophages after 24 hours) 
were found to have comparable numbers of resident macrophages in their cavity as 
DR3+/+ mice (3.2 ± 1.0 x105 total resident macrophages after 24 hours) (Figure 
4.9B). However there was a substantial reduction in the accumulation of both 
inflammatory macrophages (Figure 4.9A) (p<0.01) and eosinophils (Figure 4.9C) 
(p<0.01) in DR3-/- mice, with differences between the 2 genotypes at their greatest 
after 24 hours of inflammation (total inflammatory macrophages: DR3+/+ mice 3.0 ± 
0.5 x106, DR3-/- mice 1.6 ± 0.5 x106, p<0.01 and total eosinophils: DR3+/+ mice     
8.8 ± 1.6 x105, DR3-/- mice 2.8 ± 1.1 x105, p<0.01, Bonferonni’s post hoc test), 
matching the second timepoint at which a trend towards lower total leukocyte 
numbers in the DR3-/- cavity were observed (Figure 4.7). 
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Figure 4.9 - Significantly higher numbers of inflammatory macrophages and 
eosinophils but not resident macrophages accumulated in the peritoneal 
cavity of DR3+/+ mice compared to DR3-/- mice after induction of SES 
inflammation. Inflammation in the cavity was induced via an i.p. injection of 
SES. Peritoneal leukocytes were isolated by lavage. A) Inflammatory 
Macrophages, were identified by a CD11bint F4/80int phenotype (p<0.01 by 
ANOVA, Bonferroni post hoc test **p<0.01 after 24h). B) Resident Macrophages 
were identified by a CD11b+ F4/80+ phenotype and C) Eosinophils, identified by 
a F4/80int CD11bint phenotype and their forward and side scatter properties 
(p<0.01 by ANOVA, Bonferroni post hoc test ***p<0.001 after 24h). Subset 
numbers calculated by percentage proportion of total leukocytes, determined 
using a Beckman Coulter counter Z2 (each symbol represents mean of n=6 
DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars correspond to 
mean ± SEM, analysed by ANOVA and Bonferroni post hoc test). 
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4.2.2.4 Accumulation of lymphocyte cell subsets in DR3+/+ and DR3-/- peritoneal 
cavities during early stages of SES induced inflammation 
Lymphocyte cell subsets in the naive peritoneal cavity are composed primarily of B1 
cells (Figure 3.4), but after challenging with SES there was an initial fall in the 
number of B and T lymphocytes over the first 6 hours. Numbers of lymphocytic cell 
subsets then returned to naive levels 6 hours after SES challenge and some 
lymphocyte subsets began to exceed the numbers present during naive conditions 
(NK cells, NKT cells and CD8+ T cells). During the early stage of inflammation 
DR3+/+ and DR3-/- mice had analogous numbers of T cells (DR3+/+ mice 7.5 ±         
1.8 x105, DR3-/- mice 4.7 ± 1.1 x105 total T cells after 24 hours), CD4+ (DR3+/+ mice 
2.9 ± 1.0 x105, DR3-/- mice 1.8 ± 0.5 x105 total CD4+ T cells after 24 hours) and 
CD8+ (DR3+/+ mice 1.8 ± 0.5 x105, DR3-/- mice 7.6 ± 2.2 x104 total CD8+ T cells 
after 24 hours) (Figure 4.10); B cells (DR3+/+ mice 7.0 ± 1.9 x105, DR3-/- mice 6.9 ± 
2.1 x105 after 6 hours total B cells), B1 (DR3+/+ mice 4.0 ± 1.0 x105, DR3-/- mice     
3.5 ± 1.3 x105 total B1 cells after 6 hours) and B2 (DR3+/+ mice 8.8 ± 3.8 x104,    
DR3-/- mice 1.2  ± 0.6 x105 total B2 cells after 6 hours) (Figure 4.11) and NK cells 
(DR3+/+ mice 2.4 ± 0.5 x105, DR3-/- mice 2.3 ± 0.5 x105 total NK cells after             
24 hours) (Figure 4.12A) in the peritoneal cavities. Only NKT cell number was 
found to be significantly reduced in the DR3-/- cavity compared to DR3+/+ mice 
(Figure 4.12B) (p<0.05), with significant differences between the 2 genotypes only 
observed 24 hours after challenge (DR3+/+ mice 2.0 ± 0.6 x105, DR3-/- mice 8.8 ±   
2.3 x104 total NKT cells) (p<0.05, Bonferonni’s post hoc test).  
Thus DR3-/- mice are associated with reduced numbers of selected leukocyte subsets 
within the cavity after SES challenge. At early time points, these consist of 
152 
 
neutrophils but at 24 hours, inflammatory macrophages, eosinophils and NKT cells 
also show impaired numbers in DR3-/- mice. 
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Figure 4.10 - No significant differences were seen in the numbers of T 
cell subsets in the peritoneal cavity of DR3+/+ mice compared to DR3-/- 
mice following SES induced inflammation. Inflammation in the cavity was 
induced via an i.p. injection of SES. Peritoneal leukocytes were isolated by 
lavage A) T cells were identified by a CD3+, TCRαβ+ phenotype, B) T helper 
cells were identified by a CD3+ CD4+, TCRαβ+ phenotype and C) T 
cytotoxic cells identified by a CD3+ CD8+, TCRαβ+ phenotype. Subset 
numbers calculated by percentage proportion of total leukocytes, determined 
using a Beckman Coulter counter Z2 (each symbol represents mean of n=6 
DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars correspond 
to mean ± SEM, N.S.D by ANOVA). 
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Figure 4.11 - No significant differences were seen in the numbers of B cell 
subsets in the peritoneal cavity of DR3+/+  mice compared to DR3-/- mice 
following SES induced inflammation. Inflammation in the cavity was 
induced via an i.p. injection of SES. Peritoneal leukocytes were isolated by 
lavage A) B cells were identified by a CD19+, B220+ phenotype, B) B1 cells 
were identified by a CD19+ B220int, CD11bint phenotype and C) B2 cells 
identified by a CD19+ B220+, CD11b- phenotype. Subset numbers calculated 
by percentage proportion of total leukocytes, determined using a Beckman 
Coulter counter Z2 (each symbol represents mean of n=6 DR3+/+ mice (▲) 
and DR3-/- mice (▽) per time point, error bars correspond to mean ± SEM, 
N.S.D by ANOVA). 
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Figure 4.12 - Significantly higher numbers of NKT cells but not NK cells 
accumulated in the peritoneal cavity of DR3+/+ mice compared to DR3-/- 
mice after induction of SES inflammation. Inflammation in the cavity was 
induced via an i.p. injection of SES. Peritoneal leukocytes were isolated 
from the cavity by lavage. A) NK cells were identified by a NK1.1+, TCRαβ- 
phenotype and B) NKT cells were identified by a NK1.1+, TCRαβ+ 
phenotype (p<0.05 by ANOVA, Bonferroni post hoc test *p<0.05 after 24h). 
Subset numbers calculated by percentage proportion of total leukocytes, 
determined using a Beckman Coulter counter Z2 (each symbol represents 
mean of n=6 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars 
correspond to mean ± SEM, analysed by ANOVA and Bonferroni post hoc 
test). 
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4.2.3.1 Chemokine levels in unchallenged DR3+/+ and DR3-/- peritoneal cavities 
Because neutrophils are unable to proliferate and are generally not found in the 
naive cavity (Topley, Liberek et al. 1996; Kolaczkowska 2010), I tested the 
hypothesis that DR3/TL1A signalling controlled the level of chemoattractants as a 
potential explanation for the observed impairment in leukocyte accumulation within 
the DR3-/- cavity. Chemokines have previously been shown to be released following 
SES challenge, as part of the innate inflammatory response and play an important 
role in the movement of leukocytes from the peripheral blood to local areas of 
inflammation (McLoughlin, Hurst et al. 2004; McLoughlin, Jenkins et al. 2005). 
However before investigating chemoattractants during inflammation, chemokine 
levels present in the naive cavity were first determined to examine if they were 
significantly influenced by the absence of DR3 prior to SES challenge. No 
significant difference was observed in the level of any chemoattractant studied 
between naive DR3+/+ and DR3-/- mice. Indeed only low concentrations of 
chemokines were measured in the unchallenged cavity of either DR3+/+ or DR3-/- 
mice, with only CXCL13 (DR3+/+ mice 135 ± 3 pg/ml, DR3-/- mice 140 ± 2 pg/ml), 
CCL4 (DR3+/+ mice 51 ± 2 pg/ml, DR3-/- mice 52 ± 2 pg/ml), CXCL5 (DR3+/+ mice 
8 ± 1 pg/ml, DR3-/- mice 9 ± 2 pg/ml), CXCL10 (DR3+/+ mice 13 ± 3 pg/ml, DR3-/- 
mice 12 ± 2 pg/ml) and CCL3 (DR3+/+ mice 12 ± 2 pg/ml, DR3-/- mice 11 ± 3 pg/ml) 
above the level of detection. All other chemoattractants measured were below the 
detection level of the ELISA kits in both the DR3+/+ and DR3-/- mice (Figure 4.13). 
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Figure 4.13 - No significant differences were seen in the level of selected 
chemokines in the unchallenged peritoneal cavity of DR3+/+ and DR3-/- 
mice. Cell free supernatants from the peritoneal lavage were used to obtain 
chemokine concentrations in the cavity using ELISA (each bar represents 
mean of n=3 DR3+/+ mice () and DR3-/- mice  (☐), error bars correspond to 
mean ± SEM, N.S.D by t-test). 
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4.2.3.2 Levels of ELR+ chemoattractants in DR3+/+ and DR3-/- peritoneal 
cavities after SES induced inflammation 
As DR3 had no effect on chemokine levels in the naive cavity, the level of 
neutrophilic chemokines, which contain an N-terminal tripeptide sequence of 
glutamic acid, leucine and arginine (or ELR+ motif) was determined during 
inflammation by testing peritoneal supernatants from the challenged cavity of 
DR3+/+ and DR3-/- mice. ELR+ chemoattractants (KC, MIP2 and CXCL5) are rapidly 
released and cleared after the induction of SES inflammation (Rollins 1997).  No 
significant disparity was found in the level of MIP2 (DR3+/+ mice 1340 ± 119 pg/ml, 
DR3-/- mice 972 ± 140 pg/ml after 1 hour) (Figure 4.14B) and CXCL5 (DR3+/+ mice 
24 ± 15 pg/ml, DR3-/- mice 19 ± 17 pg/ml after 6 hours) (Figure 4.14C) in the 
peritoneal cavity of DR3+/+ and DR3-/- mice during the early phase of inflammation. 
However there were significantly reduced peak levels of the chemoattractant KC in 
the challenged cavity of DR3-/- mice (2319 ± 626 pg/ml after 1 hour) compared to 
DR3+/+ mice (5251 ± 945 pg/ml after 1 hour) (Figure 4.14A) (p=0.03). Therefore 
SES inflammation leads to the release of KC and MIP2 in both DR3+/+ and DR3-/- 
mice, with significantly lower levels of KC found in DR3-/- mice. 
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Figure 4.14 - Significantly higher levels of KC but not MIP2 and 
CXCL5 were found in the peritoneal cavity of DR3+/+ mice compared to 
DR3-/- mice after induction of SES inflammation. Inflammation in the 
cavity was induced via an i.p. injection of SES and cell free supernatants 
obtained analysed for levels of A) KC (*p<0.05) B) MIP2 and C) CXCL5 by 
ELISA (each symbol represents mean of n=5 DR3+/+ mice (▲) and DR3-/- 
mice (▽) per time point, error bars correspond to mean ± SEM, analysed by 
ANOVA and p values calculated using Bonferonni’s post hoc test). 
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4.2.3.3 RQ of ELR+ chemoattractant mRNA in DR3+/+ and DR3-/- peritoneal 
membranes after SES induced inflammation 
Mesothelial cells present within the peritoneal membrane have previously been 
shown to be a source of chemoattractants (Li, Davenport et al. 1998; Hurst, 
Wilkinson et al. 2001; McLoughlin, Hurst et al. 2004); consequently the RQ of 
ELR+ chemokines in the membrane after SES challenge was investigated by qPCR 
(Section 2.5). KC and MIP2 mRNA rapidly increased (1 hour) after the induction of 
inflammation (Figure 4.15A and 4.15B) though little increase was seen in the RQ of 
CXCL5 mRNA (Figure 4.15C). Comparable RQ of MIP2 (DR3+/+ mice 237 ± 89, 
DR3-/- mice 97 ± 39 RQ after 1 hour) (Figure 4.15B) and CXCL5 (DR3+/+ mice 24 ± 
15, DR3-/- mice 18 ± 17 RQ after 6 hours) (Figure 4.15C) mRNA was found in the 
peritoneal membrane of DR3+/+ and DR3-/- mice. Yet there were significantly 
reduced quantities of KC mRNA in the membrane of DR3-/- mice (33 ± 4 RQ after    
1 hour) compared to DR3+/+ mice (216 ± 92 RQ after 1 hour) 1 hour after SES 
challenge (Figure 4.15A) (p=0.02), and correlated with reduced levels of KC in the 
DR3-/- cavity tested by ELISA (Figure 4.14A). 
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Figure 4.15 - Significantly higher relative quantity of KC mRNA but not 
MIP2 and CXCL5 mRNA was found in the peritoneal membrane of 
DR3+/+ mice compared to DR3-/- mice after induction of SES 
inflammation. Inflammation in the cavity was induced via an i.p. injection 
of SES and peritoneal membranes obtained analysed for RQ of A) KC 
mRNA (*p<0.05) B) MIP2 mRNA and C) CXCL5 mRNA by qPCR (each 
symbol represents mean of n=5 DR3+/+ mice (▲) and DR3-/- mice  (▽) per 
time point, error bars correspond to mean ± SEM, analysed by ANOVA and 
p values calculated using Bonferonni’s post hoc test). 
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4.2.3.4 Correlation between peak level of neutrophilic chemoattractants and 
peak neutrophil accumulation after the induction of SES inflammation. 
To determine if higher ELR+ chemoattractant levels correlated with an increased 
influx of neutrophils into the peritoneal cavity, maximum neutrophil number 
observed after 6 hours of SES inflammation (Figure 4.8A) was plotted against peak 
levels of ELR+ neutrophilic chemoattractants observed 1 hour after challenge (Figure 
4.14). No significant correlation was found between the maximum number of 
neutrophils in the cavity and the peak levels of the neutrophilic chemoattractants 
MIP2 (Figure 4.16B) and CXCL5 (Figure 4.16C) in challenged supernatants. 
However correlation was found between the maximum number of neutrophils in the 
cavity and the levels of the neutrophilic chemoattractant KC in the challenged 
supernatants (Figure 4.16A, R=0.96, p=0.02), with increasing levels of KC 
positively associated with increased neutrophil accumulation.   
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Figure 4.16 - Significant correlation was found between peak number of 
neutrophils in the cavity and the level of KC but not MIP2 and CXCL5 in 
DR3+/+ mice and DR3-/- mice after induction of SES inflammation. 
Inflammation in the cavity was induced via an i.p. injection of SES and cell 
free supernatants analysed for chemokine levels by ELISA. Neutrophils in the 
cavity were identified by a 7/4+ Ly6G+  CD11bint F4/80int phenotype. 
Correlation between the peak level of A) KC (R=0.82, p<0.01) B) MIP2 and 
C) CXCL5 in the supernatants was plotted against peak number of 
neutrophils which accumulated in the cavity (each symbol represents a single 
DR3+/+ (▲) or DR3-/- mouse (▽), analysed by Pearson R correlation test).  
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4.3 Summary 
• The RQ of TL1A mRNA increased in resident macrophages after stimulation 
with SES, in contrast to the peritoneal membrane where there was no increase in 
RQ of TL1A mRNA after SES challenge. 
• DR3 is expressed in the peritoneal cavity both on the mesothelial layer of the 
membrane and selected T cell subsets, though the level of expression varies 
after the induction of inflammation. 
• DR3 is important in regulation of neutrophil accumulation into the peritoneal 
cavity following SES challenge.  
• DR3-/- mice also have a significant reduction in the accumulation of 
inflammatory macrophages, eosinophils and NKT cells into their cavity 
compared to DR3+/+ mice after the induction of inflammation.  
• DR3-/- peritoneal supernatants have reduced levels of the ELR+ neutrophilic 
chemoattractant KC and levels of KC correlate with neutrophil accumulation 
into the cavity following SES challenge. 
• The peritoneal membrane is a likely source of KC, with rapid increase in KC 
mRNA production in the DR3+/+ membrane. KC mRNA production was 
substantially reduced in the DR3-/- membrane compared to those from DR3+/+ 
mice. 
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^ Relative quantity of TL1A mRNA,  
 ¥  % DR3 expression on the mesothelial layer of peritoneal membrane,  
* Median fluorescence intensity (MFI) ratio calculated by dividing median of DR3 test 
stain by median of isotype ± SEM (n=3),         
† MFI calculated by subtracting median of DR3 test stain by median of isotype ± SEM 
(n=3),  
# MFI of positive population calculated by subtracting median of positive from DR3 test 
stain by median of isotype ± SEM (n=3),  
$  Peak/ noteworthy time point,  
~  Significance between two genotypes using ANOVA or Kruskal-Wallis test, N.S.D = 
no significant difference.  
 
 
 TL1A and DR3 expression  
Cell Subset Time (h)
$ 
 DR3
+/+
  DR3
-/-
  Significance
~ 
 
RQ of TL1A^ in the peritoneal membrane  1  0.6 ± 0.4  0.2 ± 0.1  N.S.D  
RQ of TL1A^ in resident macrophages  1 28.4 ± 9  18.2 ± 7 N.S.D 
% DR3 on the membrane
¥ 
 12  7.6 ± 1.6  0.1 ± <0.1  p<0.01  
DR3 MFI ratio* on T Cells  12  3.0 ± 0.4  1.5 ± <0.1  p<0.01 
DR3 MFI
†
 on T Cells  12  15.2 ± 3.6  2.8 ± 0.3  p<0.05 
DR3 MFI ratio* on CD4
+ 
T Cells  12  4.1 ± 0.6  1.7 ± <0.1  p<0.01  
DR3 MFI
†
 on CD4
+ 
T Cells  12  11.7 ± 2.1  2.5 ± 0.1  p<0.05 
DR3 MFI ratio* on CD8
+ 
T Cells  12  1.0 ± <0.1  1.0 ± <0.1  N.S.D  
DR3 MFI
†
 on CD8
+ 
T Cells  12  2.7 ± 1.6  1.6 ± 1.6  N.S.D  
%  DR3 positive NK Cells  12  3.4 ± 1 2.4 ± 0.2 N.S.D  
DR3 MFI of NK Cell positive population
#
  12  27 ± 1.4 27 ± 1 N.S.D  
%  DR3 positive NKT Cells  24  53 ± 2 42 ± 1  p<0.05 
DR3 MFI of NKT Cell positive population
#
 24 27 ± 1 27 ± 1 N.S.D 
Table 4.1 - Summary of TL1A and DR3 expression over the first 24 hours of SES challenge  
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Chapter 5 – The role of DR3 in 
accumulation of leukocytes into the 
peritoneal cavity during later stages of an 
in vivo acute inflammatory event 
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5.1 Introduction 
A two-staged innate immune response is provoked in the peritoneal cavity by i.p. 
injection of SES (Jones 2005). During the early phase of SES inflammation DR3 
was found to be important in regulating the recruitment of selected myeloid cell 
subsets and NKT cells into the peritoneal cavity, which was associated with a 
significant reduction in the neutrophilic chemoattractant KC in DR3-/- mice, thus 
identifying a novel pro-inflammatory role for DR3 in the innate inflammatory 
response (Chapter 4). The late phase (post 24 hours) is characterised by further 
increases in the number of leukocytes in the peritoneal cavity, with the influx of 
other (particularly lymphocytic) cell subsets before inflammation begins to be 
resolved and the typical homeostatic resident leukocyte population restored (Jones 
2005).  
The aim of this chapter was to analyse the effect of DR3 deficiency on this late 
response to a bacterial-derived agonist, including correlative studies of: (i) DR3 
expression in the mesothelial layer of the peritoneal membrane; (ii) proliferation of 
leukocytes entering the cavity during this phase, and; (iii) chemoattractant levels 
during this period. 
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5.2 Results  
5.2.1 DR3 expression on DR3+/+ and DR3-/- peritoneal membranes after SES 
induced inflammation 
DR3 expression fluctuated on the mesothelial layer in the peritoneal membrane 
during the early phase of inflammation (Section 4.2.1.3) (Figure 4.4), consequently 
DR3 expression was tracked into the late phase of inflammation. Multiple pictures 
were taken along sections of the mesothelial layer of DR3+/+ and DR3-/- mice (Figure 
5.1A). DR3 expression could no longer be detected on the mesothelial layer in the 
membrane of DR3+/+ mice during the late phase following SES challenge (0.31 ± 
0.21 % after 48 hours). Low background staining was detected on the DR3-/- control 
(0.32 ± 0.18 % after 48 hours) (Figure 5.1B) and isotype control (0.1 ± <0.1 %). 
Thus DR3 is no longer expressed on the membrane after 12 hours of SES induced 
inflammation and does not return even after 72 hours. 
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Figure 5.1 - No significant differences were seen in the level of DR3 
expression on the peritoneal membrane of DR3+/+  mice compared to 
DR3-/- mice 24 and 48 hours after SES induced inflammation. A) 
Representative pictures of DR3 staining in the mesothelial layer of the 
peritoneal membrane (Bar corresponds to 25μm.) B) DR3 expression on the 
membrane was analysed by taking multiple pictures along the section and 
measuring the % of positive (brown) pixels within the mesothelial layer of 
the membrane using Adobe Photoshop CS4 (each symbol represents mean 
of n=3 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars 
correspond to mean ± SEM, N.S.D by Mann-Whitney test).  
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5.2.2.1 Accumulation of mouse leukocytes in the DR3+/+ and DR3-/- peritoneal 
cavity during later stages of acute SES induced inflammation 
Peritoneal leukocyte numbers were reduced at selected time points (6 and 24 hours) 
during the early phase of SES induced inflammation (Chapter 4), though this was 
not significant (Figure 4.7). During the late phase substantially more leukocytes 
accumulated in the cavity of DR3+/+ mice. DR3-/- mice, however, demonstrated 
significantly fewer leukocytes compared to DR3+/+ mice (Figure 5.2A) (p<0.01). 
Peritoneal leukocyte number within the DR3+/+ cavity peaked around 48 hours after 
SES challenge (9.1 ± 0.9 x106 total cells), whereas total leukocyte number in the 
DR3-/- cavity barely changed throughout the late phase (4.5 ± 0.5 x106 total cells 
after 48 hours) (Figure 5.2B) (p<0.01).  
 
5.2.2.2 Clearance of neutrophils in DR3+/+ and DR3-/- peritoneal cavities during 
later stages of acute SES induced inflammation 
As significantly fewer leukocytes were observed in the peritoneal cavity of DR3-/- 
mice compared to DR3+/+ mice, leukocyte subsets were investigated to determine 
which were altered in the DR3-/- mice. Neutrophils are cleared from the cavity 
during the late phase and their numbers decline throughout this period (Figure 5.3A). 
Comparable kinetics of neutrophil clearance was observed between the 2 genotypes, 
however DR3-/- mice (3.7 ± 0.9 x104 total neutrophils after 48 hours) were still found 
to have significantly reduced numbers of neutrophils after the first 24 hours of SES 
challenge compared to DR3+/+ mice (8.9 ± 2.8 x104 total neutrophils after 48 hours) 
(p<0.01) (Figure 5.3B).  
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Figure 5.2 - Significantly higher numbers of leukocytes accumulated in 
the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after SES 
induced inflammation. Inflammation in the cavity was induced via an i.p. 
injection of SES. Peritoneal leukocytes were isolated from the cavity by 
lavage, total cell number over the time course was calculated using a 
Beckman Coulter counter Z2. A) Following SES challenge significantly 
reduced numbers of leukocytes were found in the cavity of DR3-/- mice 
compared to DR3+/+ (each symbol represents mean of n=6 DR3+/+ mice (▲) 
and DR3-/- mice  (▽) per time point, error bars correspond to mean ± SEM, 
p<0.01 by ANOVA, Bonferroni post hoc test **p<0.01 after 48h and 
*p<0.05 after 72h). B) At the peak of the inflammatory response (48 hours) 
DR3-/- mice present no significant increase in total leukocyte number 
compared to the DR3-/- naive control, in contrast to the significant rise in 
leukocytes in the DR3+/+ (***p<0.001) (each bar represents mean of n=6 
DR3+/+ mice () and DR3-/- mice (☐) per treatment, error bars correspond 
to mean ± SEM, analysed by t-test). 
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Figure 5.3 – Clearance of neutrophils from the peritoneal cavity of 
DR3+/+ mice compared to DR3-/- mice after SES induced inflammation. 
Inflammation in the cavity was induced via an i.p. injection of SES. 
Peritoneal leukocytes were isolated from the cavity by lavage. A) 
Neutrophils were identified by a 7/4+ Ly6G+  CD11bint F4/80int  phenotype. 
B) Neutrophil numbers at each time point were calculated by percentage 
proportion of total leukocytes, determined using a Beckman Coulter counter 
Z2 (each symbol represents mean of n=6 DR3+/+ mice (▲) and DR3-/- mice 
(▽) per time point, error bars correspond to mean ± SEM, p<0.01 by 
ANOVA). 
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5.2.2.3 Accumulation of myeloid cell subsets in the DR3+/+ and DR3-/- peritoneal 
cavity during later stages of acute SES induced inflammation 
Other inflammatory myeloid subsets (inflammatory macrophages and eosinophils) 
which peak after 24 hours are steadily removed from the cavity during the late phase 
and replaced by resident macrophages, which constitute the majority of myeloid 
subsets in the naive cavity (Figure 5.4). Post 24 hours of SES challenge analogous 
numbers of resident macrophages were found in the peritoneal cavity of DR3+/+ mice 
(7.2 ± 1.6 x105 total resident macrophages after 48 hours) and DR3-/- mice (6.1 ±      
1.2 x105 total resident macrophages after 48 hours). However, there was a 
substantial decrease in the number of both eosinophils (DR3+/+ mice 8.7 ± 3.2 x105, 
DR3-/- mice 2.4 ± 0.6 x105 total eosinophils after 48 hours) (Figure 5.4C) (p<0.01) 
and inflammatory macrophages (DR3+/+ mice 2.5 ± 0.5 x106, DR3-/- mice 8.3 ±      
0.9 x105 total inflammatory macrophages after 48 hours) (Figure 5.4A) (p<0.01) in 
DR3-/- mice.  
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Figure 5.4 - Significantly higher numbers of inflammatory macrophages 
and eosinophils but not resident macrophages accumulated in the 
peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after SES induced 
inflammation. Inflammation in the cavity was induced via an i.p. injection of 
SES. Peritoneal leukocytes were isolated from the cavity by lavage. A) 
Inflammatory Macrophages, were identified by a CD11bint F4/80int phenotype 
(p<0.01 by ANOVA, Bonferroni post hoc test **p<0.01 after 24 and 48h) B) 
Resident Macrophages were identified by a CD11b+ F4/80+ phenotype and C) 
Eosinophils identified by F4/80int, CD11bint and their forward and side scatter 
properties (p<0.01 by ANOVA, Bonferroni post hoc test ***p<0.001 after 24h). 
Subset numbers calculated by percentage proportion of total leukocytes, 
determined using a Beckman Coulter counter Z2 (each symbol represents mean 
of n=6 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars 
correspond to mean ± SEM, analysed by ANOVA and Bonferroni post hoc test). 
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5.2.2.4 Accumulation of lymphocyte cell subsets in DR3+/+ and DR3-/- peritoneal 
cavities during later stages of acute SES induced inflammation 
Lymphocyte accumulation first observed during the early phase (Section 4.2.2.4) 
continued into the late phase of inflammation (Figure 5.5-5.7). During this period 
DR3-/- mice were found to have significantly decreased numbers of T cells (DR3+/+ 
mice 8.5 ± 3.3 x105, DR3-/- mice 2.4 ± 0.5 x105 total T cells after 72 hours) (p<0.01), 
including both CD4+ (DR3+/+ mice 4.8 ± 2.2 x105, DR3-/- mice 1.5 ± 0.3 x105 total 
CD4+ T cells after 72 hours) (p<0.01) and CD8+ (DR3+/+ mice 1.6 ± 0.7 x105, DR3-/- 
mice 4.8 ± 1.2 x104 total CD8+ T cells after 72 hours) (p<0.01) (Figure 5.5) T cell 
subsets compared to DR3+/+ mice, with T cell differences in the peritoneal cavities of 
the mice of each genotype at their greatest after 72 hours. Substantially fewer B cells 
were also observed in DR3-/- mice during the late phase (DR3+/+ mice 2.3 ± 0.8 x106, 
DR3-/- mice 8.1 ± 1.9 x105 total B cells after 72 hours) (p<0.01), with lower numbers 
of both B1 (DR3+/+ mice 1.2 ± 0.3 x106, DR3-/- mice 4.1 ± 1.2 x105 total B1 cells 
after 72 hours) (p<0.01) and B2 (DR3+/+ mice 1.0 ± 0.5 x106, DR3-/- mice 3.1 ± 0.8 
x105 total B2 cells after 72 hours) (p<0.01) (Figure 5.6) B cell subsets in the cavity 
compared to DR3+/+ mice, with peak divergence between the 2 genotypes also found 
after 72 hours. DR3-/- mice (7.9 ± 1.5 x104 total NKT cells after 48 hours) also had 
significantly fewer NKT cells compared to DR3+/+ mice (1.8 ± 0.2 x105 total NKT 
cells after 48 hours) (p<0.01) (Figure 5.7B), with maximum differences between the 
2 genotypes after 48 hours of inflammation. However DR3-/- mice (2.0 ± 0.4 x105 
total NK cells after 48 hours) were found to have comparable numbers of NK cells 
in their cavity as DR3+/+ mice (3.0 ± 0.5 x105 total NK cells after 48 hours) (Figure 
5.7A).  
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In summary, DR3-/- mice exhibit lower numbers of cells in their cavity during the 
late stage of inflammation, including a wide range of leukocyte subsets. These 
include inflammatory macrophages, eosinophils, T, B and NKT cells but exclude 
resident macrophages and NK cells. 
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Figure 5.5 - Significantly higher numbers of T cell subsets accumulated in 
the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after SES 
induced inflammation. Inflammation in the cavity was induced via an i.p. 
injection of SES. Peritoneal leukocytes were isolated from the cavity by 
lavage. A) T cells were identified by a CD3+, TCRαβ+ phenotype (p<0.01 by 
ANOVA, Bonferroni post hoc test *p<0.05 after 72h). B) T helper cells were 
identified by a CD3+ CD4+, TCRαβ+ phenotype (p<0.01 by ANOVA, 
Bonferroni post hoc test *p<0.05 after 72h) and C) T cytotoxic cells identified 
by a CD3+ CD8+, TCRαβ+ phenotype (p<0.01 by ANOVA, Bonferroni post hoc 
test *p<0.05 after 72h). Subset numbers calculated by percentage proportion of 
total leukocytes, determined using a Beckman Coulter counter Z2 (each 
symbol represents mean of n=6 DR3+/+ mice (▲) and DR3-/- mice (▽) per time 
point, error bars correspond to mean ± SEM, analysed by ANOVA and 
Bonferroni post hoc test). 
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Figure 5.6 - Significantly higher numbers of B cell subsets accumulated in 
the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after SES 
induced inflammation. Inflammation in the cavity was induced via an i.p. 
injection of SES. Peritoneal leukocytes were isolated from the cavity by lavage. 
A) B cells were identified by a CD19+, B220+ phenotype (p<0.01 by ANOVA, 
Bonferroni post hoc test *p<0.05 after 72h). B) B1 cells were identified by a 
CD19+ B220int, CD11bint phenotype (p<0.01 by ANOVA, Bonferroni post hoc 
test **p<0.01 after 48 and 72h) and C) B2 cells identified by a CD19+ B220+, 
CD11b- phenotype (p<0.01 by ANOVA, Bonferroni post hoc test *p<0.05 after 
72h). Subset numbers calculated by percentage proportion of total leukocytes, 
determined using a Beckman Coulter counter Z2 (each symbol represents mean 
of n=6 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars 
correspond to mean ± SEM, analysed by ANOVA and Bonferroni post hoc test). 
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Figure 5.7 - Significantly higher numbers of NKT cells but not NK cells 
accumulated in the peritoneal cavity of DR3+/+ mice compared to DR3-/- 
mice after SES induced inflammation. Inflammation in the cavity was 
induced via an i.p. injection of SES. Peritoneal leukocytes were isolated 
from the cavity by lavage. A) NK cells were identified by a NK1.1+, TCRαβ- 
phenotype. B) NKT cells were identified by a NK1.1+, TCRαβ+ phenotype 
(p<0.01 by ANOVA, Bonferroni post hoc test *p<0.05 after 24 and 48h). 
Subset numbers calculated by percentage proportion of total leukocytes, 
determined using a Beckman Coulter counter Z2 (each symbol represents 
mean of n=6 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars 
correspond to mean ± SEM, analysed by ANOVA and Bonferroni post hoc 
test). 
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5.2.3.1 Levels of leukocyte proliferation in the peritoneal cavity of DR3+/+ and     
DR3 -/- mice 48 hours after the induction of SES inflammation 
DR3 has previously been shown to affect cell proliferation (Taraban, Slebioda et al. 
2011; Twohig, Marsden et al. 2012), therefore the proliferative levels of leukocyte 
subsets were investigated as a possible cause of reduced numbers of selected cell 
subsets in the peritoneal cavity of DR3-/- mice. Prior work has shown peak 
proliferation in the inflamed cavity occurs 48 hours after the induction of 
inflammation (Davies, Rosas et al. 2011). Proliferation at this time was studied using 
intracellular staining for Ki67 as described in Chapter 3. Significant increases in the 
percentage of proliferating cells were noted 48 hours after SES challenge in all 
subsets tested (Figure 5.8-5.11) compared to the naive cavity (Figure 3.7-3.10). 
However no disparity was observed in the proportion of any myeloid (resident 
macrophages: DR3+/+ mice 42.4 ± 13.2%, DR3-/- mice 44.5 ± 8.2%, inflammatory 
macrophages: DR3+/+ mice 43.7 ± 11.5%, DR3-/- mice 47.9 ± 7.7%) or lymphocyte 
(T cells: DR3+/+ mice 49.3 ± 2.3%, DR3-/- mice 50.5 ± 7.5%, B cells: DR3+/+ mice 
36.9 ± 2.8%, DR3-/- mice 28.8 ± 8.2%, NK cells: DR3+/+ mice 35.2 ± 10.4%, DR3-/- 
mice 38.2 ± 3.8%, NKT cells: DR3+/+ mice 47.7 ± 3.8%, DR3-/- mice 51.8 ± 10.1%) 
cell subset expressing Ki67 in the challenged cavity of DR3-/- mice compared to 
DR3+/+ mice (Figure 5.8-5.11).  
Hence, in contrast to previous reports, DR3 is not essential in maintaining leukocyte 
proliferation in this particular model. 
 
 
Figure 5.8 - No significant differences were seen in the percentages of 
proliferating macrophage subsets in the peritoneal cavity of DR3+/+ mice 
and DR3-/- mice 48 hours after induction of SES inflammation. 
Inflammation in the cavity was induced via an i.p. injection of SES. 
Peritoneal leukocytes were isolated from the cavity by lavage. A) Resident 
Macrophages were identified by a CD11b+ F4/80+ phenotype B) and 
Inflammatory Macrophages, were identified by a CD11bint F4/80int 
phenotype. Percentages of proliferating macrophage subsets were calculated 
by the percentage of the subset positive for the marker Ki67 (each symbol 
represents a single mouse, bar corresponds to mean from n=5 or 6, N.S.D by 
Mann-Whitney test). 
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Figure 5.9 - No significant differences were seen in the percentages of 
proliferating T cell subsets in the peritoneal cavity of DR3+/+ mice and 
DR3-/- mice 48 hours after induction of SES inflammation. Inflammation 
in the cavity was induced via an i.p. injection of SES. Peritoneal leukocytes 
were isolated from the cavity by lavage. A) T cells were identified by a 
CD3+, TCRαβ+ phenotype, B) T helper cells were identified by a CD3+ 
CD4+, TCRαβ+ phenotype and C) T cytotoxic cells identified by a CD3+ 
CD8+, TCRαβ+ phenotype. Percentages of proliferating T cell subsets were 
calculated by the percentage of the subset positive for the marker Ki67 (each 
symbol represents a single mouse, bar corresponds to mean from n=5 or 6, 
N.S.D by Mann-Whitney test).  
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Figure 5.10 - No significant differences were seen in the percentages of 
proliferating B cells in the peritoneal cavity of DR3+/+ mice and DR3-/- 
mice 48 hours after induction of SES inflammation. Inflammation in the 
cavity was induced via an i.p. injection of SES. Peritoneal leukocytes were 
isolated from the cavity by lavage. B cells were identified by a CD19+, 
B220+ phenotype. Percentages of proliferating B cells were calculated by the 
percentage of the subset positive for the marker Ki67 (each symbol 
represents a single mouse, bar corresponds to mean from n=5 or 6, N.S.D by 
Mann-Whitney test). 
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Figure 5.11 - No significant differences were seen in the percentages of 
proliferating NK and NKT cell subsets in the peritoneal cavity of DR3+/+ 
mice and DR3-/- mice 48 hours after induction of SES inflammation. 
Inflammation in the cavity was induced via an i.p. injection of SES. 
Peritoneal leukocytes were isolated from the cavity by lavage. A) NK cells 
were identified by a NK1.1+, TCRαβ- phenotype B) and NKT cells were 
identified by a NK1.1+, TCRαβ+ phenotype. Percentages of proliferating NK 
subsets were calculated by the percentage of the subset positive for the 
marker Ki67 (each symbol represents a single mouse, bar corresponds to 
mean from n=5 or 6, N.S.D by Mann-Whitney test). 
 
DR3+/+ DR3-/-
0
20
40
60
80
 T
ot
al
 P
er
ito
ne
al
 N
K
 c
el
ls
DR3+/+ DR3-/-
0
20
40
60
80
 T
ot
al
 P
er
ito
ne
al
 N
K
 c
el
lsA) 
B) 
0 
20 
60 
80 
40 
%
 K
i6
7+
 P
er
it
on
ea
l N
K 
Ce
lls
 
%
 K
i6
7+
 P
er
it
on
ea
l N
K 
T 
Ce
lls
 
0 
20 
60 
80 
40 
186 
187 
 
5.2.3.2 Levels of chemoattractants in DR3+/+ and DR3-/- peritoneal cavities in 
later stages of acute SES induced inflammation 
Since the absence of DR3 had no effect on the proliferation of leukocyte subsets in 
the challenged cavity, a second hypothesis was tested to explain the leukocyte 
accumulation defect observed in DR3-/- mice. Chemoattractant release has 
previously been shown to play an important role in the movement of leukocytes in 
this model (Hurst, Wilkinson et al. 2001; McLoughlin, Hurst et al. 2004; 
McLoughlin, Jenkins et al. 2005) and DR3-/- mice were found to be associated with 
reduced levels of KC (Figure 4.14A) during the early phase of SES induced 
inflammation (Chapter 4).  
Significantly lower levels of CCL2 (DR3+/+ mice 1919 ± 164 pg/ml, DR3-/- mice 524 
± 149 pg/ml after 1 hour) (Figure 5.12A) (p<0.01), CCL7 (DR3+/+ mice 1251 ±     
345 pg/ml, DR3-/- mice 113 ± 57 pg/ml after 1 hour) (Figure 5.12B) (p<0.05), CCL3 
(DR3+/+ mice 162 ± 44 pg/ml, DR3-/- mice 56 ± 7 pg/ml after 6 hours) (Figure 
5.13A) (p<0.01), CCL4 (DR3+/+ mice 1279 ± 16 pg/ml, DR3-/- mice 204 ± 52 pg/ml 
after 6 hours) (Figure 5.13B) (p<0.01), CXCL10 (DR3+/+ mice 391 ± 111 pg/ml, 
DR3-/- mice 158 ± 21 pg/ml after 3 hours) (Figure 5.14A) (p<0.01) and CXCL13 
(DR3+/+ mice 2801 ± 162 pg/ml,   DR3-/- mice 1014 ± 295 pg/ml after 24 hours) 
(Figure 5.15) (p<0.01) were detected in DR3-/- supernatants compared to DR3+/+ 
supernatants following SES challenge. However CCL5 was present at similar levels 
in the supernatants of both DR3+/+ (79 ± 9 pg/ml after 3 hours) and DR3-/- (82 ±       
8 pg/ml after 3 hours) mice (Figure 5.14B).  
Thus SES challenge leads to the release of multiple chemoattractants in DR3+/+ 
mice, with significantly lower levels of selected chemokines found in DR3-/- mice. 
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Figure 5.12 - Significantly higher levels of CCL2 and CCL7 were found 
in the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after 
induction of SES inflammation. Inflammation in the cavity was induced 
via an i.p. injection of SES and cell free supernatants analysed for levels of 
A) CCL2 (***p<0.01) B) and CCL7 (*p<0.05) by ELISA (each symbol 
represents mean of n=5 DR3+/+ mice (▲) and DR3-/- mice (▽) per time 
point, error bars correspond to mean ± SEM, analysed by ANOVA and p 
values calculated using Bonferonni’s post hoc test). 
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Figure 5.13 - Significantly higher levels of CCL3 and CCL4 were found 
in the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after 
induction of SES inflammation. Inflammation in the cavity was induced via 
an i.p. injection of SES and cell free supernatants analysed for levels of A) 
CCL3 (**p<0.01) and B) CCL4 (***p<0.01) by ELISA (each symbol 
represents mean of n=5 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, 
error bars correspond to mean ± SEM, analysed by ANOVA and p values 
calculated using Bonferonni’s post hoc test). 
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Figure 5.14 - Significantly higher levels of CXCL10 but not CCL5 were 
found in the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice 
after induction of SES inflammation. Inflammation in the cavity was 
induced via an i.p. injection of SES and cell free supernatants analysed for 
levels of A) CXCL10 (**p<0.01) and B) CCL5 by ELISA (each symbol 
represents mean of n=5 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, 
error bars correspond to mean ± SEM, analysed by ANOVA and p values 
calculated using Bonferonni’s post hoc test). 
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Figure 5.15 - Significantly higher levels of CXCL13 were found in the 
peritoneal cavity of DR3+/+ mice compared to DR3-/- mice after induction 
of SES inflammation. Inflammation in the cavity was induced via an i.p. 
injection of SES and cell free supernatants analysed for levels of CXCL13 
by ELISA (each symbol represents mean of n=5 DR3+/+ mice (▲) and DR3-/- 
mice (▽) per time point, error bars correspond to mean ± SEM, analysed by 
ANOVA, ***p<0.01 using Bonferonni’s post hoc test). 
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5.2.3.3 RQ of late phase chemoattractant mRNA in DR3+/+ and DR3-/- 
peritoneal membranes after SES induced inflammation 
Mesothelial cells found within the peritoneal membrane have previously been shown 
to express DR3 (Chapter 3) and be a source of chemoattractants (Li, Davenport et al. 
1998; Hurst, Wilkinson et al. 2001; McLoughlin, Hurst et al. 2004); the membrane 
was also shown to be a likely source of both the ELR+ chemoattractants KC and 
MIP2 in Chapter 4. Consequently the RQ of chemoattractants in the membrane 
during inflammation was investigated by qPCR (Section 2.5). Selected chemokines 
mRNA rapidly increased after the induction of SES inflammation                     
(Figure 5.16-5.19).  Comparable RQ of CCL3 (DR3+/+ mice 0.8 ± 1.0, DR3-/- mice 
2.2 ± 1.0 RQ after 3 hours) (Figure 5.17A), CCL4 (DR3+/+ mice 7.0 ± 3.3, DR3-/- 
mice 7.7 ± 3.1 RQ after 3 hours) (Figure 5.17B), CCL5 (DR3+/+ mice 0.9 ± 0.3, 
DR3-/- mice 3.3 ± 1.6 RQ after 3 hours) (Figure 5.18B) and CXCL10 (DR3+/+ mice 
22.8 ± 14, DR3-/- mice 11.3 ± 10.1 RQ after 3 hours) (Figure 5.18A) mRNA was 
found in the DR3+/+ and DR3-/- membrane. However significantly reduced quantities 
of CCL2 (DR3+/+ mice 20.7 ± 7.0, DR3-/- mice 2.5 ± 1.3 RQ after 1 hour) (Figure 
5.16A) (p<0.01), CCL7 (DR3+/+ mice 6.4 ± 1.8, DR3-/- mice 0.9 ± 0.4 RQ after          
1 hour) (Figure 5.16B) (p<0.01) and CXCL13 (DR3+/+ mice 3.2 ± 0.8, DR3-/- mice 
0.6 ± 0.4 RQ after 1 hour) (Figure 5.19) (p<0.05) mRNA was measured in the DR3-/- 
membrane compared to DR3+/+ after SES challenge and correlates with reduced 
levels of these chemoattractants in the DR3-/- cavity tested by ELISA (Figure 5.12 
and Figure 5.15). 
 
 
Figure 5.16 - Significantly higher relative quantity of CCL2 and CCL7 
mRNA was found in the peritoneal membrane of DR3+/+ mice compared 
to DR3-/- mice after induction of SES inflammation. Inflammation in the 
cavity was induced via an i.p. injection of SES and mRNA levels of A) 
CCL2 (***p<0.01) and B) CCL7 (**p<0.01) in the membrane measured by 
qPCR. Values correspond to mean ± SEM, n=5 mice per genotype per time 
point, analysed by ANOVA (each symbol represents mean of n=5 DR3+/+ 
mice (▲) and DR3-/- mice (▽) per time point, error bars correspond to mean 
± SEM, analysed by ANOVA and p values calculated using Bonferonni’s 
post hoc test). 
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Figure 5.17 - No significant differences were seen in the relative quantity 
of CCL3 and CCL4 mRNA in the peritoneal membrane of DR3+/+ mice   
and DR3-/- mice after induction of SES inflammation. Inflammation in the 
cavity was induced via an i.p. injection of SES and mRNA levels of A) 
CCL3 and B) CCL4 in the membrane measured by qPCR (each symbol 
represents mean of n=5 DR3+/+ mice (▲) and DR3-/- mice (▽) per time 
point, error bars correspond to mean ± SEM, N.S.D by ANOVA).  
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Figure 5.18 - No significant differences were seen in the relative quantity 
of CXCL10 and CCL5 mRNA in the peritoneal membrane of DR3+/+ 
mice and DR3-/- mice after induction of SES inflammation. Inflammation 
in the cavity was induced via an i.p. injection of SES and mRNA levels of  
A) CXCL10 and B) CCL5 in the membrane measured by qPCR (each 
symbol represents mean of n=5 DR3+/+ mice (▲) and DR3-/- mice (▽) per 
time point, error bars correspond to mean ± SEM, N.S.D by ANOVA).  
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Figure 5.19 - Significantly higher relative quantity of CXCL13 mRNA 
was found in the peritoneal membrane of DR3+/+ mice compared to    
DR3-/- mice after induction of SES inflammation. Inflammation in the 
cavity was induced via an i.p. injection of SES and mRNA levels of  
CXCL13 in the membrane measured by qPCR (each symbol represents 
mean of n=5 DR3+/+ mice (▲) and DR3-/- mice (▽) per time point, error bars 
correspond to mean ± SEM, analysed by ANOVA, *p<0.05 calculated using 
Bonferonni’s post hoc test.) 
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5.2.3.4 Correlation between peak chemokine level in peritoneal supernatants and 
peak chemoattractant mRNA level in the membrane after induction of SES 
inflammation. 
To examine if higher chemokine RQ in the peritoneal membrane (Figure 5.16-5.19) 
correlated with increased levels in peritoneal supernatants (Figure 5.12-5.15) after 
SES challenge, peak RQ of chemoattractants in the membrane was plotted against 
peak levels in the supernatant. No substantial correlation was present between the 
maximum level of CCL3 (Figure 5.21B), CCL4 (Figure 5.21A), CCL5 (Figure 5.22B) 
and CXCL10 (Figure 5.22A) and the RQ of that chemoattractant in the membrane. 
However correlation was found between CCL2 (Figure 5.20A) (R=0.70, p=0.02), 
CCL7 (Figure 5.20B, R=0.69, p=0.02) and CXCL13 (Figure 5.23) (R=0.68, p=0.02), 
with the peak RQ of these chemoattractants in the membrane positively associated 
with higher levels of their levels in the peritoneal supernatant.  
 
 
 
 
 
 
 
 
 
0 1000 2000 3000
0
5
10
15
CCL7 Concentration (pg/ml)
C
XC
L1
 / 
K
C
 (p
g/
m
l)
0 1000 2000 3000
0
10
20
30
40
50
CCL2 Concentration (pg/ml)
C
XC
L1
 / 
K
C
 (p
g/
m
l)
Figure 5.20 - Significant correlation was found between peak levels of 
CCL2 and CCL7 in the cavity and peak RQ of CCL2 and CCL7 mRNA 
in the peritoneal membrane of DR3+/+ mice and DR3-/- mice after 
induction of SES inflammation. Inflammation in the cavity was induced 
via an i.p. injection of SES and cell free supernatants analysed for 
chemokine levels by ELISA. Peritoneal membranes were analysed for the 
RQ of chemoattractant mRNA in the membrane by qPCR. Correlation 
between the level of A) CCL2 (R=0.70, p=0.02) and B) CCL7 (R=0.69, 
p=0.02) in the supernatants was then plotted against the RQ of the 
chemoattractant mRNA found in the membrane (each symbol represents a 
single DR3+/+ (▲) or DR3-/- mouse (▽), analysed by Pearson R correlation 
test).  
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Figure 5.21 - No significant correlation was found between peak levels of 
CCL3 and CCL4 in the cavity and peak RQ of CCL3 and CCL4 mRNA 
in the peritoneal membrane of DR3+/+ mice and DR3-/- mice after 
induction of SES inflammation. Inflammation in the cavity was induced 
via an i.p. injection of SES and cell free supernatants analysed for 
chemokine levels by ELISA. Peritoneal membranes were analysed for the 
RQ of chemoattractant mRNA in the membrane by qPCR. Correlation 
between the level of A) CCL3 and B) CCL4 in the supernatants was then 
plotted against the RQ of the chemoattractant mRNA found in the membrane 
(each symbol represents a single DR3+/+ (▲) or DR3-/- mouse (▽), analysed 
by Pearson R correlation test).  
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Figure 5.22 - No significant correlation was found between peak levels of 
CXCL10 and CCL5 in the cavity and peak RQ of CXCL10 and CCL5 
mRNA in the peritoneal membrane of DR3+/+ mice and DR3-/- mice after 
induction of SES inflammation. Inflammation in the cavity was induced 
via an i.p. injection of SES and cell free supernatants analysed for 
chemokine levels by ELISA. Peritoneal membranes were analysed for the 
RQ of chemoattractant mRNA in the membrane by qPCR. Correlation 
between the level of A) CXCL10 and B) CCL5 in the supernatants was then 
plotted against the RQ of the chemoattractant mRNA found in the membrane 
(each symbol represents a single DR3+/+ (▲) or DR3-/- mouse (▽), analysed 
by Pearson R correlation test).  
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Figure 5.23 - Significant correlation was found between the peak level of 
CXCL13 in the cavity and peak RQ of CXCL13 mRNA in the peritoneal 
membrane of DR3+/+ mice and DR3-/- mice after induction of SES 
inflammation. Inflammation in the cavity was induced via an i.p. injection 
of SES and cell free supernatants analysed for CXCL13 levels by ELISA. 
Peritoneal membranes were analysed for the RQ of CXCL13 mRNA in the 
membrane by qPCR. Correlation between the level of CXCL13 in the 
supernatants was then plotted against the RQ of CXCL13 mRNA found in 
the membrane (each symbol represents a single DR3+/+ (▲) or DR3-/- mouse 
(▽), R=0.68, p=0.02 by Pearson R correlation test).  
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5.3 Summary  
• DR3 is not expressed on the mesothelial layer of the peritoneal membrane during 
the late phase of SES induced inflammation.   
• DR3 is essential in the regulation of leukocyte trafficking during the late phase of 
the innate immune response.  
• DR3-/- mice had considerably reduced accumulation of selected myeloid and 
lymphoid subsets compared to DR3+/+ mice. 
• DR3 had no effect on the proliferation of infiltrating leukocytes in the inflamed 
cavity.  
• Significantly lower levels of selected chemoattractants from the C-C and C-X-C 
families of chemokines were found in the DR3-/- compared to DR3+/+ peritoneal 
supernatants.  
• The peritoneal membrane appears to be a likely source of chemokines, which 
peak in the supernatants 3 hours after the induction of inflammation (except 
CXCL13). 
•  RQ of mRNA from chemokines which peak in the supernatants 3 hours after 
challenge are found at lower levels in the DR3-/- compared to DR3+/+ membrane.  
• Chemokines which peak later in the supernatants (6 hours after SES challenge) 
have comparable RQ of mRNA in the membrane of the 2 genotypes.  
• Peak RQ of CCL2, CCL7 and CXCL13 mRNA in the peritoneal membrane was 
found to correlate with the maximum level of these chemoattractants found in the 
cavity. 
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Chapter 6 – The role of DR3 after the 
induction of repeated acute peritoneal 
inflammatory episodes 
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6.1 Introduction 
DR3 plays an important role in the innate immune response by regulating the 
accumulation of specific leukocyte subsets in the peritoneal cavity after the 
induction of an acute inflammatory event via SES challenge, by promoting the 
release of certain chemoattractants (Chapter 4 and 5). This early pro-inflammatory 
role during the innate anti-bacterial immune response and inferior control of bacteria 
and viruses in DR3-/- mice (Buchan, Taraban et al. 2012; Twohig, Marsden et al. 
2012) indicate that the DR3/TL1A pathway is important for immunity to pathogens, 
but contrasts with its reported damaging role in the acquired immune response 
during chronic inflammation.  
Chronic inflammatory models have found DR3 to play a significant role in 
promoting the number of inflammatory leukocytes at localised sites of inflammation 
(Bamias, Martin et al. 2003; Meylan, Davidson et al. 2008) as well as supporting 
differentiation (Bull, Williams et al. 2008), proliferation (Pappu, Borodovsky et al. 
2008) and/or maintenance (Jones, Stumhofer et al. 2011) of many of these 
infiltrating leukocytes. Currently, the influence of DR3 expression during recurrent 
inflammatory episodes in the peritoneal cavity has not been studied. 
Recurrent peritoneal inflammation can be induced by 4 i.p. injections of SES, once 
per week for 4 weeks. Multiple peritoneal inflammatory events have previously been 
shown to induce aberrant inflammation causing damage to the morphology 
membrane resulting in tissue fibrosis (Davies, Bryan et al. 1996; Selgas, Bajo et al. 
2006) which is a typical feature of disease (Wynn 2007).  
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This chapter aims to investigate the role of DR3 in driving fibrosis as a consequence 
of repeated episodes of acute SES-driven peritoneal inflammation.  
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6.2 Results  
6.2.1 The effect of repeated inflammatory episodes of SES on total mouse 
leukocyte numbers in DR3+/+ and DR3-/- peritoneal cavities 
After the induction of recurrent peritoneal inflammation (4xSES) mice were 
maintained until the endpoint of the experiment, 49 days after the first injection 
(Section 2.2.6.2). Leukocyte accumulation in DR3+/+ and DR3-/- peritoneal cavities 
during recurrent inflammation was also compared to the number of leukocytes in the 
unchallenged (Naive) cavity (unchallenged mice maintained for 49 days) and after 
induction of acute inflammation (1xSES) (single i.p. injection of SES and mice 
maintained until endpoint, 49 days after injection). No differences were observed in 
the total number of leukocytes after multiple SES injections (4xSES) in the DR3-/- 
cavity (3.6 ± 0.3 x106 total cells) compared to DR3+/+ mice (3.6 ± 0.4 x106 total 
cells). Comparable leukocyte numbers after repeated inflammatory episodes 
(4xSES) were also found at the endpoint (49 days) after the induction of either no 
(Naive) (DR3+/+ mice 3.2  ± 0.4 x106, DR3-/- mice 3.3 ± 0.8 x106 total cells) or acute 
SES inflammation (1xSES) (DR3+/+ mice 3.5 ± 0.3 x106, DR3-/- mice 3.0 ± 0.3 x106 
total cells) (Figure 6.1).  
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Figure 6.1 - No significant differences were seen in total peritoneal 
leukocyte numbers in DR3+/+ mice and DR3-/- mice after repeated 
induction of SES inflammation. Mice received either no challenge (Naive), 
a single injection of SES (1xSES) or repeated episodes of SES induced 
inflammation (4xSES) and were aged for 49 days from the start of the 
experiment. Peritoneal leukocytes were isolated from the cavity by lavage, 
total cell number was calculated using a Beckman Coulter counter Z2 (each 
bar represents mean of n=5 DR3+/+ () and DR3-/- mice (☐) per treatment 
group, error bars correspond to mean ± SEM, N.S.D by t-test). 
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6.2.2 The effect of repeated inflammatory episodes of SES on myeloid cell 
subset numbers in DR3+/+ and DR3-/- peritoneal cavities 
Although absence of DR3 did not affect the total number of cells in the cavity after 
the induction of recurrent peritoneal inflammation (acute inflammation or without 
challenge), numbers of different leukocyte subsets were examined to determine if 
there were alterations in the composition of infiltrating leukocytes after 49 days. At 
the endpoint DR3-/- and DR3+/+ mice were found to have equivalent numbers of 
macrophages (Figure 6.2A) and eosinophils (Figure 6.2B) after induction of 
recurrent inflammation and in all other treatment groups (Table 6.1). Increased 
macrophage numbers were seen in the cavities of both DR3+/+ and DR3-/- after the 
induction of recurrent inflammation (4xSES) but this was not significantly different 
compared to the numbers found in the naive cavity (Figure 6.2A).  
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Figure 6.2 - No significant differences were seen in the numbers of 
myeloid subsets in the peritoneal cavity of DR3+/+ mice compared to 
DR3-/- mice after repeated induction of SES inflammation. Mice received 
either no challenge (Naive), a single injection of SES (1xSES) or repeated 
episodes of SES induced inflammation (4xSES) and were aged for 49 days 
from the start of the experiment. Peritoneal leukocytes were isolated from 
the cavity by lavage. A) Macrophages, were identified by a CD11b+ F4/80+, 
MHC IIint phenotype and B) Eosinophils identified by F4/80int, CD11bint and 
their forward and side scatter properties. Subset numbers calculated by 
percentage proportion of total leukocytes, determined using a Beckman 
Coulter counter Z2 (each bar represents mean of n=5 DR3+/+ mice () and 
DR3-/- mice (☐) per treatment group, error bars correspond to mean ± SEM, 
N.S.D by t-test). 
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6.2.3 The effect of repeated inflammatory episodes of SES on lymphocyte cell 
subset numbers in DR3+/+ and DR3-/- peritoneal cavities 
After 49 days, DR3-/- and DR3+/+ mice had similar numbers of T cells (Figure 6.3A) 
including CD4+ (Figure 6.3B) and CD8+ (Figure 6.3C) subsets, after repeated 
injections of SES and in all other treatment groups. Comparable numbers of B cells 
(Figure 6.4A) including B1 (Figure 6.4B) and B2 (Figure 6.4C) subsets, were also 
found between the two genotypes in all experimental groups, as well as analogous 
numbers of NK (Figure 6.5A) and NKT cells (Figure 6.5B) (Table 6.1).  
Therefore at the endpoint of the experiment, no significant differences were 
observed between the number or composition of peritoneal leukocytes in DR3-/- mice 
compared to DR3+/+ mice. 
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Figure 6.3 - No significant differences were seen in the numbers of T cell 
subsets in the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice 
after repeated induction of SES inflammation. Mice received either no 
challenge (Naive), a single injection of SES (1xSES) or repeated episodes of 
SES induced inflammation (4xSES) and were aged for 49 days from the start 
of the experiment. Peritoneal leukocytes were isolated from the cavity by 
lavage. A) T cells were identified by a CD3+, TCRαβ+ phenotype, B) T helper 
cells were identified by a CD3+ CD4+, TCRαβ+ phenotype and C) T cytotoxic 
cells identified by a CD3+ CD8+, TCRαβ+ phenotype. Subset numbers 
calculated by percentage proportion of total leukocytes, determined using a 
Beckman Coulter counter Z2 (each bar represents mean of n=5 DR3+/+ mice 
() and DR3-/- mice (☐) per treatment group, error bars correspond to mean ± 
SEM, N.S.D by t-test). 
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Figure 6.4 - No significant differences were seen in the numbers of B cell 
subsets in the peritoneal cavity of DR3+/+ mice compared to DR3-/- mice 
after repeated induction of SES inflammation. Mice received either no 
challenge (Naive), a single injection of SES (1xSES) or repeated episodes of 
SES induced inflammation (4xSES) and were aged for 49 days from the start 
of the experiment. A) B cells were identified by a CD19+, B220+ phenotype, B) 
Resident B1 cells were identified by a CD19+ B220int, CD11bint phenotype and 
C) Infiltrating B2 cells identified by a CD19+ B220+, CD11b- phenotype. 
Subset numbers calculated by percentage proportion of total leukocytes, 
determined using a Beckman Coulter counter Z2 (each bar represents mean of 
n=5 DR3+/+ mice () and DR3-/- mice  (☐) per treatment group, error bars 
correspond to mean ± SEM, N.S.D by t-test). 
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Figure 6.5 No significant differences were seen in the numbers of NK 
and NKT cells in the peritoneal cavity of DR3+/+ mice compared to    
DR3-/- mice after repeated induction of SES inflammation. Mice received 
either no challenge (Naive), a single injection of SES (1xSES) or repeated 
episodes of SES induced inflammation (4xSES) and were aged for 49 days 
from the start of the experiment. A) NK cells were identified by a NK1.1+, 
TCRαβ- phenotype. B) NKT cells were identified by a NK1.1+, TCRαβ+ 
phenotype. Subset numbers calculated by percentage proportion of total 
leukocytes, determined using a Beckman Coulter counter Z2 (each bar 
represents mean of n=5 DR3+/+ mice () and DR3-/- mice  (☐) per treatment 
group, error bars correspond to mean ± SEM, N.S.D by t-test). 
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6.2.4 Histological changes to the peritoneal membrane after repeated 
inflammatory episodes of SES in DR3+/+ and DR3-/- peritoneal cavities 
Despite the fact that an absence of DR3 did not affect the quantity or constitution of 
cells residing in the cavity after the induction of recurrent inflammation, the 
mesothelial layer of the peritoneal membrane was examined to investigate if a 
deficiency in DR3 affected its morphology. The mesothelial layer is a thin layer of 
cells found on top of a layer of muscle tissue within the peritoneal membrane. The 
thickness of this layer in DR3+/+ and DR3 -/- mice was measured at multiple points 
along the membrane at the endpoint of the experiment. Comparable mesothelial 
layer thickness was recorded between DR3+/+ and DR3 -/- mice in the naive (DR3+/+ 
mice 18.6 ± 1.3 μm, DR3-/- mice 21.1 ± 1.3 μm) and acute inflammatory groups 
(1xSES) (DR3+/+ mice 19.1 ± 1.5 μm, DR3-/- mice 20.7 ± 1.5 μm) (Figure 6.6 and 
6.7). The mesothelial layer of DR3+/+ mice (30.2 ± 2.9 μm) was found to have 
undergone significant thickening after the induction of repeated inflammation 
(4xSES) (p<0.01), while the DR3-/- mesothelial layer was protected from this type of 
fibrosis (18.2 ± 0.7 μm), closely resembling the morphology of the naive membrane 
(Figure 6.6 and 6.7).   
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Figure 6.6 - Significant thickening of the mesothelial layer was found in 
the peritoneal membrane of DR3+/+ mice after repeated induction of SES 
inflammation. Mice received either no challenge (Naive), a single injection of 
SES (1xSES) or repeated episodes of SES induced inflammation (4xSES) and 
were aged for 49 days from the start of the experiment. Haematoxylin and 
eosin stained membrane slides were viewed using Qwin V3 software on a 
Leica microscope. Pictures were also taken using the Leica microscope (Bar 
corresponds to 25μm, MC- mesothelial cell layer, SMC- sub mesothelial 
compact zone). 
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Figure 6.7 - Significant thickening of the mesothelial layer was found in 
the peritoneal membrane of DR3+/+ mice compared to DR3-/- mice after 
repeated induction of SES inflammation. Mice received either no 
challenge (Naive), a single injection of SES (1xSES) or repeated episodes of 
SES induced inflammation (4xSES) and were aged for 49 days from the start 
of the experiment. Stained membrane slides were analysed by measuring the 
width of the membrane at multiple points using Qwin V3 software on a 
Leica microscope. Pictures were also taken using the Leica microscope 
(each bar represents mean of n=5 DR3+/+ mice () and DR3-/- mice  (☐) per 
treatment group, error bars correspond to mean ± SEM, analysed by t-test).  
 
30 
20 
10 
Naive 1xSES 4xSES 
Treatment 
* p=0.02 
** p<0.01 
219 
220 
 
6.3 Summary 
• No significant differences were observed in either the number of leukocytes in 
the cavity of the 2 genotypes or between the 3 experimental groups (Naive, 
1xSES and 4xSES).  
• Significant fibrosis of the DR3+/+ peritoneal membrane was observed 49 days 
after repeated induction of inflammation. Fibrosis of the membrane was 
confirmed to be associated with the induction of multiple inflammatory events 
as opposed to an acute SES inflammatory episode.  
• The mesothelial layer of the DR3-/- membrane was not susceptible to any 
fibrotic thickening even after the induction of multiple inflammatory events.  
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Chapter 7 – General Discussion  
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7.1 Discussion 
Findings presented in this thesis highlight a non-redundant role for TL1A interaction 
with stromal DR3 in promoting a pro-inflammatory phenotype, via the downstream 
release of chemoattractants after the induction of acute inflammation which effect; 
(i) the accumulation of neutrophils (Figure 7.1), inflammatory myeloid cells (Figure 
7.2) and B cells and (ii) the indirect influx of selected lymphocyte subsets (Figure 
7.3). Results in this thesis also identify a non-redundant role of DR3 in supporting 
peritoneal membrane fibrosis after repeated inflammatory events. 
 
Findings are summarised in bullet points for each section before being more fully 
discussed thereafter: 
 
7.1.1 DR3 expression patterns  
• DR3 was found on the mesothelial layer of the naive peritoneal membrane; its 
expression fluctuated after SES induced inflammation. 
• DR3 was found on naive T cells; higher levels of expression were detected on 
CD4+ T cells compared to CD8+ T cells.  
• Expression on these different T cell subsets altered following SES challenge with 
CD4+ T cells maintaining levels throughout the inflammatory time course, but 
CD8+ T cells losing expression.  
• Both naive and challenged NKT cells expressed DR3.  
• No specific DR3 expression was detected on NK cells before or after SES 
challenge.  
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• No shift in signal could be detected in DR3+/+ myeloid or B cells compared to 
those from DR3-/- mice.  
 
Although DR3 expression was originally reported to be restricted to lymphocytes 
(Marsters, Sheridan et al. 1998), more recent papers have described DR3 expression 
on stromal surfaces, including vascular endothelial (VECs) and tubular epithelial 
cells (TECs) in human renal samples (Al-Lamki, Wang et al. 2003) and healthy and 
psoriatic skin (Bamias, Evangelou et al. 2011). However, DR3 expression patterns in 
each tissue seem distinct.  
In this thesis, DR3 expression was found on the naive peritoneal membrane and 
varied after SES challenge (no longer detected at 6 hours; returning to even higher 
levels at 12 hours before disappearing again by 24, Figure 4.4), whereas no DR3 was 
found on VECs and TECs in human renal tissue until after induction of acute 
cellular rejection or ischaemic injury. Arguably the most similar pattern of stromal 
DR3 expression to the peritoneal membrane is found in human skin where DR3 is 
constitutively expressed in healthy subjects, but increases in psoriasis patients 
(Bamias, Evangelou et al. 2011).  
The variation in DR3 expression on tissue surfaces may be due to different         
tissue-specific functions of DR3, however, the immunofluorescence and IHC 
imaging techniques used in all these studies cannot differentiate between DR3 splice 
variants (which will be discussed later in this section).   
Membrane-bound DR3 expression was observed on mouse peritoneal T cells by 
flow cytometry, which is in agreement with previous reports from the mouse spleen 
(Fang, Adkins et al. 2008; Twohig, Marsden et al. 2012) and in the human system 
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e.g. IBD patient intestinal lamina propria (Bamias, Martin et al. 2003). Interestingly, 
mDR3 expression was found at lower levels on CD8+ T cells compared to CD4+ T 
cells, which is also in agreement with previous studies (Fang, Adkins et al. 2008; 
Twohig, Marsden et al. 2012) suggesting DR3 expression on these subsets may be 
differentially regulated.  
Detection of DR3 was found on mouse peritoneal NKT cells (Figure 4.6B) and is in 
agreement with reports from the spleen (Twohig, Marsden et al. 2012) and lymph 
nodes (Fang, Adkins et al. 2008). Expression has also been reported on NKT cells 
isolated from human peripheral blood monocytes (PBMCs) (Papadakis, Prehn et al. 
2004). However a non-specific signal was found on DR3-/- NKT cells (Figure 3.19), 
which was not observed in other investigations using this polyclonal reagent 
(Twohig, Marsden et al. 2012) or reports from other laboratories using their own 
monoclonal antibody (mAb) (Fang, Adkins et al. 2008). Potential explanations for 
this could be partial failure of the blocking step when staining cells for flow 
cytometry or alternatively, variation between different batches of the polyclonal 
reagent.  
No specific signal for membrane-bound DR3 was observed on naive mouse NK cells 
or at any point after challenge with SES (Figure 4.6A), which is in agreement with 
work by Twohig et al. (2012), but is in contrast to Fang et al. (2008), who detected 
DR3 expression on a subpopulation of NK cells in the spleen and lymph node using 
their in-house mAb. However, similar to NKT cells, a non-specific signal was 
detected on DR3-/- NK cells as well as with the isotype control. This signal is most 
likely due to failure in the blocking procedure, resulting in non-specific binding to 
Fc receptors on NK cells.  
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No DR3-specific shifts were observed in DR3+/+ myeloid and B cells compared to 
the DR3-/- and isotype control (Figure 3.20), suggesting that either; (i) DR3 is not 
present on these cell subsets, (ii) the DR3 specific positive signal is being masked by 
the autofluorescent properties of these cell subsets (Lohmeyer, Friedrich et al. 1994; 
Weyde, Wassermann et al. 1997) or (iii) non-specific binding of the polyclonal 
antibody. To date little work has been carried out on mouse DR3 expression on 
myeloid or B cells, however recent human studies have shown DR3 expression on B 
cells, stimulated with anti-IgM for 24 hours (Cavallini, Lovato et al. 2013) and 
myeloid cells including; THP1 cells (a human peripheral blood monocyte cell line), 
which constitutively express DR3 (Kang, Kim et al. 2005; McLaren, Calder et al. 
2010) and PBMCs stimulated with LPS (Kang, Kim et al. 2005). Thus although no 
DR3 expression was detected on mouse myeloid and B cells in this study, findings 
in humans suggest DR3 is expressed on these cell subsets.  It would be interesting to 
extend qPCR/RT-PCR techniques currently being used to profile different DR3 
isoforms on T cells to other cell types that may have the potential to express DR3, 
overcoming possible limitations of flow cytometry using the polyclonal antibody 
discussed above.  
Ideally a range of DR3 monoclonal antibodies of known specificity would be 
beneficial to standardise detection of DR3, removing; (i) potential inconsistencies 
between batches of the commercially available polyclonal antibody and (ii) 
differentiate between the expression patterns of separate DR3 isoforms, providing a 
better measure than current techniques (qPCR or RT-PCR) by avoiding               
post-translational artefacts of DR3 gene expression. In mouse, splice variants  
include variant 1 (full-length membrane-bound), variant 2 (soluble form) and variant 
3 (truncated membrane-bound) (Wang, Kitson et al. 2001). Recent work examining 
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DR3 mRNA has shown activation-induced differential regulation for different 
isoforms on T cell subsets. DR3 expression has also been found on activated and 
differentiated CD4+ T cells which have differentiated into Th1 (Bamias, Martin et al. 
2003), Th2 (Fang, Adkins et al. 2008), Th17 (Pappu, Borodovsky et al. 2008) and 
Treg (Schreiber, Wolf et al. 2010) subsets. Naive T cells were found to have low 
levels of variants 1 and 3, which were replaced by much higher levels of variants 1 
and 2 after stimulating with peptide (Bamias, Mishina et al. 2006; Twohig, Marsden 
et al. 2012). High levels of variant 3 have been found on Tregs contrasting with 
predominantly variant 1 on Th17 cells (Pappu, Borodovsky et al. 2008). Addition of 
an agonistic DR3 antibody (Schreiber, Wolf et al. 2010) or a soluble TL1A fusion 
protein (Khan, Tsai et al. 2013) has been shown to induce Treg expansion, which 
can then be maintained by daily injections of the TL1A fusion protein (Khan, Tsai et 
al. 2013). Further, mice that constitutively express TL1A were found to promote      
in vivo Treg activation and in vitro expansion, however greater TL1A driven Th17 
and Th2 phenotypes overcame Treg suppressive effects resulting in disruption of 
normal function in the intestine (Shih, Barrett et al. 2011; Taraban, Slebioda et al. 
2011). Thus differential regulation of DR3 isoforms may alter the functional 
response of these subsets and underlines the importance of further understanding the 
expression profile of these isoforms, which may place current conflicting DR3 
findings into context.  
It is tempting to draw comparisons between human and mouse systems, however up 
to 13 DR3 isoforms (10 membrane-bound, 3 soluble) have been reported in man 
(Kitson, Raven et al. 1996; Screaton, Xu et al. 1997; Warzocha, Ribeiro et al. 1998). 
DR3’s function in humans is further complicated by a decoy receptor (DcR3), which 
has no mouse homologue and binds 2 other TNFSF members in addition to TL1A; 
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FasL (Pitti, Marsters et al. 1998) and LIGHT (Yu, Kwon et al. 1999). Some studies 
have speculated sDR3 in mice may fulfil a similar role to DcR3 (Bamias, Mishina et 
al. 2006; Pappu, Borodovsky et al. 2008) however actual function has not been 
investigated and does not explain the continued presence of sDR3 isoforms in 
humans in addition to DcR3 (Screaton, Xu et al. 1997).  
The first identified role of DcR3 was as an inhibitory molecule that is upregulated in 
tumours and inflammatory diseases (Yu, Kwon et al. 1999; Connolly, Cho et al. 
2001; Zhang, Salcedo et al. 2001; Yang, Wang et al. 2004; Han and Wu 2009), the 
levels of which have been shown to correlate with disease progression (Chen, Yang 
et al. 2009), including peritonitis (Chang, Lin et al. 2012). Other non-decoy effector 
functions such as, promotion of cell differentiation (Hsu, Lin et al. 2004; Chang, 
Chen et al. 2008) and invasion (Lin and Hsieh 2011), have more recently been 
reported. Further transgenic mice expressing human DcR3 were found to reduce Th1 
responses and presented a predisposition towards a Th2 polarized phenotype (Hsu, 
Wu et al. 2005; Han, Bojalil et al. 2008). DcR3 may also be able to differentially 
bind its 3 TNFSF ligands and in so doing preferentially act on one pathway in 
preference to another (Wroblewski, Witcher et al. 2003; Bossen, Ingold et al. 2006; 
Han, Moore et al. 2007). Despite stronger structural binding kinetics for TL1A 
(Migone, Zhang et al. 2002), DcR3 has been most commonly implicated in        
FasL-dependent effects, such as preventing FasL-dependent chemotaxis (Roth, 
Isenmann et al. 2001; Shi, Wu et al. 2003) and Fas/LIGHT induced apoptosis (Pitti, 
Marsters et al. 1998; Yu, Kwon et al. 1999). Therefore whilst comparisons between 
mouse and human systems should not be ignored, careful consideration of the 
greater number of isoforms and the role of DcR3 in humans should be borne in mind 
when comparing findings between the 2 species. 
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7.1.2 The role of DR3 in maintaining the number of peritoneal or blood 
leukocytes in the unchallenged mouse  
• Similar numbers of resident leukocytes were found in the naive peritoneal cavity 
of DR3-/- and DR3+/+ mice, reflected in analogous numbers of individual myeloid 
and lymphoid cell subsets. 
• No significant differences were found in proliferation or cell death of leukocyte 
subsets in the DR3-/- and DR3+/+ cavity. 
• Equivalent levels of chemoattractant were observed in the naive DR3-/- and 
DR3+/+ cavity. 
• Parallel numbers of leukocytes subsets were found in the naive peripheral blood 
of DR3-/- and DR3+/+ mice.  
 
Findings outlined in Chapter 3 show DR3 to be non-essential in the maintenance of 
leukocytes during resting conditions in the peritoneal cavity. This is in keeping with 
other work in the Wang laboratory showing comparable leukocyte subset numbers in 
the unchallenged lung and spleen (Singh and Twohig respectively, personal 
communication). Initial analysis of the DR3-/- mouse demonstrated a non-redundant 
role for DR3 in negative selection in the thymus, though no autoimmunity was 
observed and DR3-/- mice had normal immune cell phenotype in the naive state 
(Wang, Thern et al. 2001). Observations in Chapter 3 are consistent with the 
literature that suggests DR3 primarily exerts its effects after immune challenge. 
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7.1.3 Regulation of neutrophil influx into the peritoneal cavity by the 
DR3/TL1A pathway 
• The levels of TL1A mRNA increased in resident macrophages, but not the 
peritoneal membrane, following SES induced inflammation.  
• Significantly reduced levels of the ELR+ neutrophilic chemoattractant KC were 
found in DR3-/- compared to DR3+/+ supernatants after SES challenge. 
• This mirrored levels of KC mRNA in DR3-/- and DR3+/+ membranes following 
the induction of inflammation.  
• Reduced numbers of neutrophils accumulated in the DR3-/- cavity compared to 
DR3+/+ mice after challenge and this correlated with the level of KC. 
 
Acute inflammation was provoked using SES and the innate immune response 
engaged by SES interaction with TLR2 on resident macrophages (Hurst, Wilkinson 
et al. 2001; McLoughlin, Witowski et al. 2003). Detection of SES or zymosan by 
these resident macrophages has previously been shown to lead to the release of      
pro-inflammatory cytokines such as IFNγ (McLoughlin, Witowski et al. 2003), IL6 
(Hurst, Wilkinson et al. 2001; McLoughlin, Witowski et al. 2003) and TNFα 
(Vonasmuth, Maessen et al. 1990), which then co-ordinate the production of 
chemoattractants and adhesion molecules that promote leukocyte accumulation 
(Jones 2005).  
Based on observations in Chapter 4, TL1A can also be considered as one of these 
pro-inflammatory cytokines present prior to the release of the first chemoattractants, 
with increased levels triggered after SES detection by the TLR pathway (Figure 7.1). 
Whilst this time point is the earliest report of an increase in TL1A mRNA expression 
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from macrophages (Figure 4.2), numerous studies have found increased TL1A 
mRNA production in myeloid cells following various stimulation protocols. These 
include Ova/anti-Ova immune complexes (after 3 hours) (Cassatella, da Silva et al. 
2007) or LPS stimulation of: (i) monocytes and DCs isolated from PBMC after 6 
hours (Prehn, Thomas et al. 2007); (ii) bone marrow derived DCs (~100 fold 
increase after 3 hours) (Meylan, Davidson et al. 2008); (iii) U937 cells (a human 
monocytic cell line) after 24 hours (Endo, Kinouchi et al. 2009) and; (iv) mouse 
CD11c+ DCs (after 4 hours). In the latter case, TL1A was also triggered by 
polyinosinic-polycytidylic acid (pIC) stimulation after 6 hours (Taraban, Slebioda et 
al. 2011), while a 12 fold increase in TL1A mRNA was also described from splenic 
macrophages 4 hours after Salmonella enterica infection (Buchan, Taraban et al. 
2012).  
TL1A may then directly bind DR3 present on the naive mesothelium (Figure 3.16) 
leading to the downstream release of chemoattractants from mesothelial cells in the 
membrane (Robson, Witowski et al. 1997; Jones 2005), suggesting a novel role for 
DR3/TL1A signalling on a stromal surface (Figure 7.1). However this model 
assumes DR3 is membrane-bound and not in a soluble form (as postulated in Section 
7.1.1) and requires further investigation. Following DR3/TL1A interaction ELR+ 
chemoattractants are the first chemokines to be released and have been reported to 
come from the membrane (Hurst, Wilkinson et al. 2001; McLoughlin, Witowski et 
al. 2003; McLoughlin, Hurst et al. 2004). Consistent with this, significantly reduced 
levels of KC mRNA were detected in the membranes of DR3-/- compared to DR3+/+ 
mice after challenge (Figure 4.15A) and correlated with reduced protein levels in 
peritoneal supernatants (Figure 4.14A).  
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Lower levels of KC in DR3-/- supernatants correlated with a significant reduction in 
the accumulation of neutrophils into the cavity (Figure 4.8B), which is in agreement 
with findings of Wang, Newton et al. (appendix), who found reduced levels of KC 
and neutrophil numbers in the DR3-/- knee joint 3 days after inducing AIA. 
Therefore DR3 acts to promote rather than curtail the initial stages of the innate 
inflammatory response. 
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7.1.4 Regulation of accumulation of other myeloid and lymphocytic subsets by 
the DR3/TL1A pathway 
• Reduced numbers of inflammatory macrophages and eosinophils, but not 
resident macrophages, accumulated in the peritoneal cavity of DR3-/- compared 
to DR3+/+ mice after SES challenge. 
• Lower numbers of several lymphocyte subsets including T, B and NKT, but not 
NK, cells were found in the DR3-/- compared to DR3+/+ cavity after challenge. 
• No significant differences in proliferation were observed in any of these subsets.  
• Significantly reduced levels of multiple chemokines associated with the 
recruitment of myeloid and lymphoid cell subsets were noted in DR3-/- 
compared to DR3+/+ supernatants. 
• The mRNA levels of several chemoattractants that promote the accumulation of 
myeloid cells were found to be considerably reduced in the DR3-/- compared to 
the DR3+/+ membrane following the induction of inflammation.  
• No significant differences were seen in mRNA levels of most chemoattractants 
linked to the recruitment of lymphocytes, with the exception of CXCL13 that 
was significantly reduced in the DR3-/- membrane after SES challenge.  
 
The rapid influx of neutrophils into the cavity is followed by a more prolonged 
accumulation of other myeloid cell subsets and a later influx of lymphocytes from 
the peripheral blood. These subsets are recruited by other chemoattractants, which 
may be released by both leukocytes and mesothelial cells (Hurst, McLoughlin et al. 
2002; McLoughlin, Hurst et al. 2004; Jones 2005; McLoughlin, Jenkins et al. 2005; 
Hams, Colmont et al. 2008).  
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DR3-/- mice were found to have significantly reduced numbers of both (i) selected 
myeloid subsets including; inflammatory macrophages (Figure 5.4A) and 
eosinophils (Figure 5.4C) and (ii) all lymphocyte subsets studied, with the exception 
of NK cells including; T cells, B cells, and NKT cells (Figure 5.5-5.7) following 
SES challenge. Initial studies implicated DR3 signalling with the NFκB pathway 
suggesting DR3 is capable of influencing cellular expansion and has since been 
shown in CD4+ and CD8+ T cells (Marsters, Sheridan et al. 1996; Meylan, Davidson 
et al. 2008). However DR3-/- mice showed no defect in the percentage of 
proliferating cells of any myeloid or lymphocyte cell subset investigated in the 
peritonitis model (Figure 5.8-5.11). Eosinophil expansion was also investigated at 
this point (data not shown) but no proliferation was observed. Thus DR3 is not 
interacting with the proliferative pathway to promote expansion of leukocytes in this 
model.   
Findings presented in this thesis found DR3-/- supernatants to have significant 
reductions in the level of multiple chemoattractants including; CCL2, CCL3, CCL4, 
CCL7, CXCL10 and CXCL13 (Figure 5.12-5.15). The membrane was shown to be a 
source of selected chemokines including; CCL2, CCL7 (Figure 5.16) and CXCL13 
(Figure 5.19), that were all present at reduced levels in the DR3-/- membrane. 
Differences observed in the other chemoattractants do not appear to originate from 
the membrane (Figure 5.17-5.18) and may be released by leukocytes recruited 
earlier in the innate immune response, such as neutrophils, which have previously 
been shown to release CCL3 (Kasama, Strieter et al. 1993), CCL4 (Kasama, Strieter 
et al. 1994) and CXCL10 (Cassatella, Gasperini et al. 1997; Molesworth-Kenyon, 
Popham et al. 2012). 
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Consistent with the impairment in certain leukocyte subsets (discussed earlier) 
CCL2 and CCL7 have formerly been associated with promoting the accumulation of 
myeloid cells and CXCL13 is exclusively involved in B cell recruitment (Ansel, 
Harris et al. 2002). However, attributing specific chemoattractants to the recruitment 
of individual subsets can be difficult due to the promiscuity of some chemokines and 
previous studies have shown many of them to be capable of recruiting different cell 
subsets based on the context of inflammation (Murphy, Baggiolini et al. 2000; 
Zlotnik and Yoshie 2000; Moser, Wolf et al. 2004).  
Nonetheless, these findings allow a model to be proposed whereby TL1A interaction 
with DR3 on mesothelial cells can lead (i) directly to the downstream production of 
monocytic chemoattractants, which promote the influx of selected myeloid cell 
subsets (Figure 7.2) and (ii) indirectly effect lymphocyte accumulation, as initial 
defects in selected myeloid subset influx earlier in the innate response may cause 
lower overall levels of lymphocytic chemoattractants (Figure 7.3). 
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7.1.5 Contribution of the DR3/TL1A pathway to tissue damage in the peritoneal 
cavity after repeated peritoneal inflammatory episodes 
• Equivalent numbers of leukocytes and all subsets investigated were found in 
both genotypes in each experimental group. 
• Repeated SES induced inflammation resulted in significant fibrosis of the 
DR3+/+ peritoneal membrane. 
• The mesothelial layer of the DR3-/- membrane was not susceptible to fibrotic 
thickening after the induction of a single or multiple inflammatory events.  
 
Following the accumulation of lymphocytes after the induction of acute 
inflammation, the inflammatory leukocyte profile is resolved and naive conditions 
restored by the replenishment of resident cell subsets in the cavity. However, if 
repeated inflammatory events occur preventing the resolution of inflammation, 
aberrant inflammatory conditions can develop, which lead to dysregulation of the 
immune response and ultimately tissue damage (Davies, Bryan et al. 1996; 
Williams, Craig et al. 2002; Jones 2005; Wynn 2007).  
After repeated inflammatory events the peritoneal membranes of DR3+/+ mice were 
found to have undergone significant fibrosis (Figure 6.7A), which has been observed 
in previous studies using the SES model (Fielding et al. appendix) and other 
experimental models of peritoneal inflammation (Takahashi, Taniguchi et al. 2009; 
Jiang, Zhang et al. 2011; Washida, Wakino et al. 2011; Nishino, Ashida et al. 2012). 
Conversely, DR3-/- mice were found to be protected from any thickening of their 
mesothelial layer (Figure 6.7B). This fibrosis in DR3+/+ mice suggests that the      
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pro-inflammatory role of DR3/TL1A during the innate immune response may exert 
detrimental effects after repeated inflammatory episodes.  
However no significant differences were observed in the number of any peritoneal 
leukocyte subset investigated between the 2 genotypes after the induction of 
repeated inflammatory events. Comparable leukocyte numbers may be explained by 
the nature of the challenge and as the cavity was not sampled until day 49 (28 days 
since the last inflammatory event was induced) the inflammatory leukocyte profile 
may have been resolved. Indeed similar leukocyte subset numbers are observed in 
both the repeat hit group and the naive group (Figure 6.2-6.5), and lack of 
neutrophils and inflammatory macrophages in the repeat hit group (data not shown) 
are consistent with resolution of inflammation.  
Without further investigation into the mechanism DR3 utilises to cause tissue 
damage, only a hypothesis can be proposed by considering other studies using the 
SES model in the context of previous DR3 findings. During repeated peritoneal 
inflammation TL1A produced by resident macrophages (Figure 4.2) (Endo, 
Kinouchi et al. ; Cassatella, da Silva et al. 2007; Prehn, Thomas et al. 2007; Meylan, 
Davidson et al. 2008; Buchan, Taraban et al. 2012) may bind DR3 expressed on T 
cells (Figure 4.5) (Fang, Adkins et al. 2008; Jones, Stumhofer et al. 2011; Twohig, 
Marsden et al. 2012), which are maintained in the cavity (by repeated SES 
challenge). DR3 then effects T cell responses which co-ordinate the immune 
reaction, such as the release of IFNγ (Fielding et al. appendix).  
IFNγ may promote an increased inflammatory profile by; (i) increased STAT1 
(which is not present during acute inflammation) (Boehm, Klamp et al. 1997) and 
enhanced STAT3 signalling by mesothelial cells (that promotes stronger 
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chemoattractant release) (Platanias 2005; Fielding et al. appendix). (ii) Upregulation 
of adhesion molecules, such as, ICAM-1, VCAM-1 and CD62L that further promote 
cellular influx (Jonjic, Peri et al. 1992; Betjes, Tuk et al. 1993; Liberek, Topley et al. 
1996; Li, Davenport et al. 1998) and (iii) IL15 production by mesothelial cells, 
which is a potent activator of leukocytes (Hausmann, Rogachev et al. 2000).  
Myeloid subsets sustained in the cavity by recurrent inflammation may then release 
degrading enzymes (such as MMPs) and reactive oxygen species (NO, H2O2), which 
promote tissue damage (Duffield, Erwig et al. 2000; Duffield, Ware et al. 2001; 
Kipari and Hughes 2002; Serbina, Salazar-Mather et al. 2003; Gueders, Foidart et al. 
2006; Stary, Bangert et al. 2007). TGFβ release to repair the tissue can then result in 
fibrosis by driving epithelial to mesenchymal transition (EMT) of mesothelial cells 
leading to the production of increased extracellular matrix (fibrosis) (Bissell, Wang 
et al. 1995; Selgas, Bajo et al. 2006).  
 
              7.2 Future Work  
The findings of this thesis have shown a role for DR3 in controlling the release of 
selected chemoattractants and the downstream accumulation of multiple leukocyte 
subsets in the innate immune response, though DR3/TL1A interaction can also lead 
to tissue damage after repeated SES inflammation. However further experiments are 
necessary to understand these findings and the transition from DR3’s effects during 
the innate immune response to the tissue damage caused during recurrent 
inflammation.   
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• Examining the differential regulation and potential roles of DR3 splice 
variants. To date a lack of reagents to identify DR3 and TL1A have hindered 
profiling their expression and how this alters during inflammation, throughout 
the experiments described in this thesis and in the wider literature. However, 
development of specific monoclonal antibodies against each DR3 isoform 
should allow the expression patterns of each DR3 variant to be scrutinised and 
any differential effects exerted by them to be further elucidated, both in the 
context of this model and others. In addition new TL1A reagents, including; 
development of specific TL1A primers and a soon to be released mouse TL1A 
ELISA (eBioscience) will further improve the range of reagents available to 
investigate DR3/TL1A biology.  
 
• Determining the role of DR3 in the transition between innate and adaptive 
immunity and how the mechanism of DR3 signalling may alter during 
adaptive immunity. Preliminary findings in this thesis have identified a      
DR3-dependent effect (fibrosis) after repeated inflammatory events. Analysis of 
intracellular mechanisms which act during acute inflammation and how these 
may alter after the induction of recurrent inflammation, such as the ratio of 
STAT1/STAT3 signalling is crucial to understand if DR3’s effect during acute 
inflammation may influence the shift towards adaptive immunity. It would also 
be interesting to examine levels of other important factors associated with 
recurrent inflammation, which promote autoimmunity, such as up-regulation of 
adhesion molecules, IFNγ, IL15, TNFα, IL1β, TGFβ and MMPs after repeated 
induction of inflammation and if these levels vary between the 2 genotypes.  
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Additionally, investigation of leukocyte subsets over a time course after the 
induction of the fourth inflammatory event (Day 21) is important to determine 
how the leukocyte accumulation profile changes compared to the profile during 
an acute inflammatory event, and what differences are observed between the 2 
genotypes which encourage fibrosis in DR3+/+ mice. However it may be more 
appropriate to use a more severe experimental model, such as infection with live 
S. epidermidis or E. coli which more closely replicates continuous episodes of 
chronic peritonitis (Gallimore, Gagnon et al. 1987; Wang, Nie et al. 2010) and 
allows investigation into potential DR3-dependent effects on peritoneal bacterial 
clearance which has been shown in S. enterica infection (Buchan, Taraban et al. 
2012) in addition to increased viral titres in MCMV (Twohig, Marsden et al. 
2012). Investigation with other TLR agonists is also important to examine TLR 
cross talk with DR3 signalling.  
 
• Investigating DR3 findings outlined in this thesis in the human system and 
the potential of anti-TL1A as a potential therapeutic target. Initial study of 
TL1A and DR3 expression levels in human samples, particularly from end stage 
renal failure patients undergoing peritoneal dialysis treatment (compared to 
healthy controls) is required to investigate if DR3/TL1A interaction is also 
induced in human disease. However any DR3/TL1A dependent role in the 
human immune response may diverge from findings in the mouse system due to 
the presence of other DR3 splice variants (at least 13) and a decoy receptor 
(DcR3), which binds TL1A as well as other TNFSF members. Injections of     
anti-TL1A in DR3+/+ mice would also be interesting to test if it resulted in 
ameliorated fibrosis and aligned with DR3-/- mice, potentially identifying       
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anti-TL1A as a possible therapeutic target for treating fibrosis of the peritoneal 
membrane.  
 
• Further examining the source of chemoattractants after DR3/TL1A 
interaction. Data presented within this thesis suggest certain chemokines 
(namely KC, CCL2, CCL7 and CXCL13) are produced by the membrane. 
However additional experiments i.e. bone marrow chimeras are required to 
definitively identify the cellular source (be it the stroma, leukocytes or both) of 
each chemoattractant that promotes the accumulation of leukocytes during 
inflammation.  
 
• Investigating DR3’s effect on other leukocyte subsets during inflammation. 
Although Chapter 3 measured the number of DCs in the naive cavity, 
investigation of DCs by flow cytometry during inflammation was not possible 
due to the influx of inflammatory macrophages. Recent findings allow the use of 
CD226 along with antibodies already utilised (CD11c, CD11b and F4/80) to 
separate DCs from other leukocyte subsets, including inflammatory 
macrophages (Liao, personal communication). Mast cells were also not 
investigated in this thesis, though investigation into their role may be important 
as they are significant producers of cytokines such as; IL3, IL4, IL6, TNFα and 
IFNγ (Metcalfe, Baram et al. 1997) and are present in the resident population of 
the naive cavity. The use of CD117 and FcεR1 will allow these to be 
investigated by flow cytometry. 
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7.3 Final Conclusion  
This work has shown for the first time an important role for stromal DR3 signalling 
in the innate inflammatory response after the induction of acute peritoneal 
inflammation and that repeated induction of inflammation leads to changes in the 
immune response, which result in fibrosis of the peritoneal membrane. Removal of 
DR3 via a gene knockout impairs the innate immune response but conveys 
protection to any damage of the peritoneal membrane during recurrent inflammation. 
Further work is necessary to determine how the apparently protective innate DR3-
dependent response, outlined in this thesis, interlinks with adverse DR3-dependent 
effects during the acquired immune response and at which point during the immune 
response DR3 exerts its most important effects.  
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